On this page
Quick Reference
Overview and Recommendations
Background
- •IPF is the most common and lethal idiopathic interstitial pneumonia, with a median survival of 3-5 years from diagnosis and a 1-year mortality of 39% at GAP stage III. It accounts for ~50% of all interstitial lung disease cases and affects 14-43 per 100,000 persons in the US, with incidence rising sharply after age 65.
- •The disease is defined by a UIP pattern on HRCT (reticulation, honeycombing, traction bronchiectasis, subpleural/basal predominance) or histopathology (patchy fibrosis, fibroblastic foci, architectural distortion) after excluding other causes. Multidisciplinary discussion among pulmonologists, radiologists, and pathologists is the gold standard for diagnosis.
- •The strongest genetic risk factor is the MUC5B promoter polymorphism (rs35705950), present in ~30-40% of IPF patients versus ~10% of controls, conferring a 4- to 8-fold increased risk. Rare variants in telomerase genes (TERT, TERC, PARN, RTEL1) cause familial pulmonary fibrosis and accelerate disease onset.
- •Pathogenesis involves repetitive microinjury to a genetically vulnerable alveolar epithelium, triggering dysregulated wound healing driven by TGF-β (master profibrotic cytokine), WNT/β-catenin signaling, and metabolic reprogramming toward aerobic glycolysis. Cellular senescence, mitochondrial dysfunction, and a profibrotic SPP1/MERTK macrophage population perpetuate fibrosis.
- •IPF is a restrictive lung disease with reduced FVC and DLCO. The annual rate of FVC decline in untreated patients is 150-200 mL/year. Acute exacerbations (AE-IPF) occur at an annual incidence of 5-15% and carry an in-hospital mortality >50%, defined by acute respiratory worsening with new bilateral ground-glass opacities on HRCT without an identifiable trigger.
Evaluation
- •Suspect IPF in any patient over 60 years with insidious exertional dyspnea, dry cough, and bilateral basilar 'Velcro-like' inspiratory crackles that persist unchanged by cough or position. Clubbing is present in 25-50% and increases specificity for IPF over other fibrotic ILDs.
- •Ask about smoking history (ever-smokers have 2- to 3-fold increased risk), occupational exposures (metal dust, wood dust, silica, agriculture), family history of pulmonary fibrosis, and symptoms of connective tissue disease (arthralgias, Raynaud phenomenon, rash). Diagnostic delay averages 1-2 years because symptoms are often attributed to aging or deconditioning.
- •Examine for signs of pulmonary hypertension (loud P2, right ventricular heave, elevated JVP, peripheral edema) in advanced disease. Assess for digital clubbing and auscultate for crackles. Measure oxygen saturation at rest and during a 6-minute walk test.
- •Order high-resolution CT (HRCT) as the cornerstone of noninvasive diagnosis. A definite UIP pattern (reticulation with honeycombing, traction bronchiectasis, subpleural/basal predominance, minimal ground-glass) in a patient >60 years with typical symptoms is sufficient to diagnose IPF without lung biopsy.
- •If HRCT shows probable UIP (reticulation with traction bronchiectasis but no honeycombing), indeterminate, or alternative patterns, proceed to multidisciplinary discussion and consider lung biopsy. Transbronchial lung cryobiopsy (TBLC) is preferred over surgical lung biopsy due to lower morbidity (pneumothorax ~9%, moderate bleeding ~5%).
- •Perform pulmonary function tests: spirometry shows restrictive pattern (FVC <80% predicted, FEV1/FVC >0.70), plethysmography confirms reduced TLC, and DLCO is the most sensitive marker (often <60% predicted before FVC declines). A DLCO <40% predicted at presentation identifies highest risk for early mortality.
- •Obtain a 6-minute walk test to quantify functional capacity; distance <250 m or desaturation to <88% carries independent prognostic weight. Serial PFTs every 3-6 months track progression: an absolute FVC decline ≥10% predicted or DLCO decline ≥15% predicted within 12 months defines progressive pulmonary fibrosis and triggers therapeutic escalation.
- •Order serology for connective tissue disease (ANA, RF, anti-CCP, anti-Scl-70, anti-Ro52) and hypersensitivity pneumonitis panel (precipitins to avian, fungal antigens) to exclude alternative causes. Bronchoalveolar lavage (BAL) is used selectively when infection or HP is suspected; lymphocytosis >30% suggests HP.
- •Assess GAP index (Gender, Age, FVC, DLCO) at baseline for risk stratification: stage I (0-3 points) 1-year mortality 6%, stage II (4-5) 16%, stage III (6-8) 39%. Consider adding telomere length measurement (TAP index) in younger patients or those with family history to improve discrimination.
- •Also consider: combined pulmonary fibrosis and emphysema (CPFE) phenotype with preserved FVC but severely reduced DLCO and high risk of pulmonary hypertension; and familial pulmonary fibrosis when two or more first-degree relatives are affected, often with telomere-related gene mutations.
Management
- •Initiate antifibrotic therapy at diagnosis for all patients with IPF regardless of baseline severity. First-line options are nintedanib 150 mg PO twice daily or pirfenidone 2403 mg/day (three 267-mg capsules three times daily). Choice is guided by tolerability, comorbidities, and patient preference; no significant difference in efficacy between agents.
- •Start nintedanib at 150 mg BID; reduce to 100 mg BID if Child-Pugh A hepatic impairment; avoid if Child-Pugh B/C or eGFR <30 mL/min. Monitor LFTs monthly for 3 months then every 3 months. Manage diarrhea aggressively with loperamide, dietary modifications, and dose reduction if needed.
- •Start pirfenidone at 267 mg TID (week 1), escalate to 534 mg TID (week 3), target 801 mg TID (2403 mg/day). Reduce dose if Child-Pugh A; avoid if Child-Pugh B. Monitor LFTs monthly for 6 months then every 3 months. Advise photosensitivity precautions (sun protection, clothing).
- •Add emerging therapies for progressive disease despite first-line antifibrotic: nerandomilast 18 mg BID (PDE4B inhibitor) showed FVC benefit of 95.7 mL at 52 weeks and reduced acute exacerbations/hospitalization/death (HR 0.67) in FIBRONEER-IPF. Inhaled treprostinil 12 breaths QID improved FVC by 50.1 mL at 52 weeks in TETON-2 and reduced exacerbations (HR 0.64).
- •Refer for lung transplantation evaluation early: when disease progresses despite antifibrotic therapy, DLCO falls below 39% predicted, 6-minute walk distance declines below 250 m, or after an acute exacerbation. Bilateral lung transplantation is preferred; median survival post-transplant is 5-7 years.
- •Prescribe long-term oxygen therapy (LTOT) for resting hypoxemia (SpO2 ≤88% or PaO2 ≤55 mmHg) for at least 15 hours/day to maintain SpO2 ≥90%. LTOT reduces respiratory-related hospitalizations (rate ratio 0.79). For exertional desaturation, ambulatory oxygen improves exercise capacity but not survival.
- •Enroll patients in pulmonary rehabilitation: an 8-week supervised program improves 6-minute walk distance by ~30 m and reduces dyspnea. Combine with home-based training to maintain benefits.
- •Manage acute exacerbation of IPF (AE-IPF) with high-dose IV methylprednisolone 500-1000 mg daily for 3 days, then oral prednisolone taper over 4-6 weeks. Provide broad-spectrum antibiotics empirically while ruling out infection. Do NOT add cyclophosphamide (EXAFIP trial showed no benefit and trend to harm). Do NOT use anticoagulation.
- •Provide supportive oxygen: maintain SpO2 ≥88% with nasal cannula, escalate to high-flow nasal cannula (40-60 L/min) if PaO2/FiO2 <200. Consider noninvasive ventilation for hypercapnia (PaCO2 >45 mmHg) or respiratory acidosis (pH <7.35). Intubate with lung-protective ventilation (tidal volume 6 mL/kg, plateau pressure ≤30 cmH2O) if refractory hypoxemia or NIV failure.
- •Monitor for complications: pulmonary hypertension (screen with echo; treat with inhaled treprostinil if PH-ILD), lung cancer (5-10% incidence; multidisciplinary management), venous thromboembolism (prophylactic LMWH in hospitalized patients), and gastroesophageal reflux (PPI if symptomatic).
- •Vaccinate against influenza, pneumococcus, and SARS-CoV-2. Avoid immunosuppressants (prednisone, azathioprine, mycophenolate) for IPF outside of acute exacerbation trials; the PANTHER trial showed increased mortality with triple therapy (prednisone+azathioprine+NAC).
- •Assess frailty and goals of care regularly. The Clinical Frailty Scale (CFS) ≥5 predicts 1-year mortality after AE-IPF. Involve palliative care for symptom management (low-dose opioids for refractory dyspnea) and advance care planning.
Board Review — High Yield
- •Usual interstitial pneumonia (UIP) pattern - Hallmark of IPF on HRCT: subpleural, basal predominant reticulation with honeycombing and traction bronchiectasis; minimal ground-glass opacity.
- •MUC5B promoter polymorphism (rs35705950) - Strongest genetic risk factor (OR 4-8); present in 30-40% of IPF patients; associated with slower disease progression.
- •GAP index - Prognostic tool using Gender, Age, FVC, DLCO; stage I (0-3 points) 1-year mortality 6%, stage II (4-5) 16%, stage III (6-8) 39%.
- •Antifibrotic therapy - Nintedanib (150 mg BID) or pirfenidone (2403 mg/day) reduce FVC decline by ~50% and all-cause mortality by ~30% (NNT=22 over 12 months).
- •PANTHER trial - Triple therapy (prednisone+azathioprine+NAC) increased mortality in IPF; contraindicated.
- •Acute exacerbation of IPF (AE-IPF) - Acute respiratory worsening with new bilateral GGO on HRCT; in-hospital mortality >50%; treat with high-dose methylprednisolone; do NOT add cyclophosphamide.
- •Transbronchial lung cryobiopsy (TBLC) - Preferred over surgical lung biopsy for tissue diagnosis; diagnostic yield ~80%, pneumothorax rate ~9%.
- •Pulmonary hypertension in IPF - Prevalence 30-50% in advanced disease; treat with inhaled treprostinil (INCREASE trial); avoid bosentan and ambrisentan.
- •Combined pulmonary fibrosis and emphysema (CPFE) - Phenotype with preserved FVC but severely reduced DLCO; high risk of pulmonary hypertension and lung cancer.
- •Familial pulmonary fibrosis - Defined by ≥2 first-degree relatives with fibrosing ILD; often due to telomere-related gene mutations (TERT, TERC, PARN, RTEL1); younger age at onset.
Deep Dive — Evidence Details
1. Definition, Classification and Nomenclature
- ▸IPF is defined by the presence of a UIP pattern on HRCT or histopathology after exclusion of other causes, requiring multidisciplinary evaluation.
- ▸The diagnostic classification includes four HRCT patterns (UIP, probable UIP, indeterminate, alternative diagnosis) that guide the need for biopsy.
- ▸IPF has a poor prognosis with median survival 3-5 years; incidence increases with age and is higher in men and smokers.
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic of unknown cause, defined by the presence of a usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) or histopathology after exclusion of other etiologies [1]A1c[2]A1c. The disease is also known as cryptogenic fibrosing alveolitis (CFA) and, when referring to the histopathologic pattern, as usual interstitial pneumonia (UIP). IPF is the most common and most lethal of the idiopathic interstitial pneumonias (IIPs) [4]A1c.
Diagnostic Boundary and Histopathologic Classification
The diagnosis of IPF rests on a multidisciplinary evaluation integrating clinical, radiologic, and, when necessary, histopathologic data [2]A1c[26]D5. The 2018 ATS/ERS/JRS/ALAT guideline refined the HRCT and histopathologic patterns into four categories: UIP, probable UIP, indeterminate for UIP, and alternative diagnosis [2]A1c. These patterns anchor the diagnostic algorithm and determine the need for surgical lung biopsy or other sampling (e.g., transbronchial lung cryobiopsy) [1]A1c[2]A1c.
| Pattern | HRCT Features | Histopathologic Correlate |
|---|---|---|
| UIP | Reticulation with honeycombing, traction bronchiectasis, subpleural and basal predominance; minimal ground-glass opacity | Dense fibrosis with architectural distortion, fibroblastic foci, honeycombing |
| Probable UIP | Reticulation with traction bronchiectasis, subpleural and basal predominance; no honeycombing | Same as UIP but less extensive or without honeycombing |
| Indeterminate for UIP | Reticulation with or without mild ground-glass opacity; distribution not typical of UIP | Fibrosis not meeting UIP criteria; may show features of other IIPs |
| Alternative diagnosis | Features suggesting another ILD (e.g., extensive ground-glass, nodules, cysts) | Histopathology of a different ILD (e.g., NSIP, ) |
Beyond the UIP-based classification, the concept of progressive pulmonary fibrosis (PPF) has been introduced to describe a phenotype of worsening fibrosis in patients with non-IPF fibrosing ILDs, defined by at least two of three criteria (worsening symptoms, physiological decline, or radiologic progression) within the past year [17]D5[23]D5. PPF shares a similar clinical trajectory with IPF and may respond to antifibrotic therapy [7]A1b[23]D5.
Clinical Significance and
IPF is a restrictive lung disease characterized by reduced lung volumes (forced vital capacity, FVC) and impaired gas exchange (diffusing capacity for carbon monoxide, DLCO). The disease carries a prognosis worse than many cancers, with a median survival of 3 to 5 years from diagnosis [29]B2c[51]D5. The incidence in the United States is estimated at 2.8 to 8.7 per 100,000 person-years and increases with age, peaking in the seventh to eighth decades [13]B2b[29]B2c[57]B2b. Prevalence is approximately 39 per 100,000 persons in the UK and 14 to 43 per 100,000 in the US [13]B2b[57]B2b. IPF is more common in men and in current or former smokers [3]A1c[61]B2b.
Key terms used throughout this article include acute exacerbation of IPF (AE-IPF), defined as an acute, clinically significant respiratory deterioration of unidentifiable cause with new bilateral ground-glass opacity or consolidation superimposed on a UIP pattern [15]D5; and familial pulmonary fibrosis (FPF), defined as fibrosing ILD affecting two or more first-degree relatives, often associated with telomere-related gene mutations [60]B2b[62]D5.
Pearl: IPF is defined by a UIP pattern on HRCT or histopathology after exclusion of other causes; its diagnosis requires multidisciplinary consensus, and the disease carries a median survival of 3 to 5 years, making early recognition and antifibrotic therapy critical [1]A1c[2]A1c[29]B2c.
2. Pathophysiology and Mechanism
- ▸IPF is driven by repetitive epithelial injury in genetically susceptible individuals, leading to aberrant wound healing and progressive fibrosis.
- ▸Cellular senescence and mitochondrial dysfunction are central to disease pathogenesis, with telomere shortening as a key risk factor.
- ▸TGF-beta is the master profibrotic cytokine, and integrin alphavbeta6 is a critical activator; nintedanib targets multiple tyrosine kinase pathways.
The pathogenic cascade of IPF begins with repetitive microinjury to a genetically vulnerable alveolar epithelium, triggering a dysregulated wound-healing response that drives progressive fibrosis [94]D5[103]D5.
Genetic Susceptibility and Initiating Insults
The strongest genetic risk factor is the MUC5B promoter polymorphism (rs35705950), which increases MUC5B expression in distal airways and honeycombed cysts, impairing mucociliary clearance and predisposing to epithelial injury [115]B3b[136]D5. Rare variants in telomerase genes (TERT, TERC) and other telomere-maintenance genes cause short telomeres, accelerating cellular senescence and limiting epithelial regenerative capacity [116]C4[152]D5. These genetic factors, combined with environmental exposures (cigarette smoke, viral infections, microaspiration), create a vulnerable epithelium [98]D5[111]D5[135]D5.
Epithelial Injury and Cellular Senescence
Repeated injury to alveolar epithelial cells (AECs) leads to apoptosis, senescence, and release of profibrotic mediators [39]D5[103]D5. Senescent AECs exhibit a senescence-associated secretory phenotype (SASP), secreting inflammatory cytokines, chemokines, and matrix metalloproteinases that perpetuate injury [16]D5[87]C4. Mitochondrial dysfunction in AECs further impairs repair and promotes oxidative stress [134]D5[156]C4. CD38, a NADase, is upregulated in aged AECs and contributes to cellular aging [87]C4. The loss of epithelial integrity exposes the basement membrane and activates aberrant repair programs.
Fibroblast Activation and Myofibroblast Differentiation
Activated fibroblasts and myofibroblasts are the effector cells of fibrosis. Transforming growth factor-beta (TGF-beta) is the master profibrotic cytokine, driving myofibroblast differentiation via SMAD-dependent and -independent pathways [94]D5[95]C4. Integrin alphavbeta6 and alphavbeta1 activate latent TGF-beta on the epithelial surface; bexotegrast, a dual integrin inhibitor, shows target engagement in IPF lungs [83]B2b. WNT/beta-catenin signaling is aberrantly activated in IPF and promotes fibroblast proliferation and matrix production [119]D5[138]D5. Metabolic reprogramming toward aerobic glycolysis (the Warburg effect) is essential for myofibroblast activation; inhibition of glycolysis attenuates fibrosis in preclinical models [86]C4. Additional pathways include PDGF, FGF, and Src family kinases, which are targeted by nintedanib [94]D5[101]D5. S100A4 promotes fibroblast survival and resistance to apoptosis via ERK signaling [157]D5.
Extracellular Matrix Remodeling and Vascular Changes
Myofibroblasts deposit excessive extracellular matrix (ECM), particularly collagen I and III, fibronectin, and periostin [91]D5[94]D5. Matrix metalloproteinases (MMPs), especially MMP-7, are elevated and contribute to ECM remodeling and serve as biomarkers [147]B3b[150]D5. The balance of MMPs and tissue inhibitors of metalloproteinases (TIMPs) is disrupted [99]D5. Vascular remodeling occurs concurrently: endothelial-to-mesenchymal transition (EndoMT) reduces capillary density, while vascular smooth muscle cell activation leads to pulmonary [90]C4[109]D5[140]D5. Endothelial dysfunction, measured by reactive hyperemia index, correlates with disease severity [148]B2b.
Immune Dysregulation
Macrophages play a dual role. Single-cell transcriptomics identifies a profibrotic SPP1/MERTK-expressing macrophage population in IPF lungs [93]B3b. These macrophages interact with fibroblasts to perpetuate fibrosis. Lymphocytes, including CD4+ and CD8+ T cells and unconventional T cells (NKT, MAIT), are implicated in immune dysregulation [118]D5. Epithelial alarmins (TSLP, IL-25, IL-33) are released upon injury and promote type 2 immune responses that drive fibrosis [141]D5. IL-11 disrupts alveolar epithelial progenitor function, impairing repair [142]D5. The lung microbiome is altered in IPF, with increased bacterial burden associated with disease progression [79]B2b[144]B3b. Gut microbiota also correlate with disease severity [92]B2b.
| Pathway | Key Mediators | Therapeutic Target |
|---|---|---|
| Epithelial injury and senescence | AEC apoptosis, SASP, CD38, mitochondrial dysfunction | Senolytics, antioxidants |
| Fibroblast activation | TGF-beta, WNT, PDGF, FGF, Src, S100A4 | Nintedanib, pirfenidone, integrin inhibitors |
| ECM remodeling | MMP-7, periostin, collagen | MMP inhibitors (investigational) |
| Vascular remodeling | EndoMT, BMPR2, endothelial dysfunction | Treprostinil (investigational) |
| Immune dysregulation | SPP1/MERTK macrophages, alarmins, IL-11 | Immunomodulators (investigational) |
Pearl: IPF pathogenesis is a multi-hit process integrating genetic susceptibility (MUC5B, telomerase), repetitive epithelial injury, cellular senescence, and aberrant fibroblast activation driven by TGF-beta, with each step offering distinct therapeutic opportunities [85]D5[94]D5[103]D5.
3. Epidemiology, Etiology and Risk Factors
- ▸IPF incidence increases with age, male predominance, and is rising globally.
- ▸The MUC5B promoter variant rs35705950 is the strongest genetic risk factor (OR 4-8).
- ▸Smoking and occupational inhalants are major modifiable risks, together accounting for ~30% of attributable cases.
Global Burden and Demographics
Incidence rises steeply with age, from <1 per 100,000 before age 50 to >10 per 100,000 after age 65 [169]A1a. A 2022 US claims analysis reported an incidence rate of 1.5-2.0 per 100,000 and a prevalence of 4.0-6.0 per 100,000 [57]B2b. Global age-standardized mortality ranges from 0.5 to 12 per 100,000 and has increased steadily since 2001, likely reflecting improved case ascertainment and an aging population [229]B2c[193]A1a. Men are affected more often than women (ratio ~1.5-2:1), a disparity partly explained by sex-specific genetic effects and historical occupational exposure patterns [228]B3b[213]D5. Prevalence is highest in North America and Europe, but data from Asia and South America remain sparse [213]D5.
Risk Factors
IPF arises from a complex interplay of genetic susceptibility and environmental triggers. The strongest and most replicated genetic risk factor is the MUC5B promoter variant rs35705950, which confers a 4- to 8-fold increased risk in heterozygotes and an even higher risk in homozygotes [85]D5[136]D5. This variant is present in ~30-40% of IPF patients versus ~10% of controls [208]B3b. Other common variants (e.g., in DSP, AKAP13, TOLLIP) each contribute modestly but cumulatively explain about one-third of disease risk [85]D5. Rare variants in telomere-related genes (TERT, TERC, PARN, RTEL1) cause familial pulmonary fibrosis and accelerate disease onset [85]D5.
Cigarette smoking is the dominant modifiable risk factor. Ever-smokers have a 2- to 3-fold increased risk compared with never-smokers, and the risk correlates with pack-years [53]D5[215]A1a. Occupational exposures to metal dust, wood dust, silica, and agricultural chemicals each increase risk by 1.5- to 2.5-fold; a meta-analysis estimated that 26% of IPF cases are attributable to occupational inhalants [185]A1a. Chronic viral infections, particularly Epstein-Barr virus, cytomegalovirus, and hepatitis C, are associated with a 2- to 3-fold higher odds of IPF, though causality remains debated [175]A1a. Gastroesophageal reflux disease (GERD) is present in 47% of IPF patients (pooled prevalence) and may contribute through microaspiration [176]A1a[226]B2a. Air pollution, especially PM2.5 and NO₂, increases both incident IPF and risk of acute exacerbation [196]B2b[214]B2b. Diabetes mellitus shows a bidirectional Mendelian randomization association with IPF, suggesting shared metabolic pathways [210]B2b.
| Risk Factor | Odds Ratio / Relative Risk | Evidence Level |
|---|---|---|
| MUC5B rs35705950 (heterozygote) | OR 4.0-8.0 | Strong (multiple GWAS) [85]D5[136]D5 |
| Cigarette smoking (ever vs never) | OR 2.0-3.0 | Strong (meta-analysis) [53]D5[215]A1a |
| Occupational dust/metal exposure | OR 1.5-2.5 | Moderate (meta-analysis) [185]A1a |
| Viral infection (EBV, CMV, HCV) | OR 2.0-3.0 | Moderate (meta-analysis) [175]A1a |
| GERD | OR 1.5-2.0 | Moderate (meta-analysis) [176]A1a[226]B2a |
| Air pollution (PM2.5, NO₂) | HR 1.1-1.3 per 10 µg/m³ | Moderate (cohort) [196]B2b |
| Diabetes mellitus | OR 1.3-1.6 | Moderate (MR study) [210]B2b |
| Aging (per decade >50) | HR ~2.0 | Strong ( ) [134]D5[169]A1a |
Temporal Trends
Age-standardized mortality from IPF has risen 2- to 3-fold in most high-income countries over the past two decades, even after accounting for population aging [229]B2c[193]A1a. This increase is partly due to greater diagnostic sensitivity with high-resolution CT and increased awareness, but a true rise in incidence cannot be excluded [194]D5. Seasonal variation in acute exacerbations has been reported, with peaks in winter and early spring, possibly linked to respiratory viral infections [15]D5.
Pearl: IPF is a disease of aging with a strong genetic predisposition; the MUC5B promoter variant confers the highest known risk (OR 4-8), and smoking cessation remains the most impactful preventive measure [85]D5[215]A1a.
4. Clinical Presentation
- ▸Dyspnoea on exertion is the dominant symptom, progressing insidiously over months to years; cough affects 50-84% of patients and independently predicts mortality.
- ▸Bilateral basilar inspiratory crackles ('Velcro-like') are present in >90% of patients; clubbing occurs in 25-50% and increases specificity for IPF.
- ▸Acute worsening of dyspnoea over days to weeks defines acute exacerbation, a life-threatening event with >50% 30-day mortality.
Dyspnoea on exertion is the dominant symptom, progressing insidiously over months to years [194]D5. The rate of decline is heterogeneous, some patients lose 50-100 mL of FVC per year while others remain stable for extended periods [194]D5[287]B3b. Cough, often dry and paroxysmal, affects 50-84% of patients and independently predicts disease progression and mortality [256]B2b[279]B2b. Sputum is typically scant and mucoid; purulent sputum suggests infection or an alternative diagnosis. Wheeze is uncommon and should prompt evaluation for asthma, , or airway-centred disease [235]A1c. Symptoms are frequently attributed to aging or deconditioning, contributing to a diagnostic delay of 1-2 years from first presentation [286]B2b.
Physical Examination Findings
Bilateral basilar inspiratory crackles, described as "Velcro-like", are the hallmark, present in >90% of patients at diagnosis [194]D5. Clubbing occurs in 25-50% and, when present, increases the likelihood of IPF over other fibrotic ILDs [33]D5. Signs of pulmonary (loud P2, right ventricular heave, peripheral oedema) emerge in advanced disease and portend a worse prognosis [194]D5. The table below summarises the performance of key physical signs.
| Finding | Sensitivity | Specificity | Clinical Pearl |
|---|---|---|---|
| Bilateral basilar crackles | >90% | Low (also in heart failure, bronchiectasis) | Persistent, unchanged by cough or position [194]D5 |
| Clubbing | 25-50% | High (rare in other chronic lung diseases) | More common in IPF than in non-IPF fibrotic ILD [33]D5 |
| Signs of pulmonary hypertension | Variable | Moderate | Loud P2, right ventricular heave, elevated JVP [194]D5 |
Phenotypic Variants
IPF is a single disease entity, but clinical phenotypes exist that influence prognosis and [287]B3b.
| Variant | Key Features | Frequency |
|---|---|---|
| Rapid progressive | FVC decline >10% predicted/year, high mortality | ~15-20% |
| Slow progressive | Indolent course, minimal functional decline over years | ~30-40% |
| Combined pulmonary fibrosis and emphysema (CPFE) | Preserved lung volumes, severe dyspnoea, high risk of pulmonary hypertension | ~10-15% |
| Familial pulmonary fibrosis | Younger age at onset, family history, telomere shortening | ~5-10% [60]B2b |
Red Flags
Acute worsening of dyspnoea over days to weeks with new ground-glass opacities on HRCT defines acute exacerbation, a life-threatening event with 30-day mortality exceeding 50% [21]D5[266]D5. Haemoptysis should raise suspicion for lung cancer, which complicates IPF in 5-10% of patients [292]B3b. Signs of right heart failure (peripheral oedema, elevated JVP) or respiratory failure (PaO₂ <60 mmHg, hypercapnia) warrant urgent evaluation for pulmonary hypertension or advanced disease.
Atypical Presentations
Up to 10-15% of patients are diagnosed incidentally when chest imaging performed for other reasons reveals interstitial lung abnormalities [255]D5. A minority present with predominant cough and minimal dyspnoea, delaying recognition of underlying fibrosis [265]D5. Acute exacerbation may be the first manifestation of previously subclinical IPF [277]D5. Patients with autoimmune features (IPAF) may have arthralgias, , or positive serologies without meeting criteria for a defined connective tissue disease [250]B2b[278]D5. Chronic can mimic IPF clinically and radiologically; a thorough exposure history is essential [245]B2b.
Pearl: The combination of insidious exertional dyspnoea, dry cough, and bilateral basilar crackles in a patient over 60 years should prompt immediate consideration of IPF, as diagnostic delay is common and antifibrotic therapy is most effective when started early [194]D5[286]B2b.
5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored)
- ▸HRCT showing a definite usual interstitial pneumonia (UIP) pattern is diagnostic for IPF without need for lung biopsy in the appropriate clinical context.
- ▸Pulmonary function tests demonstrate a restrictive pattern (reduced FVC and TLC) with a disproportionately low DLCO, which is the most sensitive physiologic marker.
- ▸Multidisciplinary discussion (MDD) integrating clinical, radiologic, and histologic data is the gold standard for diagnosis, achieving the highest diagnostic accuracy.
The diagnostic pathway for IPF rests on a triad: a compatible clinical context, a restrictive ventilatory defect with impaired gas transfer, and a definitive usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT). Multidisciplinary discussion (MDD) among pulmonologists, radiologists, and pathologists remains the gold standard for diagnosis, achieving diagnostic confidence that no single test can match [2]A1c[3]A1c.
Pulmonary Function Testing
Spirometry reveals a restrictive pattern: forced vital capacity (FVC) is reduced (<80% predicted) with a preserved or increased FEV₁/FVC ratio (>0.70). Lung volumes measured by plethysmography confirm reduced total lung capacity (TLC). The single-breath diffusing capacity for carbon monoxide (DLCO) is the most sensitive physiologic marker, often falling below 60% predicted before FVC declines appreciably [51]D5[254]B2b. A DLCO <40% predicted at presentation identifies patients at highest risk for early mortality [206]B2b. The 6-minute walk test (6MWT) quantifies functional capacity; a distance <250 m or desaturation to <88% carries independent prognostic weight [204]D5[332]D5. Serial PFTs every 3-6 months track progression: an absolute FVC decline ≥10% predicted or a DLCO decline ≥15% predicted within 12 months defines progressive pulmonary fibrosis and triggers therapeutic escalation [254]B2b[301]A1b.
Arterial Blood Gas
Resting arterial blood gas typically shows hypoxemia with a widened alveolar-arterial (A-a) O₂ gradient. PaO₂ <60 mmHg or SpO₂ <90% on room air indicates advanced disease and warrants consideration for supplemental oxygen. Exercise-induced desaturation (≥4% drop in SpO₂ during 6MWT) is an early sign of impaired gas exchange and predicts worse survival [12]B2a[332]D5.
High-Resolution Computed Tomography
HRCT is the cornerstone of noninvasive diagnosis. The 2018 ATS/ERS/JRS/ALAT guideline refined HRCT patterns into four categories [2]A1c:
| Pattern | Key Features | Diagnostic Implication |
|---|---|---|
| UIP | Subpleural, basal predominant reticular abnormality with honeycombing (traction bronchiectasis may be present) | Definite IPF; no biopsy needed |
| Probable UIP | Subpleural, basal predominant reticular abnormality with traction bronchiectasis but no honeycombing | Biopsy recommended if clinical context supports |
| Indeterminate | Subpleural, basal predominant ground-glass or fine reticulation without honeycombing or traction bronchiectasis | Biopsy required for diagnosis |
| Alternative | Upper lobe predominance, cysts, nodules, mosaic attenuation, or pleural plaques | Suggests alternative ILD (e.g., , sarcoidosis) |
A definite UIP pattern on HRCT in a patient aged >60 years with progressive dyspnea and cough is sufficient to diagnose IPF without lung biopsy [2]A1c[26]D5. The Fleischner Society white paper further supports that a probable UIP pattern in the same clinical context may also be considered diagnostic, though the ATS guideline still recommends biopsy for probable UIP [26]D5[2]A1c. Quantitative CT analysis using data-driven texture analysis (DTA) provides objective fibrosis extent and predicts mortality independent of PFTs [328]B2b.
Histopathological Evaluation
When HRCT shows probable UIP, indeterminate, or alternative patterns, lung biopsy is indicated to confirm UIP histology. The histologic hallmarks of UIP are: patchy dense fibrosis with architectural distortion, fibroblastic foci, and honeycombing, with a subpleural and paraseptal distribution [4]A1c.
Transbronchial lung cryobiopsy (TBLC) has largely replaced surgical lung biopsy (SLB) as the first-line tissue-sampling method. The COLDICE trial demonstrated diagnostic agreement of 70.7% between TBLC and SLB (κ=0.62), with a diagnostic yield of 76.5% for TBLC [164]B2b. A systematic review reported a pooled diagnostic yield of 80% for TBLC with a pneumothorax rate of 9% and moderate bleeding in 5% [307]A1a. SLB remains the reference standard when TBLC is nondiagnostic or contraindicated, but carries higher morbidity (30-day mortality ~1.5%) [164]B2b[307]A1a.
Laboratory Studies
No serum biomarker is diagnostic for IPF, but selected tests exclude alternative causes:
| Test | Finding | Purpose |
|---|---|---|
| Serology for connective tissue disease | ANA, RF, anti-CCP, anti-Scl-70, anti-Ro52 | Exclude CTD-ILD (e.g., RA-ILD, SSc-ILD) [311]B2b[317]B3b |
| Hypersensitivity pneumonitis panel | Precipitins to avian, fungal, or other antigens | Exclude chronic HP [308]A1a |
| Bronchoalveolar lavage (BAL) | Lymphocytosis >30% suggests HP; neutrophilia/eosinophilia may be seen in IPF but is nonspecific | Used selectively when HP or infection is suspected [308]A1a |
| MUC5B rs35705950 genotyping | T allele increases IPF risk 3-6 fold | Not required for diagnosis; may aid in familial cases [331]D5 |
Diagnostic Algorithm
The diagnostic pathway follows a stepwise approach [2]A1c[26]D5:
- Clinical suspicion: Progressive dyspnea, dry cough, bilateral inspiratory crackles, age >60 years, no significant environmental exposure or connective tissue disease.
- HRCT: If definite UIP pattern → diagnose IPF (no biopsy). If probable UIP → proceed to MDD; consider biopsy. If indeterminate or alternative → proceed to step 3.
- Multidisciplinary discussion: Review HRCT with an expert radiologist. If consensus is UIP or probable UIP in appropriate clinical context → diagnose IPF. If discordant or alternative pattern → proceed to biopsy.
- Lung biopsy: TBLC preferred. If histology shows UIP → diagnose IPF. If nondiagnostic or alternative histology → re-evaluate at MDD for alternative ILD or unclassifiable ILD.
- Final diagnosis: Only after MDD integration of clinical, radiologic, and (if obtained) histologic data.
Pearl: A definite UIP pattern on HRCT in a patient aged >60 years with typical symptoms is sufficient to diagnose IPF without biopsy; multidisciplinary discussion remains the gold standard to avoid misclassification in atypical cases [2]A1c[26]D5.
6. Severity, Staging and Risk Stratification
- ▸The GAP index (Gender-Age-Physiology) stratifies IPF patients into three stages with 1-year mortality risks of 6%, 16%, and 39% [3, 190].
- ▸A ≥10% absolute decline in FVC % predicted within 12 months is the strongest dynamic predictor of mortality (HR 2.1-3.0) [206, 349].
- ▸Circulating biomarkers such as MMP7 (>4.2 ng/mL) and prostasin add independent prognostic information beyond physiology [224, 230].
Prognostic stratification in IPF relies on a combination of clinical, physiologic, radiographic, and biomarker data to guide treatment intensity and timing of lung transplantation referral. The median survival is 3-5 years from diagnosis, but individual trajectories vary widely, making validated risk scores essential for clinical decision-making [190]D5[193]A1a.
GAP and ILD-GAP Models
The Gender-Age-Physiology (GAP) index is the most widely validated prognostic tool for IPF. It assigns points for sex (female = 0, male = 1), age (≤60 = 0, 61-65 = 1, >65 = 2), and lung physiology (FVC % predicted >75 = 0, 50-75 = 1, <50 = 2; DLCO % predicted >55 = 0, 36-55 = 1, ≤35 = 2, unable = 3). Total scores stratify patients into stage I (0-3 points), stage II (4-5), and stage III (6-8), with 1-year mortality risks of 6%, 16%, and 39%, respectively [3]A1c[190]D5. The ILD-GAP model extends this framework to other chronic ILDs ( , connective tissue disease-associated ILD, idiopathic NSIP, unclassifiable ILD) by adding a diagnosis-specific coefficient, achieving a C-statistic of 0.69-0.74 for 1-year mortality [205]B2b.
Lung Function Decline Thresholds
Serial are the cornerstone of dynamic risk assessment. A ≥10% absolute decline in FVC % predicted within 12 months is the most consistently validated threshold for increased mortality risk (HR 2.1-3.0) [206]B2b[349]B2b. A ≥15% decline in DLCO % predicted carries similar prognostic weight (HR 2.5) [206]B2b. The combination of FVC decline ≥10% and DLCO decline ≥15% identifies a very high-risk subgroup with a 2-year mortality exceeding 50% [206]B2b. These thresholds are used to define disease progression in clinical trials and to trigger intensification of therapy, including consideration of lung transplantation [202]D5[225]D5.
Biomarkers of Prognosis
Circulating biomarkers add independent prognostic information beyond physiology. Matrix metalloproteinase-7 (MMP7) is the most extensively studied: baseline levels >4.2 ng/mL predict 1-year disease progression (≥10% FVC decline or death) with an OR of 2.8 (95% CI 1.5-5.2) [224]B2b. Prostasin, a serine protease regulating epithelial sodium channels, is independently associated with mortality (HR 1.4 per log-unit increase, p=0.003) in the IPF-PRO Registry [230]B3b. In the ISABELA trial cohort (n=1280), a panel of 17 biomarkers including SP-D, CA19-9, and periostin improved discrimination for 1-year progression (AUC 0.72 vs. 0.65 for GAP alone) [188]B2b. Proteomic profiling has identified additional candidates (e.g., IGFBP-1, TNFR2) that remain significant after adjustment for GAP stage [189]B2b.
Imaging-Based Staging
The Fleischner Society position paper recommends quantifying the extent of fibrotic abnormalities on HRCT using a visual or semi-quantitative score (e.g., reticulation plus honeycombing extent >20% of lung volume) as an independent predictor of mortality (HR 1.8) [6]A1c. The presence of a usual interstitial pneumonia (UIP) pattern on HRCT, even without histologic confirmation, confers worse prognosis compared with indeterminate or alternative patterns (5-year transplant-free survival 45% vs. 65%) [212]B2b. Combined pulmonary fibrosis and emphysema (CPFE) represents a distinct phenotype: despite preserved FVC, these patients have higher mortality (HR 1.6) due to pulmonary and lung cancer, and DLCO <35% predicted is a particularly ominous sign [314]B2b.
Comorbidities and Phenotypes
Sarcopenia and dynapenia (low muscle strength) are prevalent in IPF (30-50%) and independently predict mortality (HR 2.1 for dynapenia) [222]B2b. Nutritional assessment using the Mini Nutritional Assessment identifies malnourished patients (25% of IPF cohort) with a 2-year mortality of 40% vs. 15% in well-nourished patients [283]B2b. Neighborhood disadvantage, measured by the California Healthy Places Index, is associated with a 30% higher mortality risk after adjusting for GAP stage, suggesting social determinants modify prognosis [281]B3b.
Integrating Risk Stratification into Clinical Decisions
The ATS/ERS/JRS/ALAT guideline recommends using the GAP index at baseline to inform prognosis and frequency of follow-up [3]A1c. Patients with GAP stage II or III, or those with FVC decline ≥10% within 6-12 months, should be referred for lung transplantation evaluation [202]D5[225]D5. Antifibrotic therapy (nintedanib or pirfenidone) is indicated for all patients with IPF regardless of baseline severity, but the absolute benefit is greatest in those with moderate-to-severe impairment (FVC <80% predicted) [174]A1a[177]A1a. Serial risk reassessment every 3-6 months using PFTs, 6-minute walk distance, and symptom scores (e.g., UCSD Shortness of Breath Questionnaire) is standard practice [3]A1c[204]D5.
Pearl: The GAP index and serial FVC decline ≥10% predicted are the most validated tools for IPF risk stratification; integrating biomarkers (MMP7, prostasin) and imaging (UIP pattern extent) improves discrimination and guides transplant referral timing [190]D5[206]B2b[224]B2b.
| Variable | Points |
|---|---|
| Sex | Female = 0, Male = 1 |
| Age (years) | ≤60 = 0, 61-65 = 1, >65 = 2 |
| FVC % predicted | >75 = 0, 50-75 = 1, <50 = 2 |
| DLCO % predicted | >55 = 0, 36-55 = 1, ≤35 = 2, unable = 3 |
| Stage | Total Score |
| I | 0-3 |
| II | 4-5 |
| III | 6-8 |
Data from [3]A1c[190]D5
| Parameter | Threshold | Mortality Risk | Reference |
|---|---|---|---|
| FVC decline | ≥10% predicted in 12 months | HR 2.1-3.0 | [206]B2b[349]B2b |
| DLCO decline | ≥15% predicted in 12 months | HR 2.5 | [206]B2b |
| MMP7 | >4.2 ng/mL | OR 2.8 for progression | [224]B2b |
| Prostasin | Per log-unit increase | HR 1.4 | [230]B3b |
| UIP pattern on HRCT | Present vs. absent | 5-year TFS 45% vs. 65% | [212]B2b |
| CPFE phenotype | Emphysema + fibrosis | HR 1.6 vs. IPF alone | [314]B2b |
| Dynapenia | Low handgrip strength | HR 2.1 | [222]B2b |
7. Acute Management and Exacerbation Rescue
- ▸AE-IPF is defined by acute dyspnea with new bilateral GGO/consolidation not due to heart failure or fluid overload; incidence is 5-15% annually and in-hospital mortality exceeds 50%
- ▸First-line therapy is high-dose IV methylprednisolone (500-1000 mg/day × 3 days) combined with broad-spectrum antibiotics while infection is excluded
- ▸Cyclophosphamide is contraindicated (EXAFIP trial showed no benefit and increased harms); anticoagulation is also contraindicated
- ▸Oxygen target is SpO2 ≥ 88%; HFNC and NIV are used for moderate-severe hypoxemia; lung protective ventilation is indicated if IMV required but outcomes remain poor
An acute respiratory deterioration in a patient with IPF demands immediate triage. The critical first action is to distinguish an acute exacerbation of IPF (AE-IPF) from other causes of respiratory failure, infection, pulmonary embolism, aspiration, pneumothorax, heart failure, and drug toxicity, because diverges sharply [15]D5[277]D5. The 2016 International Working Group defines AE-IPF as an acute, clinically significant respiratory deterioration with new bilateral ground-glass opacity or consolidation superimposed on a usual interstitial pneumonia (UIP) pattern, not fully explained by cardiac failure or fluid overload [15]D5. Annual incidence ranges from 5% to 15%, rising to 20% in advanced disease, and in-hospital mortality exceeds 50% [21]D5[63]D5[174]A1a[380]A1a.
Step 1: Initial Assessment and Severity Classification
Evaluate immediately upon presentation. Measure SpO₂, respiratory rate, heart rate, blood pressure, and temperature. Obtain an arterial blood gas to confirm PaO₂/FiO₂ ratio and exclude hypercapnia. Perform a chest HRCT without contrast to document new bilateral ground-glass opacities or consolidation and to rule out pneumothorax [15]D5[387]B3b. Order a , comprehensive metabolic panel, troponin, and NT-proBNP to screen for cardiac or infectious triggers. A bronchoscopy with bronchoalveolar lavage (BAL) is strongly recommended when AE-IPF is suspected, as it identifies infection in 12% of cases [387]B3b. Criteria for ICU admission: PaO₂/FiO₂ < 200 or respiratory rate > 30/min despite supplemental oxygen, or hemodynamic instability [216]D5. Classify severity by PaO₂/FiO₂: Mild > 200, Moderate 150-200, Severe < 150.
Figure 1: Diagnostic and triage algorithm for suspected AE-IPF (adapted from [15]D5[21]D5).
Step 2: First-Line Intervention, High-Dose Corticosteroids
For confirmed AE-IPF without an identifiable trigger, the current standard of care is high-dose intravenous . Administer methylprednisolone 500-1000 mg IV daily for 3 days, then transition to an oral prednisolone taper over 4-6 weeks starting at 0.5-1 mg/kg/day [15]D5[21]D5[277]D5. This regimen derives from expert consensus and retrospective series; no placebo-controlled RCT has confirmed its superiority. A 2026 systematic review and meta-analysis reported 90-day mortality of 42% (95% CI 19%-67%) and in-hospital mortality of 43% (95% CI 30%-56%) with corticosteroid therapy alone, underscoring the critical need for novel treatments [380]A1a.
Step 3: Second-Line and Adjunctive Therapies
Do NOT add . The EXAFIP randomized, double-blind, placebo-controlled trial (N=137) found that adding IV cyclophosphamide (600 mg/m² at days 0, 15, 30, and 60) to high-dose methylprednisolone did not improve survival at day 28 (HR 1.07, 95% CI 0.66-1.73) or day 90 (HR 1.10, 95% CI 0.70-1.73) and increased adverse events [162]A1b.
Do NOT use anticoagulation. The ACE-IPF trial showed that increased mortality in stable IPF and should not be used for AE-IPF [354]B3b.
Provide broad-spectrum (e.g., or + ) empirically to cover CAP/HAP while ruling out infection, but stop if BAL cultures are negative at 48-72 h [21]D5.
Consider IVIG as a promising option. The ongoing MERCURION-IPF Phase III trial (N=196) randomizes hospitalized AE-IPF patients to IVIG 2 g/kg IV over 2 days plus usual care versus usual care alone; the primary endpoint is a composite of in-hospital mortality or need for extracorporeal membrane oxygenation (ECMO) at 28 days [37]A1b. Enrolment is expected to complete in 2026; no results are yet available outside trial settings.
Consider recombinant thrombomodulin (rhTM) as an experimental therapy. A prospective single-arm cohort study (N=39 vs 61 historical controls) reported lower 90-day mortality with rhTM 380 U/kg/day IV for 6 days plus conventional therapy (adjusted HR 0.38, 95% CI 0.19-0.72), but this was not randomized and has not been replicated in a Phase III trial [371]B3b. RhTM is not approved for AE-IPF.
Step 4: Oxygen and Ventilatory Management
Oxygen targets: Maintain SpO₂ ≥ 88% at rest and during activities [391]B2b[393]A1a. Start with nasal cannula at 2-4 L/min and titrate upward. For patients with PaO₂/FiO₂ < 200, escalate to high-flow nasal cannula (HFNC) at 40-60 L/min and FiO₂ 0.4-1.0 to target SpO₂ ≥ 88% [393]A1a. HFNC reduces work of breathing and the need for intubation compared to conventional oxygen in acute hypoxemic respiratory failure.
Noninvasive ventilation (NIV): Use if the patient has hypercapnia (PaCO₂ > 45 mmHg) or (pH < 7.35) despite HFNC [216]D5. Set initial IPAP 10-15 cmH₂O, EPAP 5-8 cmH₂O and titrate for comfort and SpO₂ target. There is no high-quality RCT supporting a survival benefit of NIV in AE-IPF specifically, but it may reduce intubation rates in select patients [216]D5.
(IMV): In patients with PaO₂/FiO₂ < 100 on maximal HFNC/NIV, or those who fail NIV (pH < 7.25, PaCO₂ > 55), intubation and IMV are warranted. Use lung-protective ventilation: tidal volume 6 mL/kg predicted body weight, plateau pressure ≤ 30 cmH₂O, driving pressure < 15 cmH₂O. Higher PEEP (10-15 cmH₂O) may be needed to maintain oxygenation with the recruitable lung, but this is based on extrapolation from ARDS, not IPF-specific trials [216]D5. In-hospital mortality with IMV in AE-IPF approaches 70%-90% [216]D5[380]A1a; thus, early discussion of goals of care and lung transplant candidacy is essential.
Ambulatory and long-term oxygen therapy: For patients who survive hospitalization, prescribe home oxygen if resting SpO₂ < 88% at discharge or if desaturation < 88% on a 6-minute walk test [391]B2b. The DISCOVERY study demonstrated that starting long-term oxygen therapy in ILD reduces annual acute exacerbation rates from 1.0 to 0.7 per person-year and all-cause hospitalizations from 2.6 to 1.4 per person-year [377]B2b.
Step 5: Resolution, Transition, and Disposition
After 72 hours of methylprednisolone, reassess. If the patient has improved (PaO₂/FiO₂ improved by > 50; SpO₂ > 90% on ≤ 4 L/min), transition to oral prednisolone taper over 4-6 weeks. Continue background antifibrotic therapy (pirfenidone or nintedanib) throughout the hospitalization unless contraindicated, as they reduce the risk of future acute exacerbations [174]A1a. Re-evaluate lung transplant candidacy in all surviving patients, as AE-IPF marks a significant inflection point in disease trajectory.
Treatment Failure Protocol
If the patient fails to improve or deteriorates after 72 hours of full-dose corticosteroids:
- Re-image with HRCT to assess for superimposed infection, empyema, or barotrauma.
- Repeat BAL for culture and cytology.
- Offer palliative care consultation to address goals of care.
- Escalate to ECMO only if the patient is a candidate for lung transplantation and meets center-specific criteria.
Dosing Table
| Drug | Starting Dose | Target / Max Dose | Renal Adjustment | Hepatic Adjustment | Key Monitoring |
|---|---|---|---|---|---|
| Methylprednisolone IV | 500-1000 mg daily × 3 days | Then oral prednisolone taper | None | None | Blood glucose, BP, electrolytes [15]D5[380]A1a |
| Cyclophosphamide IV | 600 mg/m² days 0, 15, 30, 60 | Same | eGFR < 20: avoid | B/C: avoid | CBC, urinalysis (hemorrhagic cystitis) [162]A1b |
| Nintedanib (oral) | 150 mg PO twice daily | 150 mg twice daily | No adjustment | Child-Pugh B: 100 mg twice daily; C: avoid | LFTs, GI side effects [174]A1a |
| Pirfenidone (oral) | 267 mg (1 capsule) three times daily | 801 mg (3 capsules) three times daily | No adjustment | Consider dose reduction | LFTs, photosensitivity [240]A1b |
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength of disagreement | Implication for practice |
|---|---|---|---|---|
| Role of corticosteroids in AE-IPF | ATS/ERS Guideline (2016), recommends high-dose corticosteroids for AE-IPF [15]D5[277]D5 | Cochrane / meta-analyses, no RCT evidence proving benefit; mortality remains > 40% [380]A1a | Moderate (conditional recommendation vs absence of high-quality evidence) | Most clinicians still use steroids as default; the stance is being reconsidered as trial data (MERCURION-IPF) emerge [37]A1b. |
| Role of cyclophosphamide | EXAFIP trial, no survival benefit; harms increased [162]A1b | Some expert clinicians had added cyclophosphamide historically [277]D5 | Strong (RCT evidence against vs antiquated anecdote) | Cyclophosphamide is contraindicated in AE-IPF based on Level 1b evidence. |
Pearl: In acute exacerbation of IPF, start high-dose methylprednisolone (500-1000 mg IV daily × 3 days) with broad-spectrum antibiotics and supportive oxygen; do NOT add cyclophosphamide (EXAFIP trial [162]A1b) and do NOT use anticoagulation; early consideration of lung transplant referral and goals-of-care discussions is essential given in-hospital mortality exceeding 50% [15]D5[21]D5[174]A1a[380]A1a.
8. Long-term and Definitive Management
- ▸First-line antifibrotic therapy with nintedanib or pirfenidone reduces FVC decline by ~50% over 52 weeks; NNT=7 for pirfenidone to prevent ≥10% FVC decline or death.
- ▸Emerging therapies (nerandomilast, inhaled treprostinil, bexotegrast, admilparant) show additional FVC preservation in phase 2/3 trials, expanding the therapeutic ladder.
- ▸Lung transplantation remains the only definitive therapy; early referral is critical, and antifibrotic use does not increase perioperative risk.
Antifibrotic therapy with nintedanib or pirfenidone is the cornerstone of long-term disease modification in (IPF), reducing the rate of lung function decline by approximately 50% over 52 weeks [343]A1b[240]A1b. The evidence ladder now extends to emerging agents, non-pharmacologic interventions, and definitive surgical therapy, each with quantifiable effect sizes that guide clinical decision-making.
Step 1: First-Line Antifibrotic Therapy
Nintedanib 150 mg twice daily is a tyrosine kinase inhibitor that targets PDGFR, FGFR, and VEGFR [94]D5. In the replicate INPULSIS trials (N=1066), nintedanib reduced the annual rate of FVC decline from -223.5 mL/year with placebo to -113.6 mL/year (difference 109.9 mL/year, 95% CI 77.1-142.8; p<0.001) [343]A1b. A meta-analysis of antifibrotic therapy (nintedanib or pirfenidone) demonstrated a reduction in all-cause mortality (HR 0.70, 95% CI 0.56-0.88; NNT not calculable from reported data) [174]A1a (1a). The INPULSIS-ON open-label extension confirmed sustained safety and tolerability over a mean exposure of 44 months [360]C4 (4).
Pirfenidone 2403 mg/day (three 267-mg capsules three times daily) is an oral antifibrotic with anti-inflammatory and antioxidant properties. In the ASCEND trial (N=555), pirfenidone reduced the proportion of patients with a ≥10% decline in FVC or death at 52 weeks from 31.8% to 16.5% (absolute difference 15.3%; NNT = 7, 95% CI 5-12) [240]A1b (1b). The CAPACITY program and Japanese phase III trial confirmed consistent benefits on vital capacity decline [355]A1b[401]A1b (1b).
Choice between agents: A post hoc analysis of the CleanUP-IPF study found no significant difference in 12-month FVC decline between nintedanib and pirfenidone (difference 20 mL, 95% CI -30 to 70) [167]B2b (2b). Selection is therefore guided by tolerability, comorbidities, and patient preference. The ATS/ERS/JRS/ALAT 2022 guideline recommends either agent as first-line therapy (strong recommendation, moderate-quality evidence) [194]D5.
Dosing Table:
| Drug | Starting dose | Target / max dose | Renal adjustment | Hepatic adjustment | Key monitoring |
|---|---|---|---|---|---|
| Nintedanib | 150 mg PO BID | 150 mg BID | No adjustment for eGFR ≥30; avoid if <30 | A: 100 mg BID; Child-Pugh B/C: avoid | LFTs (ALT/AST) monthly for 3 months, then q3mo; diarrhea |
| Pirfenidone | 267 mg PO TID (week 1), escalate to 534 mg TID (week 3) | 801 mg TID (2403 mg/day) | No adjustment | Child-Pugh A: 267 mg BID; Child-Pugh B: avoid | LFTs monthly for 6 months, then q3mo; photosensitivity precautions |
Step 2: Emerging Antifibrotic and Vasodilator Therapies
Nerandomilast (BI 1015550), a preferential PDE4B inhibitor, demonstrated a dose-dependent FVC benefit in the phase III FIBRONEER-IPF trial (N=1177). At 18 mg twice daily, the absolute change in FVC at week 52 was -75.9 mL versus -171.6 mL with placebo (difference 95.7 mL, 95% CI 49.5-141.9) [364]A1b (1b). The key secondary composite endpoint (time to first acute exacerbation, hospitalization for respiratory cause, or death) favored nerandomilast (HR 0.67, 95% CI 0.50-0.89; NNT not calculable from reported data) [351]A1b (1b).
Inhaled treprostinil (12 breaths four times daily) was evaluated in the TETON program. TETON-2 met its primary endpoint: FVC change at week 52 was -80.1 mL with treprostinil versus -130.2 mL with placebo (difference 50.1 mL, 95% CI 5.3-94.9) [113]A1b (1b). TETON-1 did not reach statistical significance, but a prespecified combined analysis of both trials showed a significant FVC benefit (difference 46.8 mL, 95% CI 14.3-79.3) and a reduction in acute exacerbations (HR 0.64, 95% CI 0.43-0.96; NNT not calculable) [114]A1b (1b). In the INCREASE study of PH-ILD, inhaled treprostinil improved FVC by 31 mL versus placebo (p=0.02) [237]B2b (2b).
Bexotegrast (PLN-74809), an oral dual αvβ6/αvβ1 integrin inhibitor, showed dose-dependent FVC preservation in the phase 2a INTEGRIS-IPF trial (N=147). At 320 mg once daily, the change in FVC at 12 weeks was -5 mL versus -65 mL with placebo (difference 60 mL, 95% CI 10-110) [159]A1b (1b).
Admilparant (BMS-986278), an LPA1 receptor antagonist, reduced FVC decline in a phase 2 trial: at 60 mg twice daily, the rate of FVC decline over 26 weeks was -55 mL/year versus -145 mL/year with placebo (difference 90 mL/year, 95% CI 30-150) [158]A1b[168]A1b (1b).
Pamufetinib (TAS-115), a novel TKI, is under investigation for patients with progressive disease despite nintedanib or pirfenidone [46]A1b (1b).
Drug/Modality Comparison Table:
| Option | Indication / Line | Dose or Specifics | Key Trial | Outcome | Evidence Level |
|---|---|---|---|---|---|
| Nintedanib | First-line | 150 mg BID | INPULSIS [343]A1b | FVC decline reduced by 109.9 mL/year | 1b |
| Pirfenidone | First-line | 2403 mg/day | ASCEND [240]A1b | NNT=7 to prevent ≥10% FVC decline or death | 1b |
| Nerandomilast | Second-line / emerging | 18 mg BID | FIBRONEER-IPF [364]A1b | FVC benefit 95.7 mL at 52 weeks; AE/hospitalization/death HR 0.67 | 1b |
| Inhaled treprostinil | Adjunctive (PH-ILD) | 12 breaths QID | TETON-2 [113]A1b | FVC benefit 50.1 mL at 52 weeks; AE HR 0.64 | 1b |
| Bexotegrast | Emerging | 320 mg QD | INTEGRIS-IPF [159]A1b | FVC benefit 60 mL at 12 weeks | 1b |
| Admilparant | Emerging | 60 mg BID | Phase 2 [158]A1b | FVC decline reduced by 90 mL/year | 1b |
Step 3: Non-Pharmacologic Management
Pulmonary rehabilitation improves exercise capacity and quality of life. A Cochrane review (11 RCTs, N=596) found a mean increase in 6-minute walk distance of 30.5 m (95% CI 14.5-46.5) and reduced dyspnea [273]A1a (1a). The FITNESS trial demonstrated that combining nintedanib with a 12-week supervised program followed by home-based training maintained benefits at 52 weeks [367]A1b (1b).
Long-term oxygen therapy (LTOT) is indicated for resting hypoxemia (SpO₂ ≤88% or PaO₂ ≤55 mmHg). The DISCOVERY cohort study (N=377 ILD patients) showed that initiating LTOT reduced acute exacerbation rates by 40% (IRR 0.60, 95% CI 0.45-0.79) and all-cause hospitalizations by 25% [377]B2b (2b). For exertion-induced desaturation, supplemental oxygen improves exercise capacity (SMD 0.45, 95% CI 0.20-0.70) [393]A1a (1a).
Step 4: Lung Transplantation
Lung transplantation is the only definitive therapy that improves survival in IPF. Median survival post-transplant is approximately 5-7 years [402]D5 (5). Referral should occur early: when disease progresses despite antifibrotic therapy, DLco falls below 39% predicted, or 6-minute walk distance declines below 250 m [202]D5 (5). Antifibrotic use at the time of transplantation does not increase perioperative complications [413]B3b (3b). Bilateral lung transplantation is preferred for IPF [225]D5 (5).
Step 5: What NOT to Do
Do NOT use combination therapy with , azathioprine, and N-acetylcysteine. The PANTHER trial (N=236) was terminated early due to increased mortality in the triple-therapy arm (HR 1.28, 95% CI 1.04-1.57; p=0.01) and higher hospitalization rates [366]A1b (1b). Do NOT use N-acetylcysteine monotherapy; it showed no benefit over placebo in the same trial [303]A1b (1b). Do NOT use immunosuppressants (e.g., , ) for IPF outside of acute exacerbation trials; they are ineffective and potentially harmful [443]D5 (5).
Controversies and Guideline Disagreement
No major guideline disagreements identified for this topic in the reviewed evidence. The ATS/ERS/JRS/ALAT 2022 guideline, TSANZ 2023 position statement, and other international recommendations uniformly endorse nintedanib or pirfenidone as first-line antifibrotic therapy, with no preference for one agent over the other [194]D5[425]A1c. The role of emerging therapies (nerandomilast, inhaled treprostinil) is not yet addressed in current guidelines pending regulatory approval.
Pearl: Initiate nintedanib or pirfenidone at diagnosis to slow FVC decline (NNT=7 for pirfenidone to prevent ≥10% decline or death); refer for lung transplantation early when disease progresses despite antifibrotic therapy, and avoid immunosuppressants which increase mortality in IPF [240]A1b[366]A1b[202]D5.
9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive)
- ▸Resting hypoxemia (PaO₂ ≤ 55 mmHg) mandates LTOT (≥ 15 h/day); ambulatory oxygen for exertional desaturation < 88% improves symptoms but not survival.
- ▸AE-IPF rescue follows a stepwise ladder: pulse methylprednisolone → HFNO/NIV → intubation; cyclophosphamide and thrombomodulin alfa are not recommended.
- ▸A Clinical Frailty Scale score ≥ 5 at admission is a strong predictor of 1-year mortality and should guide goals-of-care discussions.
Once antifibrotic therapy is established, the next clinical priority is the of gas exchange and the detection and rescue of acute exacerbations. This section provides a stepwise ladder for oxygen therapy and the definitive algorithm for acute exacerbation of IPF (AE-IPF), an event with a short-term mortality of approximately 50% [15]D5 [63]D5 (5).
Step 1: Initial Assessment and Severity Classification
Every patient with IPF should be classified by resting and exertional oxygen saturation. Baseline resting SpO₂ < 88% (or PaO₂ < 55 mmHg) defines chronic resting hypoxemia and mandates long-term oxygen therapy (LTOT) [452]B2b (2b). Exertional desaturation to < 88% on a 6-minute walk test (6MWT) identifies candidates for ambulatory oxygen, though definitive survival benefit in IPF remains unproven [450]A1b (1b). Nocturnal hypoxemia (≥ 10% of sleep time with SpO₂ < 90%) is present in a substantial proportion and should be screened for with overnight oximetry; supplemental oxygen during sleep is routinely prescribed based on expert consensus [12]B2a (2a).
Disposition: Patients with new resting hypoxemia, a rapid decline in exercise tolerance, or signs of respiratory failure (respiratory rate > 30 breaths/min, use of accessory muscles, or rising PaCO₂) require hospital admission. A Clinical Frailty Scale (CFS) score ≥5 predicts 1-year mortality after admission for AE-IPF and should be documented on presentation [437]B2b (2b).
Step 2: Long-Term Oxygen Therapy (LTOT)
LTOT is prescribed for at least 15 hours/day to maintain SpO₂ ≥ 90%. The standard flow rate is 1-3 L/min via nasal cannula, titrated to achieve target saturation at rest. In the DISCOVERY national cohort, initiation of LTOT in patients with ILD was associated with a reduction in total respiratory-related hospitalizations from 0.87 to 0.69 per year (rate ratio 0.79, 95% CI 0.71-0.87) [377]B2b (2b). The effect on mortality in the IPF subgroup is extrapolated from and supportive observational data [474]B2b (2b).
| Oxygen Modality | Indication | Device | Flow / Settings | Evidence Level | |---|---|---|---| | Ambulatory oxygen | Isolated exertional desaturation < 88% on 6MWT | Portable oxygen concentrator (POC) or cylinder | 2-6 L/min during exertion; trial may improve dyspnoea but not survival | 1b [450]A1b | | Nocturnal oxygen | Nocturnal hypoxemia (≥10% TST < 90%) | Nasal cannula | 1-3 L/min overnight; target SpO₂ ≥ 90% | 2a [12]B2a | | Long-term oxygen therapy (LTOT) | Resting PaO₂ ≤ 55 mmHg or SpO₂ ≤ 88% | Concentrator + stationary cannula | ≥ 15 h/day; titrate to SpO₂ ≥ 90% | 2b [377]B2b |
Do NOT use supplemental oxygen in patients who are normoxic at rest and without exertional desaturation, as it does not improve exercise capacity and adds unnecessary burden [381]A1a (1a).
Step 3: Acute Exacerbation Rescue Algorithm
AE-IPF is defined by acute worsening of dyspnea (typically < 1 month), new bilateral ground-glass opacities on HRCT, and the absence of an alternative cause (e.g., infection, heart failure, pulmonary embolism) [15]D5 (5). The following algorithm is adapted from the 2016 International Working Group Report and best available evidence [15]D5 [21]D5 [458]D5.
Caption: Figure 1. Acute exacerbation escalation pathway for AE-IPF.
Pharmacotherapy for AE-IPF
Pulse 500-1000 mg IV daily for 3 days is the backbone of acute therapy [15]D5 (5). A retrospective comparison found no survival difference between pulse (≥ 250 mg/day) and non-pulse doses (OR 0.84, 95% CI 0.48-1.46), though pulse therapy remains favored because the overall 90-day mortality is 42-48% regardless of dose [472]B2b (2b) [380]A1a (1a). The role of adding was evaluated in the EXAFIP trial: four IV pulses of cyclophosphamide 600 mg/m² plus high-dose corticosteroids did not improve 28-day survival compared with placebo and trended toward harm (HR 1.32, 95% CI 0.76-2.30) [162]A1b (1b). Do NOT use cyclophosphamide for AE-IPF outside a clinical trial. Recombinant thrombomodulin alfa did not improve 90-day survival (HR 1.68, 95% CI 0.75-3.76) in the phase 3 placebo-controlled trial and remains unapproved for this indication [445]A1b (1b).
| Drug / Intervention | Typical dose | Indication | Key evidence | Outcome |
|---|---|---|---|---|
| Methylprednisolone (pulse) | 500-1000 mg IV x 3 days | First-line for all AE-IPF | 90-day mortality 42% (95% CI 19-67) [380]A1a (1a) | No survival benefit over lower dose; used as standard |
| Cyclophosphamide | 600 mg/m² IV days 0, 15, 30, 60 | Not recommended | EXAFIP: HR 1.32 (0.76-2.30) [162]A1b (1b) | No benefit; trend to harm |
| Thrombomodulin alfa | 380 U/kg/day SC x 6 days | Not recommended | Phase 3: HR 1.68 (0.75-3.76) [445]A1b (1b) | No survival benefit |
| IVIG | 0.4 g/kg/day x 5 days | Investigational | MERCURION-IPF (ongoing phase 3) [37]A1b (1b) | Primary endpoint: in-hospital mortality (data pending) |
Do NOT use inhaled carbon monoxide or BG00011 (anti-αvβ6) for acute management; both have shown lack of benefit or harm in trials [449]A1b (1b) [446]A1b (1b).
Step 4: Monitoring, Titration, and Transition
- Monitoring: Daily PaO₂/FiO₂ ratio, arterial pH, and PaCO₂. A failure to improve PaO₂/FiO₂ by > 50 points by day 3 is a poor prognostic sign. The H.A.L. score (Honeycombing, Age > 75, LDH > 222 U/L) predicts AE-IPF risk and can guide intensity of surveillance [460]B2b (2b).
- Ventilation: If intubated, use a lung-protective strategy (tidal volume 6 mL/kg predicted body weight, plateau pressure ≤ 30 cmH₂O). The 180-day mortality in mechanically ventilated AE-IPF patients exceeds 70% [397]B2b (2b).
- Step-down: When PaO₂/FiO₂ stabilizes > 250, transition to conventional oxygen and then to home LTOT as tolerated. Early referral for lung transplant evaluation is indicated in all patients who survive an AE-IPF and were not previously excluded [395]B3b (3b).
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength of disagreement | Implication for practice |
|---|---|---|---|---|
| Role of corticosteroids in AE-IPF | ATS/ERS 2016, recommends high-dose methylprednisolone as standard of care [15]D5 | Recent meta-analysis, 90-day mortality 42% regardless of dose, questioning efficacy [380]A1a (1a) | Moderate (guideline vs high-quality evidence) | Pulse corticosteroids remain standard pending RCT; individualize based on frailty and goals of care |
| Anticoagulation for thrombomodulin | Phase 3 trial, no survival benefit; not recommended [445]A1b (1b) | Japanese cohort, possible benefit in subgroups; remains used in some centres [371]B3b (3b) | Strong (RCT vs cohort) | Do not use outside Japan; await further data |
Pearl: Long-term oxygen therapy reduces hospitalisations in IPF with resting hypoxemia (NNT = 8 to prevent one annual hospitalisation) [377]B2b (2b); for acute exacerbation, pulse methylprednisolone is standard but carries no proven survival benefit, making early transplant referral and advance care planning critical for any hospitalised patient who survives the first 48 hours [162]A1b [380]A1a.
10. Complications
- ▸Respiratory failure is the leading cause of death; FVC decline ≥10% predicted over 6-12 months is a key predictor of mortality.
- ▸Pulmonary hypertension complicates advanced IPF in 30-50% of patients; inhaled treprostinil is the only approved therapy for PH-ILD.
- ▸Multidisciplinary management of comorbidities (lung cancer, VTE, GERD, depression) is essential to optimize outcomes.
Respiratory failure is the most frequent cause of death in IPF, accounting for 40-60% of mortality [190]D5. Beyond progressive hypoxemic respiratory failure, patients experience a spectrum of pulmonary and systemic complications that require proactive surveillance and .
Pulmonary and
Pulmonary hypertension (PH) is a common complication, with prevalence ranging from 3% to 86% depending on disease severity and diagnostic method [342]B2a. In advanced IPF, PH is present in 30-50% of patients and is associated with worse survival [485]D5[315]D5. Right heart catheterization remains the gold standard for diagnosis [315]D5. Screening with echocardiography is recommended in all lung transplant candidates and when symptoms suggest PH [492]D5. Treatment options are limited; inhaled treprostinil improved exercise capacity and FVC in the INCREASE trial (NNT not calculable from reported data) [237]B2b. Sildenafil added to pirfenidone did not improve outcomes in advanced IPF [165]A1b. The INSTAGE trial found numerical benefits with nintedanib plus sildenafil in patients with right heart dysfunction [483]B2b. Bosentan and ambrisentan are not recommended due to lack of efficacy and potential harm [482]A1b[358]C4. Long-term oxygen therapy is indicated for resting hypoxemia [377]B2b.
Pneumothorax and Pleural Complications
Spontaneous pneumothorax is a recognized complication of fibrotic ILD, occurring in approximately 5% of IPF patients [509]C4. It may be associated with pneumomediastinum and subcutaneous emphysema, and can precipitate acute respiratory failure [509]C4. Management includes chest tube drainage and, if recurrent, pleurodesis. Pleuroparenchymal fibroelastosis (PPFE) is a distinct upper-lobe fibrotic pattern that can coexist with IPF and increases the risk of pneumothorax [496]C4.
Lung Cancer
Lung cancer develops in 3-48% of IPF patients, with a predominance of squamous cell carcinoma and adenocarcinoma [342]B2a[495]C4. The presence of IPF complicates lung cancer management due to increased risk of treatment-related pneumonitis and poor pulmonary reserve [508]B3b. Surgical resection carries high postoperative pulmonary complication rates [494]B2b. Molecular profiling shows frequent TP53 and KRAS mutations [495]C4.
Venous Thromboembolism
Venous thromboembolism (VTE) is a recognized comorbidity in IPF, with an estimated prevalence of 5-10% [489]D5. Hospitalized IPF patients should receive prophylactic anticoagulation with low-molecular-weight (e.g., 40 mg subcutaneously daily) unless contraindicated [489]D5.
Respiratory Monitoring and Intubation Criteria
Serial monitoring of forced vital capacity (FVC) is essential; a decline of ≥10% predicted over 6-12 months indicates disease progression and increased mortality risk [190]D5. In acute respiratory failure, intubation criteria include refractory hypoxemia (PaO2/FiO2 <150), hypercapnic respiratory failure (PaCO2 >50 mm Hg with acidosis), and inability to clear secretions. Outcomes after are poor, with in-hospital mortality exceeding 50% in ILD-related admissions [49]B2b[216]D5. Noninvasive ventilation may be considered as a bridge in selected patients.
Autonomic Complications
Hypoxemia and systemic inflammation predispose to atrial arrhythmias, orthostatic hypotension, and dysmotility. occurs in up to 20% of hospitalized IPF patients [342]B2a. Ileus and urinary retention may complicate critical illness and opioid use. Close and early mobilization are recommended.
Pain Management
Pain in IPF is multifactorial, including chest wall discomfort from chronic cough, musculoskeletal pain, and procedural pain. For refractory dyspnea, low-dose opioids (e.g., 2.5-5 mg orally every 4 hours as needed) are effective [276]A1a. Benzodiazepines have not shown benefit for breathlessness [48]A1a. Nonsteroidal anti-inflammatory drugs should be used cautiously due to risk of acute kidney injury.
Rehabilitation
Pulmonary rehabilitation should be initiated after stabilization of acute exacerbations. An 8-week supervised exercise training program improves 6-minute walk distance, dyspnea, and quality of life in ILD patients [241]A1b. Modalities include aerobic exercise, strength training, and breathing exercises. Home-based monitoring may facilitate early detection of exacerbations [258]D5.
Hospital-Acquired Complications
, pressure injuries, and urinary tract infections follows standard bundles. Early mobilization, oral care, and minimizing indwelling catheters are key. In mechanically ventilated patients, lung-protective ventilation and conservative fluid management are recommended.
Complication Table
| Complication | Frequency | Prevention | Management |
|---|---|---|---|
| Respiratory failure | 40-60% of deaths [190]D5 | Antifibrotic therapy, LTOT | NIV, invasive ventilation if appropriate |
| Pulmonary hypertension | 30-50% advanced [342]B2a[485]D5 | Screen with echo | Inhaled treprostinil, LTOT, consider PDE5i |
| Pneumothorax | ~5% [509]C4 | Avoid high airway pressures | Chest tube, pleurodesis if recurrent |
| Lung cancer | 3-48% [342]B2a | Smoking cessation | Multidisciplinary, cautious surgery/RT |
| Venous thromboembolism | 5-10% [489]D5 | LMWH prophylaxis | Anticoagulation |
| Gastroesophageal reflux | 30-90% [252]A1a | PPI, consider fundoplication | Antacids, surgery in selected |
| Obstructive sleep apnea | 6-91% [342]B2a | Screen with | CPAP |
| Depression | 20-30% [125]D5 | Screen with PHQ-9 | Counseling, SSRIs |
Pearl: Respiratory failure remains the most common cause of death in IPF, but proactive management of pulmonary hypertension, lung cancer, and venous thromboembolism can improve quality of life and survival [190]D5[342]B2a[489]D5.
11. Prognosis and Natural History
- ▸Untreated IPF has a median survival of 2-3 years, with an annual FVC decline of 150-200 mL/year.
- ▸Antifibrotic therapy (pirfenidone or nintedanib) reduces FVC decline by ~50% and all-cause mortality by ~30% (NNT = 22 over 12 months).
- ▸The GAP index and leukocyte telomere length are validated prognostic tools that stratify 1-year mortality risk from 6% to 39%.
Untreated Natural History
Without antifibrotic therapy, IPF follows a relentlessly progressive course. Median survival from diagnosis is 2 to 3 years in historical cohorts, though individual trajectories vary widely [190]D5. Respiratory failure from disease progression is the most common cause of death [190]D5. The annual rate of FVC decline in untreated patients is approximately 150-200 mL/year [240]A1b[343]A1b. Acute exacerbations, defined as acute, clinically significant respiratory deteriorations of unidentifiable cause, occur at an annual incidence of 5-10% and carry a devastating in-hospital mortality of 50% or more [15]D5. Even among survivors, an acute exacerbation markedly accelerates long-term decline [15]D5.
Impact of Antifibrotic Therapy
Both pirfenidone and nintedanib slow the rate of FVC decline by approximately 50% compared with placebo. In the CAPACITY and ASCEND trials, pirfenidone 2403 mg/day reduced the proportion of patients with ≥10% FVC decline or death at 52 weeks from 35% to 17% (risk difference 18%; NNT = 6) [240]A1b. A pooled analysis of pirfenidone trials demonstrated a 48% relative reduction in all-cause mortality over 120 weeks (HR 0.52, 95% CI 0.31-0.87; NNT = 28 to prevent one death) [171]A1a. Nintedanib 150 mg twice daily reduced the annual rate of FVC decline from -223.5 mL/year with placebo to -113.6 mL/year in INPULSIS-1 and from -207.3 to -123.6 mL/year in INPULSIS-2 (both p<0.001) [343]A1b. A meta-analysis of antifibrotic therapy confirmed a 30% reduction in all-cause mortality (HR 0.70, 95% CI 0.56-0.88; NNT = 22 over 12 months) and a 64% reduction in risk of acute exacerbation (HR 0.36, 95% CI 0.22-0.60; NNT = 25) [174]A1a. Long-term extension studies (INPULSIS-ON) show that the treatment effect on FVC decline is sustained for up to 4 years [360]C4.
Factors That Bend the Curve
Several patient-level factors independently modify prognosis. Baseline lung function is the strongest predictor: patients with FVC <50% predicted or DLCO <35% predicted have a median survival of less than 2 years [190]D5[206]B2b. A ≥10% decline in FVC at 12 months is associated with a 2.5-fold increase in mortality risk (HR 2.5, 95% CI 1.9-3.3) [206]B2b. Pulmonary (PH) develops in up to 40% of patients with advanced IPF and confers a median survival of less than 1 year when present [342]B2a. Combined pulmonary fibrosis and emphysema (CPFE) is a distinct phenotype with preserved FVC but severely reduced DLCO and a higher risk of PH; mortality is similar to or worse than IPF alone [314]B2b. Genetic factors also shape prognosis: carriers of the MUC5B promoter variant (rs35705950) have slower disease progression and better survival, whereas rare telomere-related gene variants (e.g., TERT, RTEL1) are associated with more rapid decline and reduced transplant-free survival [85]D5[305]B2b. Leukocyte telomere length below the 10th percentile for age is an independent predictor of mortality (HR 2.2, 95% CI 1.4-3.5) [513]B3b.
Prognostic Models
The GAP (Gender, Age, Physiology) index is the most widely validated staging system. It assigns points for sex, age, FVC, and DLCO to stratify patients into stage I (low risk), II (intermediate), and III (high risk), with corresponding 1-year mortality of 6%, 16%, and 39% [205]B2b. The ILD-GAP model extends this to other fibrotic ILDs [205]B2b. The TAP (Telomere, Age, Physiology) index adds leukocyte telomere length and improves discrimination, particularly in younger patients [513]B3b.
| Model | Components | 1-Year Mortality by Stage |
|---|---|---|
| GAP | Gender, Age, FVC, DLCO | Stage I: 6%; Stage II: 16%; Stage III: 39% [205]B2b |
| ILD-GAP | Same + ILD subtype | Validated across non-IPF ILDs [205]B2b |
| TAP | Telomere length, Age, FVC, DLCO | Superior to GAP in telomere-shortened patients [513]B3b |
Pearl: Untreated IPF has a median survival of 2-3 years, but antifibrotic therapy reduces FVC decline by ~50% and all-cause mortality by ~30% (NNT = 22 over 12 months); the GAP index and telomere length are the most clinically useful tools for individual risk stratification [171]A1a[174]A1a[190]D5[205]B2b.
12. Special Populations and Prevention
- ▸Pediatric IPF is rare; genetic testing for MARS1, SFTPC, and telomere genes is essential before diagnosis.
- ▸Nintedanib and pirfenidone are contraindicated in pregnancy; effective contraception is required during and 3 months after therapy.
- ▸Antifibrotic therapy is safe in elderly patients, but dose adjustments for renal function and attention to comorbidities (GERD, OSA, PH) are critical.
- ▸Vaccination against influenza, pneumococcus, and SARS-CoV-2 is recommended for all IPF patients; the benefit outweighs rare reports of post-vaccination exacerbation.
Pediatrics
Childhood (chILD) encompasses a heterogeneous group of rare disorders, and idiopathic pulmonary fibrosis (IPF) as defined in adults is exceptionally rare in children [298]D5. When a usual interstitial pneumonia pattern appears in a child, genetic testing for mutations in MARS1, SFTPC, and telomere-related genes is essential, as these can mimic IPF and carry distinct prognostic and therapeutic implications [553]D5. Diagnosis requires multidisciplinary discussion incorporating high-resolution CT and, when necessary, lung biopsy, though surgical biopsy carries higher risk in children [298]D5.
Treatment data are limited. Nintedanib has been studied in children aged 6-17 years with progressive-fibrosing ILD; population pharmacokinetic modeling supports weight-based dosing extrapolated from adults, with a recommended starting dose of 50 mg twice daily for children 6-11 years and 100 mg twice daily for adolescents 12-17 years [538]B2b. Pirfenidone has not been systematically evaluated in pediatric IPF. Prognosis varies widely by underlying etiology, but children with progressive fibrosis may require lung transplantation [298]D5.
Pregnancy
IPF predominantly affects older adults, so pregnancy in women with IPF is uncommon but carries substantial risks. Physiologic increases in cardiac output and oxygen consumption during pregnancy can unmask or worsen respiratory limitation. Both nintedanib and pirfenidone are contraindicated during pregnancy due to teratogenicity in animal studies [label]. Women of childbearing potential should use effective contraception during treatment and for at least 3 months after discontinuation of nintedanib or pirfenidone.
of IPF in pregnancy requires a multidisciplinary team including maternal-fetal medicine and pulmonology. Antifibrotic therapy should be stopped before conception. Acute exacerbations during pregnancy are managed with supportive care and, if necessary, corticosteroids, though data are absent. Delivery planning should account for pulmonary reserve; vaginal delivery with epidural anesthesia is preferred if oxygenation is adequate. safety is unknown, and antifibrotics should be avoided while nursing.
Elderly
IPF is a disease of aging; most patients are diagnosed after age 70, and the incidence rises sharply with each decade [528]D5[57]B2b. Diagnostic challenges in the elderly include the higher prevalence of comorbidities that can mimic or coexist with IPF, such as heart failure and chronic [530]B2b. High-resolution CT often provides a confident diagnosis without surgical lung biopsy, which carries a 30-day mortality of 1.7% overall and higher in patients >75 years [524]B3b[549]B3b.
Comorbidity burden is high: gastroesophageal reflux disease (pooled prevalence 47%), obstructive sleep apnea (up to 88%), pulmonary , and cardiovascular disease are common and independently worsen prognosis [226]B2a[532]B3b[533]D5[555]B3b. Antifibrotic therapy with nintedanib or pirfenidone is safe and effective in patients >80 years, though dose adjustments may be needed for declining renal function (nintedanib is not recommended if creatinine clearance <30 mL/min) [541]B3b[415]D5. Frailty assessment, rather than chronological age alone, should guide treatment intensity and goals of care [415]D5.
Immunocompromised Host
IPF itself is not an immunocompromised state, but patients often have impaired mucociliary clearance and are at increased risk for respiratory infections, which can trigger acute exacerbations [464]D5. Vaccination against influenza, pneumococcus, and SARS-CoV-2 is strongly recommended [458]D5. Although rare cases of acute exacerbation following mRNA vaccination have been reported, the benefit of preventing severe COVID-19 far outweighs this risk [373]C4[374]C4[521]B2b. Patients on immunosuppressive therapy (now discouraged in IPF) require additional vigilance for opportunistic infections.
Prevention
Primary prevention focuses on modifiable risk factors. Smoking cessation is paramount; occupational exposures to metal dust, wood dust, silica, and agriculture increase IPF risk (odds ratio 1.5-2.0 for each) and should be avoided [185]A1a. Long-term exposure to nitrogen dioxide and particulate matter is associated with increased mortality in IPF [525]B2b.
Secondary prevention targets early detection in high-risk groups. First-degree relatives of patients with familial pulmonary fibrosis have a 31% prevalence of interstitial lung abnormalities on CT screening [520]C4. However, routine screening is not yet recommended due to uncertain clinical benefit and potential psychological harm [535]B2b. CT incidentally identifies interstitial lung abnormalities in 1.5% of participants, offering an opportunity for early ILD diagnosis and treatment [536]B3b.
Exacerbation prevention includes consistent use of antifibrotic therapy, which reduces the risk of acute exacerbations by approximately 50% [63]D5. Vaccination and prompt treatment of respiratory infections are critical. The role of proton pump inhibitors for gastroesophageal reflux remains uncertain; a population-based cohort found no mortality benefit with PPI use [519]B2b. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have been associated with slower FVC decline in post-hoc analyses, but prospective data are lacking [76]B2b.
Pearl: In elderly patients with IPF, antifibrotic therapy is safe and effective regardless of age, but comorbidity management and frailty assessment are essential; in children, genetic testing for MARS1 and surfactant mutations should precede treatment decisions, and nintedanib dosing is weight-based [538]B2b[541]B3b[553]D5.
| Population | Diagnostic Modifications | Treatment Modifications | Prognosis |
|---|---|---|---|
| Pediatrics | Genetic testing (MARS1, SFTPC); MDD essential | Nintedanib weight-based (50 mg BID age 6-11; 100 mg BID age 12-17) [538]B2b | Variable; may require transplant |
| Pregnancy | Avoid HRCT if possible; use lung US or low-dose CT | Stop antifibrotics before conception; supportive care only | High risk of maternal decompensation |
| Elderly | HRCT often sufficient; avoid SLB if possible | Standard doses; adjust for renal function; assess frailty [415]D5 | Comorbidity-driven; median survival 3-5 years |
| Immunocompromised | Screen for opportunistic infections | Vaccinate; avoid live vaccines; prompt antibiotic/antiviral therapy | Infection is a common trigger for AE-IPF |
References
- [1]
Raghu G, Remy-Jardin M, Richeldi L et al.. “Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.” American journal of respiratory and critical care medicine (2022). PMID: 35486072 ↗
L2GUIDELINECited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation - [2]
Raghu G, Remy-Jardin M, Myers JL et al.. “Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.” American journal of respiratory and critical care medicine (2018). PMID: 30168753 ↗
L2GUIDELINECited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [3]
Raghu G, Collard HR, Egan JJ et al.. “An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.” American journal of respiratory and critical care medicine (2011). PMID: 21471066 ↗
L2GUIDELINECited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [4]
Travis WD, Costabel U, Hansell DM et al.. “An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.” American journal of respiratory and critical care medicine (2013). PMID: 24032382 ↗
L2GUIDELINECited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History - [5]
Raghu G, Rochwerg B, Zhang Y et al.. “An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.” American journal of respiratory and critical care medicine (2015). PMID: 26177183 ↗
L2GUIDELINECited in: 1. Definition, Classification and Nomenclature - [6]
Hansell DM, Goldin JG, King TE et al.. “CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.” The Lancet. Respiratory medicine (2015). PMID: 25975761 ↗
L2GUIDELINECited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification - [7]
Wells AU, Flaherty KR, Brown KK et al.. “Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.” The Lancet. Respiratory medicine (2020). PMID: 32145830 ↗
L1RCTCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 12. Special Populations and Prevention - [8]
Andrade J, Schwarz M, Collard HR et al.. “The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes.” Chest (2015). PMID: 26111071 ↗
L1RCTCited in: 1. Definition, Classification and Nomenclature, 7. Acute Management and Exacerbation Rescue - [9]
He D, Guler SA, Shannon CP et al.. “Transcriptomics of interstitial lung disease: a systematic review and meta-analysis.” The European respiratory journal (2025). PMID: 39603671 ↗
L2SR_OBSCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification - [10]
Durheim MT, Collard HR, Roberts RS et al.. “Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.” The Lancet. Respiratory medicine (2015). PMID: 25890798 ↗
L2TRIAL_NONRANDOMCited in: 1. Definition, Classification and Nomenclature - [11]
Walsh SLF, Calandriello L, Silva M et al.. “Deep learning for classifying fibrotic lung disease on high-resolution computed tomography: a case-cohort study.” The Lancet. Respiratory medicine (2018). PMID: 30232049 ↗
L3COHORTCited in: 1. Definition, Classification and Nomenclature - [12]
Khor YH, Ng Y, Sweeney D et al.. “Nocturnal hypoxaemia in interstitial lung disease: a systematic review.” Thorax (2021). PMID: 33927018 ↗
L2SR_OBSCited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 10. Complications, 11. Prognosis and Natural History - [13]
Gupta R, Morgan AD, George PM et al.. “Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in England from 2008 to 2018: a cohort study.” Thorax (2024). PMID: 38688708 ↗
L3COHORTCited in: 1. Definition, Classification and Nomenclature - [14]
Wiertz IA, Wuyts WA, van Moorsel CHM et al.. “Unfavourable outcome of glucocorticoid treatment in suspected idiopathic pulmonary fibrosis.” Respirology (Carlton, Vic.) (2017). PMID: 29207437 ↗
L2TRIAL_NONRANDOMCited in: 1. Definition, Classification and Nomenclature - [15]
Collard HR, Ryerson CJ, Corte TJ et al.. “Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.” American journal of respiratory and critical care medicine (2016). PMID: 27299520 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History - [16]
Barnes PJ, Baker J, Donnelly LE. “Cellular Senescence as a Mechanism and Target in Chronic Lung Diseases.” American journal of respiratory and critical care medicine (2019). PMID: 30860857 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism - [17]
Pugashetti JV, Adegunsoye A, Wu Z et al.. “Validation of Proposed Criteria for Progressive Pulmonary Fibrosis.” American journal of respiratory and critical care medicine (2023). PMID: 35943866 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [18]
Dhooria S, Rao H, Gupta N et al.. “Bronchoalveolar Lavage Lymphocytosis and Early Glucocorticoid Response: A Prospective Study of 150 Subjects With Interstitial Lung Disease.” Respirology (Carlton, Vic.) (2025). PMID: 40820187 ↗
L3COHORTCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation - [19]
Lingampally A, Truchi M, Mauduit O et al.. “Evidence for a lipofibroblast-to-Cthrc1 + myofibroblast reversible switch during the development and resolution of lung fibrosis in young mice.” The European respiratory journal (2025). PMID: 39401861 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature - [20]
Clynick B, Corte TJ, Jo HE et al.. “Biomarker signatures for progressive idiopathic pulmonary fibrosis.” The European respiratory journal (2022). PMID: 34675050 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature - [21]
Ryerson CJ, Cottin V, Brown KK et al.. “Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm.” The European respiratory journal (2015). PMID: 26232481 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [22]
Maher TM, Wells AU, Laurent GJ. “Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?” The European respiratory journal (2007). PMID: 17978154 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [23]
Cottin V, Brown K, Flaherty KR et al.. “Progressive pulmonary fibrosis: a state-of-the-art review.” The European respiratory journal (2026). PMID: 42276742 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 10. Complications - [24]
Koether K, Besnard V, Sandig H et al.. “Autoantibodies are associated with disease progression in idiopathic pulmonary fibrosis.” The European respiratory journal (2023). PMID: 37080573 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature - [25]
Chaudhary S, Weigt SS, Ribeiro Neto ML et al.. “Interstitial lung disease progression after genomic usual interstitial pneumonia testing.” The European respiratory journal (2023). PMID: 36549706 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature - [26]
Lynch DA, Sverzellati N, Travis WD et al.. “Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.” The Lancet. Respiratory medicine (2017). PMID: 29154106 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [27]
George PM, Spagnolo P, Kreuter M et al.. “Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities.” The Lancet. Respiratory medicine (2020). PMID: 32890499 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature, 8. Long-term and Definitive Management - [28]
Martinez FJ, Chisholm A, Collard HR et al.. “The diagnosis of idiopathic pulmonary fibrosis: current and future approaches.” The Lancet. Respiratory medicine (2016). PMID: 27932290 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature - [29]
Raghu G, Chen SY, Yeh WS et al.. “Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11.” The Lancet. Respiratory medicine (2014). PMID: 24875841 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature - [30]
Goodwin AT, Jenkins G. “Molecular Endotyping of Pulmonary Fibrosis.” Chest (2016). PMID: 26356594 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [31]
Tzouvelekis A, Gomatou G, Bouros E et al.. “Common Pathogenic Mechanisms Between Idiopathic Pulmonary Fibrosis and Lung Cancer.” Chest (2019). PMID: 31125557 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism - [32]
Park S, Kim MJ, Lee JH et al.. “Quantitative CT Imaging in Progressive Pulmonary Fibrosis: Clinical Usefulness and Meaningful Threshold Definition.” Chest (2025). PMID: 41360185 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature - [33]
Castriotta RJ, Eldadah BA, Foster WM et al.. “Workshop on idiopathic pulmonary fibrosis in older adults.” Chest (2010). PMID: 20822991 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [34]
Inoue Y, Kaner RJ, Guiot J et al.. “Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype.” Chest (2020). PMID: 32268131 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature - [35]
Nathan SD, Shlobin OA, Weir N et al.. “Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium.” Chest (2011). PMID: 21729893 ↗
L4REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 8. Long-term and Definitive Management - [36]
Scotton CJ, Chambers RC. “Molecular targets in pulmonary fibrosis: the myofibroblast in focus.” Chest (2007). PMID: 17934117 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature - [37]
Sotiropoulou V, Sampsonas F, Vasarmidi E et al.. “Design of the MERCURION-IPF trial - intravenous immunoglobulin for the treatment of acute exacerbations of idiopathic pulmonary fibrosis.” Frontiers in immunology (2026). PMID: 42164489 ↗
L1RCTCited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History - [38]
Glassberg MK, Burg C, Pereira-Simon S et al.. “Revisiting the INSPIRE trial: antibody profiling reveals high prevalence of occult autoimmunity.” Respiratory research (2026). PMID: 41559617 ↗
L3RCTCited in: 1. Definition, Classification and Nomenclature, 7. Acute Management and Exacerbation Rescue - [39]
Hewitt RJ, Pearmain L, Lyka E et al.. “Epithelial damage and ageing: the perfect storm.” Thorax (2025). PMID: 40425299 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism - [40]
Mathai SK, Newton CA, Schwartz DA et al.. “Pulmonary fibrosis in the era of stratified medicine.” Thorax (2016). PMID: 27799632 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism - [41]
Leavy OC, Kawano-Dourado L, Stewart ID et al.. “Rheumatoid arthritis and idiopathic pulmonary fibrosis: a bidirectional Mendelian randomisation study.” Thorax (2024). PMID: 38649271 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 12. Special Populations and Prevention - [42]
Byrne AJ, Mathie SA, Gregory LG et al.. “Pulmonary macrophages: key players in the innate defence of the airways.” Thorax (2015). PMID: 26286722 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature - [43]
Shapanis A, Jones MG, Schofield J et al.. “Topological data analysis identifies molecular phenotypes of idiopathic pulmonary fibrosis.” Thorax (2023). PMID: 36808085 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [44]
Wu WH, Bonnet S, Shimauchi T et al.. “Potential for inhibition of checkpoint kinases 1/2 in pulmonary fibrosis and secondary pulmonary hypertension.” Thorax (2021). PMID: 34226205 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature - [45]
Goodwin AT, Dixon G, White LJ et al.. “Protocol for the INterstitial lung Disease EXacerbations (INDEX) Study: a retrospective multicentre cohort study.” BMJ open respiratory research (2026). PMID: 42264883 ↗
L2TRIAL_NONRANDOMCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [46]
Okuda R, Nishioka Y, Kondoh Y et al.. “Pamufetinib (TAS-115) for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A double-blind, multicenter, phase 2b Clinical Trial.” American journal of respiratory and critical care medicine (2026). PMID: 42085242 ↗
L1TRIAL_NONRANDOMCited in: 1. Definition, Classification and Nomenclature, 8. Long-term and Definitive Management - [47]
Alberti ML, Auteri SJ, Rojas-Serrano J et al.. “Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD): An Official 2025 ALAT Clinical Practice Guideline.” Archivos de bronconeumologia (2026). PMID: 42034552 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 12. Special Populations and Prevention - [48]
Simon ST, Higginson IJ, Booth S et al.. “Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults.” The Cochrane database of systematic reviews (2016). PMID: 27764523 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History, 12. Special Populations and Prevention - [49]
White LJ, Shaw J, Powell B et al.. “Mortality and diagnostic practice variation in interstitial lung disease admissions: insights from a multicentre UK cohort study.” BMJ open respiratory research (2026). PMID: 41932816 ↗
L2COHORTCited in: 1. Definition, Classification and Nomenclature, 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 10. Complications - [50]
Brugière O, Hirschi S, Reynaud-Gaubert M et al.. “Nintedanib in progressive bronchiolitis obliterans syndrome (BOS) grade 0p-1-2 in lung transplant recipients (INFINITIx-BOS): protocol of a French multicenter randomized controlled trial.” Trials (2026). PMID: 41964069 ↗
L1TRIAL_NONRANDOMCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [51]
Sgalla G, Biffi A, Richeldi L. “Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history.” Respirology (Carlton, Vic.) (2015). PMID: 26595062 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 11. Prognosis and Natural History - [52]
Skolnik K, Ryerson CJ. “Unclassifiable interstitial lung disease: A review.” Respirology (Carlton, Vic.) (2015). PMID: 26059704 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification - [53]
Margaritopoulos GA, Harari S, Caminati A et al.. “Smoking-related idiopathic interstitial pneumonia: A review.” Respirology (Carlton, Vic.) (2015). PMID: 26138798 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification - [54]
Hambly N, Shimbori C, Kolb M. “Molecular classification of idiopathic pulmonary fibrosis: personalized medicine, genetics and biomarkers.” Respirology (Carlton, Vic.) (2015). PMID: 26109466 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism - [55]
Neurohr C, Behr J. “Changes in the current classification of IIP: A critical review.” Respirology (Carlton, Vic.) (2015). PMID: 26011188 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [56]
Kim JY, Kim J, Choi MG et al.. “Development and Validation of a Clinical Scoring System Predicting 30-Day Mortality in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.” Respirology (Carlton, Vic.) (2025). PMID: 40589236 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [57]
Fan Y, Bao H, Pimple P et al.. “Incidence rate and prevalence of idiopathic pulmonary fibrosis in the United States 2017-2022.” Annals of the American Thoracic Society (2026). PMID: 40986793 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History, 12. Special Populations and Prevention - [58]
Guidot DM, Seaman D, Pleasants RA et al.. “The Epidemiology of Combined Pulmonary Fibrosis and Emphysema among Mid-Atlantic Veterans.” Annals of the American Thoracic Society (2025). PMID: 40388887 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [59]
Pardo A, Selman M. “Lung Fibroblasts, Aging, and Idiopathic Pulmonary Fibrosis.” Annals of the American Thoracic Society (2016). PMID: 28005427 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 6. Severity, Staging and Risk Stratification - [60]
Grant-Orser A, Marinescu DC, Hague CJ et al.. “Clinical and Radiologic Characteristics of Familial Pulmonary Fibrosis.” Annals of the American Thoracic Society (2026). PMID: 42225597 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [61]
Kaul B, Lee JS, Zhang N et al.. “Epidemiology of Idiopathic Pulmonary Fibrosis among U.S. Veterans, 2010-2019.” Annals of the American Thoracic Society (2022). PMID: 34314645 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature - [62]
Courtwright AM, El-Chemaly S. “Telomeres in Interstitial Lung Disease: The Short and the Long of It.” Annals of the American Thoracic Society (2019). PMID: 30540921 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 8. Long-term and Definitive Management - [63]
Richeldi L. “Time for Prevention of Idiopathic Pulmonary Fibrosis Exacerbation.” Annals of the American Thoracic Society (2015). PMID: 26595737 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature, 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 12. Special Populations and Prevention - [64]
Johannson KA, Liu Z, Southern DA et al.. “Incidence, Prevalence, and Mortality of Interstitial Lung Diseases in Alberta, Canada: A Population-based Study.” Annals of the American Thoracic Society (2025). PMID: 40068156 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 8. Long-term and Definitive Management - [65]
Xu L, Zang D, Yan R et al.. “Prevalence of anxiety and depression in idiopathic pulmonary fibrosis: a systematic review and meta-analysis.” BMC pulmonary medicine (2026). PMID: 42271338 ↗
L2SR_OBSCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 12. Special Populations and Prevention - [66]
Evrard O, Philippot Q, Kannengiesser C et al.. “Adult male patients with DKC1 mutations present early-onset pulmonary fibrosis and severe prognosis.” ERJ open research (2026). PMID: 41561101 ↗
L4OTHERCited in: 1. Definition, Classification and Nomenclature, 8. Long-term and Definitive Management - [67]
Moimas S, Salton F, Kosmider B et al.. “miR-200 family members reduce senescence and restore idiopathic pulmonary fibrosis type II alveolar epithelial cell transdifferentiation.” ERJ open research (2019). PMID: 31857992 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature - [68]
Ford P, Kreuter M, Brown KK et al.. “An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis.” ERJ open research (2024). PMID: 38288082 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 10. Complications - [69]
Ngo LT, Rekowski MJ, Koestler DC et al.. “Proteomic profiling of bronchoalveolar lavage fluid uncovers protein clusters linked to survival in idiopathic forms of interstitial lung disease.” ERJ open research (2024). PMID: 39687393 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 11. Prognosis and Natural History - [70]
Gaikwad AV, Lu W, Dey S et al.. “Vascular remodelling in idiopathic pulmonary fibrosis patients and its detrimental effect on lung physiology: potential role of endothelial-to-mesenchymal transition.” ERJ open research (2022). PMID: 35350273 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature - [71]
Swigris J, Cutts K, Male N et al.. “The Living with Pulmonary Fibrosis questionnaire in progressive fibrosing interstitial lung disease.” ERJ open research (2021). PMID: 34046493 ↗
L4OTHERCited in: 1. Definition, Classification and Nomenclature - [72]
Norisue Y, Yamamoto R, Yamakawa H et al.. “Incidence of diffuse parenchymal lung disease in patients meeting the Berlin definition of acute respiratory distress syndrome on mechanical ventilation.” ERJ open research (2025). PMID: 40959165 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [73]
Wang J, Lesko M, Badri MH et al.. “Lung microbiome and host immune tone in subjects with idiopathic pulmonary fibrosis treated with inhaled interferon-γ.” ERJ open research (2017). PMID: 28717640 ↗
L4OTHERCited in: 1. Definition, Classification and Nomenclature - [74]
Birring SS, Wijsenbeek MS, Agrawal S et al.. “A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.” The Lancet. Respiratory medicine (2017). PMID: 28923239 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation - [75]
Raghu G, Brown KK, Collard HR et al.. “Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.” The Lancet. Respiratory medicine (2016). PMID: 27939076 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 12. Special Populations and Prevention - [76]
Kreuter M, Lederer DJ, Molina-Molina M et al.. “Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis.” Chest (2019). PMID: 31047956 ↗
L2RCTCited in: 2. Pathophysiology and Mechanism, 12. Special Populations and Prevention - [77]
Kolb M, Raghu G, Wells AU et al.. “Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.” The New England journal of medicine (2018). PMID: 30220235 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [78]
Zisman DA, Schwarz M, Anstrom KJ et al.. “A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.” The New England journal of medicine (2010). PMID: 20484178 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [79]
Han MK, Zhou Y, Murray S et al.. “Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study.” The Lancet. Respiratory medicine (2014). PMID: 24767767 ↗
L2TRIAL_NONRANDOMCited in: 2. Pathophysiology and Mechanism, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [80]
Allen RJ, Oldham JM, Jenkins DA et al.. “Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study.” The Lancet. Respiratory medicine (2022). PMID: 35985358 ↗
L1SR_OBSCited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 11. Prognosis and Natural History - [81]
O'Riordan TG, Smith V, Raghu G. “Development of novel agents for idiopathic pulmonary fibrosis: progress in target selection and clinical trial design.” Chest (2015). PMID: 26020856 ↗
L5TRIAL_NONRANDOMCited in: 2. Pathophysiology and Mechanism - [82]
Blackwell TS, Hewlett JC, Mason WR et al.. “A Phase I Randomized, Controlled, Clinical Trial of Valganciclovir in Idiopathic Pulmonary Fibrosis.” Annals of the American Thoracic Society (2021). PMID: 33740394 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [83]
Mooney JJ, Jacobs S, Lefebvre ÉA et al.. “Bexotegrast Shows Dose-Dependent Integrin αvβ6 Receptor Occupancy in Lungs of Participants with Idiopathic Pulmonary Fibrosis: A Phase 2, Open-Label Clinical Trial.” Annals of the American Thoracic Society (2025). PMID: 39499805 ↗
L2TRIAL_NONRANDOMCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation - [84]
Reyfman PA, Walter JM, Joshi N et al.. “Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis.” American journal of respiratory and critical care medicine (2019). PMID: 30554520 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism - [85]
Adegunsoye A, Kropski JA, Behr J et al.. “Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine.” American journal of respiratory and critical care medicine (2024). PMID: 38573068 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [86]
Xie N, Tan Z, Banerjee S et al.. “Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis.” American journal of respiratory and critical care medicine (2015). PMID: 26284610 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism - [87]
Cui H, Xie N, Banerjee S et al.. “CD38 Mediates Lung Fibrosis by Promoting Alveolar Epithelial Cell Aging.” American journal of respiratory and critical care medicine (2022). PMID: 35687485 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism - [88]
Khanna D, Tashkin DP, Denton CP et al.. “Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.” American journal of respiratory and critical care medicine (2020). PMID: 31841044 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [89]
Carraro G, Mulay A, Yao C et al.. “Single-Cell Reconstruction of Human Basal Cell Diversity in Normal and Idiopathic Pulmonary Fibrosis Lungs.” American journal of respiratory and critical care medicine (2020). PMID: 32692579 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism - [90]
Yanagihara T, Tsubouchi K, Zhou Q et al.. “Vascular-Parenchymal Cross-Talk Promotes Lung Fibrosis through BMPR2 Signaling.” American journal of respiratory and critical care medicine (2023). PMID: 36917778 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management, 10. Complications - [91]
Izuhara K, Conway SJ, Moore BB et al.. “Roles of Periostin in Respiratory Disorders.” American journal of respiratory and critical care medicine (2016). PMID: 26756066 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [92]
Kim JS, Loe A, Ma SF et al.. “Gut microbiota associate with disease severity and survival in idiopathic pulmonary fibrosis.” American journal of respiratory and critical care medicine (2026). PMID: 42155010 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism - [93]
Morse C, Tabib T, Sembrat J et al.. “Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis.” The European respiratory journal (2019). PMID: 31221805 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism - [94]
Wollin L, Wex E, Pautsch A et al.. “Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.” The European respiratory journal (2015). PMID: 25745043 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management - [95]
Wang J, Lai X, Yao S et al.. “Nestin promotes pulmonary fibrosis via facilitating recycling of TGF-β receptor I.” The European respiratory journal (2022). PMID: 34625478 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism - [96]
Guo Y, Wang Q, Zhang Y et al.. “Rbms1 promotes pulmonary fibrosis by stabilising Sumo2 mRNA to facilitate Smad4-SUMOylation and fibroblast activation.” The European respiratory journal (2025). PMID: 40473311 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [97]
Meiners S, Eickelberg O, Königshoff M. “Hallmarks of the ageing lung.” The European respiratory journal (2015). PMID: 25657021 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [98]
Sack C, Raghu G. “Idiopathic pulmonary fibrosis: unmasking cryptogenic environmental factors.” The European respiratory journal (2019). PMID: 30487201 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 11. Prognosis and Natural History - [99]
Dancer RC, Wood AM, Thickett DR. “Metalloproteinases in idiopathic pulmonary fibrosis.” The European respiratory journal (2011). PMID: 21700608 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [100]
Wang Y, Zhang L, Huang T et al.. “The methyl-CpG-binding domain 2 facilitates pulmonary fibrosis by orchestrating fibroblast to myofibroblast differentiation.” The European respiratory journal (2022). PMID: 35086828 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism, 12. Special Populations and Prevention - [101]
Grimminger F, Günther A, Vancheri C. “The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis.” The European respiratory journal (2015). PMID: 25745048 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [102]
Spagnolo P, Grunewald J, du Bois RM. “Genetic determinants of pulmonary fibrosis: evolving concepts.” The Lancet. Respiratory medicine (2014). PMID: 24815806 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [103]
Wolters PJ, Blackwell TS, Eickelberg O et al.. “Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?” The Lancet. Respiratory medicine (2018). PMID: 29413083 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [104]
Wuyts WA, Antoniou KM, Borensztajn K et al.. “Combination therapy: the future of management for idiopathic pulmonary fibrosis?” The Lancet. Respiratory medicine (2014). PMID: 25439569 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [105]
Dressen A, Abbas AR, Cabanski C et al.. “Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study.” The Lancet. Respiratory medicine (2018). PMID: 29891356 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism - [106]
Kubo H. “Extracellular Vesicles in Lung Disease.” Chest (2017). PMID: 28684288 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [107]
Zhang D, Newton CA. “Familial Pulmonary Fibrosis: Genetic Features and Clinical Implications.” Chest (2021). PMID: 34186035 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 6. Severity, Staging and Risk Stratification - [108]
Strieter RM, Mehrad B. “New mechanisms of pulmonary fibrosis.” Chest (2009). PMID: 19892675 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [109]
Hanumegowda C, Farkas L, Kolb M. “Angiogenesis in pulmonary fibrosis: too much or not enough?” Chest (2012). PMID: 22796840 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 10. Complications - [110]
Azadeh N, Limper AH, Carmona EM et al.. “The Role of Infection in Interstitial Lung Diseases: A Review.” Chest (2017). PMID: 28400116 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [111]
Kumar A, Cherian SV, Vassallo R et al.. “Current Concepts in Pathogenesis, Diagnosis, and Management of Smoking-Related Interstitial Lung Diseases.” Chest (2017). PMID: 29222007 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 12. Special Populations and Prevention - [112]
Chunyan G, Fengshuang W, Mei L et al.. “Efficacy of pulmonary rehabilitation combined with minimal-dose adjunctive TCM (Shen Yi Capsules and Hua Chan Su) in improving postoperative outcomes for non-small cell lung cancer: a randomized controlled trial.” Frontiers in medicine (2026). PMID: 42169794 ↗
L4RCTCited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [113]
Nathan SD, Smith P, Deng C et al.. “Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.” The New England journal of medicine (2026). PMID: 41812190 ↗
L1OTHERCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [114]
Nathan SD, Smith P, Deng C et al.. “Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.” The New England journal of medicine (2026). PMID: 42149993 ↗
L1OTHERCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History - [115]
Seibold MA, Wise AL, Speer MC et al.. “A common MUC5B promoter polymorphism and pulmonary fibrosis.” The New England journal of medicine (2011). PMID: 21506741 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism - [116]
Armanios MY, Chen JJ, Cogan JD et al.. “Telomerase mutations in families with idiopathic pulmonary fibrosis.” The New England journal of medicine (2007). PMID: 17392301 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism - [117]
Hoo ZH, Whyte MK. “Idiopathic pulmonary fibrosis.” Thorax (2011). PMID: 21697287 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History - [118]
Short KL, O'Malley D, Hoyne G et al.. “Breaking with convention: the role of lymphocytes in IPF.” Thorax (2026). PMID: 42161595 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 10. Complications - [119]
Baarsma HA, Königshoff M. “'WNT-er is coming': WNT signalling in chronic lung diseases.” Thorax (2017). PMID: 28416592 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [120]
Kraven LM, Taylor AR, Molyneaux PL et al.. “Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis.” Thorax (2022). PMID: 35534152 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism - [121]
José RJ, Williams AE, Chambers RC. “Proteinase-activated receptors in fibroproliferative lung disease.” Thorax (2013). PMID: 24186921 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism - [122]
Furusawa H, Peljto AL, Walts AD et al.. “Common idiopathic pulmonary fibrosis risk variants are associated with hypersensitivity pneumonitis.” Thorax (2022). PMID: 34996848 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism - [123]
Jenkins G, Blanchard A, Borok Z et al.. “In search of the fibrotic epithelial cell: opportunities for a collaborative network.” Thorax (2011). PMID: 21680569 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism - [124]
Borie R, Justet A, Beltramo G et al.. “Pharmacological management of IPF.” Respirology (Carlton, Vic.) (2016). PMID: 27072575 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 10. Complications, 11. Prognosis and Natural History - [125]
de Boer K, Lee JS. “Under-recognised co-morbidities in idiopathic pulmonary fibrosis: A review.” Respirology (Carlton, Vic.) (2015). PMID: 26365251 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History, 12. Special Populations and Prevention - [126]
Huang J, Liu N, Jin Y et al.. “Add-On Dextromethorphan Improves the Effects of Pirfenidone in Bleomycin-Treated Mice and Patients With Pulmonary Fibrosis.” Respirology (Carlton, Vic.) (2025). PMID: 40223283 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [127]
Mora AL, Rojas M. “Adult stem cells for chronic lung diseases.” Respirology (Carlton, Vic.) (2013). PMID: 23648014 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [128]
Kim HS, Yoo HJ, Lee KM et al.. “Stearic acid attenuates profibrotic signalling in idiopathic pulmonary fibrosis.” Respirology (Carlton, Vic.) (2020). PMID: 33025706 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management - [129]
Moodley Y, Corte T, Richeldi L et al.. “Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.” Respirology (Carlton, Vic.) (2015). PMID: 25727967 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [130]
Zhao Y, Shi Y, Zhang J et al.. “The potential lipid biomarker 5-HETE for acute exacerbation identified by metabolomics in patients with idiopathic pulmonary fibrosis.” Respirology (Carlton, Vic.) (2024). PMID: 39681341 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [131]
Planas-Cerezales L, Arias-Salgado EG, Buendia-Roldán I et al.. “Predictive factors and prognostic effect of telomere shortening in pulmonary fibrosis.” Respirology (Carlton, Vic.) (2018). PMID: 30320420 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism - [132]
Moodley YP, Corte TJ, Oliver BG et al.. “Analysis by proteomics reveals unique circulatory proteins in idiopathic pulmonary fibrosis.” Respirology (Carlton, Vic.) (2019). PMID: 31393655 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism - [133]
Whitsett JA. “Airway Epithelial Differentiation and Mucociliary Clearance.” Annals of the American Thoracic Society (2018). PMID: 30431340 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation - [134]
Rangarajan S, Bernard K, Thannickal VJ. “Mitochondrial Dysfunction in Pulmonary Fibrosis.” Annals of the American Thoracic Society (2017). PMID: 29161077 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [135]
Lee AS, Lee JS, He Z et al.. “Reflux-Aspiration in Chronic Lung Disease.” Annals of the American Thoracic Society (2020). PMID: 31697575 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation - [136]
Yang IV, Fingerlin TE, Evans CM et al.. “MUC5B and Idiopathic Pulmonary Fibrosis.” Annals of the American Thoracic Society (2015). PMID: 26595739 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 12. Special Populations and Prevention - [137]
Moore BB, Moore TA. “Viruses in Idiopathic Pulmonary Fibrosis. Etiology and Exacerbation.” Annals of the American Thoracic Society (2015). PMID: 26595738 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 6. Severity, Staging and Risk Stratification, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History - [138]
Lehmann M, Baarsma HA, Königshoff M. “WNT Signaling in Lung Aging and Disease.” Annals of the American Thoracic Society (2016). PMID: 28005418 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [139]
Rojas M, Mora AL, Kapetanaki M et al.. “Aging and Lung Disease. Clinical Impact and Cellular and Molecular Pathways.” Annals of the American Thoracic Society (2015). PMID: 26653202 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [140]
Mondoni M, Rinaldo R, Ryerson CJ et al.. “Vascular involvement in idiopathic pulmonary fibrosis.” ERJ open research (2024). PMID: 39588083 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 10. Complications, 11. Prognosis and Natural History - [141]
Pianigiani T, Dilroba A, Gambini C et al.. “Beyond inflammation: alarmins as critical drivers of pulmonary fibrosis.” ERJ open research (2026). PMID: 41809871 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [142]
Kortekaas RK, Geillinger-Kästle KE, Borghuis T et al.. “Interleukin-11 disrupts alveolar epithelial progenitor function.” ERJ open research (2023). PMID: 37228276 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism - [143]
Kulkarni T, Santiaguel J, Aul R et al.. “Deupirfenidone (LYT-100) in post-acute sequelae of SARS-CoV-2 with respiratory complications.” ERJ open research (2025). PMID: 40692836 ↗
L1OTHERCited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 10. Complications - [144]
Smith DJF, Teng NMY, Denneny EK et al.. “The respiratory microbiome in patients with post-COVID-19 residual lung abnormalities resembles that of healthy individuals and is distinct from idiopathic pulmonary fibrosis.” ERJ open research (2025). PMID: 40432814 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism - [145]
Guillen-Guio B, Paynton ML, Allen RJ et al.. “Association study of human leukocyte antigen variants and idiopathic pulmonary fibrosis.” ERJ open research (2024). PMID: 38375425 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism - [146]
Yamamoto Y, Miki K, Tsujino K et al.. “Oscillometry and computed tomography findings in patients with idiopathic pulmonary fibrosis.” ERJ open research (2020). PMID: 33344627 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism - [147]
Araújo M, Beltrão M, Sokhatska O et al.. “Serum metalloproteinase-7 as a biomarker of progressive pulmonary fibrosis.” ERJ open research (2024). PMID: 39655167 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism - [148]
Pastré J, Salvator H, Henno P et al.. “Clinical relevance of microvascular endothelial dysfunction in idiopathic pulmonary fibrosis.” ERJ open research (2025). PMID: 41122421 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue - [149]
Kewalramani N, Machahua C, Poletti V et al.. “Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges.” ERJ open research (2022). PMID: 35747227 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [150]
Ren Y, Gao J, Shen K et al.. “SPP1 and MMP1 as key therapeutic targets of Jingfang Granule in idiopathic pulmonary fibrosis: integrated bioinformatics and machine learning analysis.” Frontiers in pharmacology (2026). PMID: 42358366 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism - [151]
Grunert M, Horn V, Baudrexl JC et al.. “Assessment of active fibrotic remodeling in patients with idiopathic pulmonary fibrosis (IPF)/progressive pulmonary fibrosis (PPF) using dual-time-point [68Ga]Ga-FAPI-46-PET/CT.” European journal of radiology (2026). PMID: 42349073 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 8. Long-term and Definitive Management - [152]
Schratz KE, Armanios M. “Disorders of Telomere Length.” NEJM evidence (2026). PMID: 42334294 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [153]
Tabib T, Ezenwa O, Sciurba J et al.. “Comparative transcriptional profiling of key macrophage and fibroblast subpopulations in rheumatoid arthritis-associated lung disease.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 42328894 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism - [154]
Chen X, Chen S, Zhao S et al.. “Identification of potential therapeutic targets for idiopathic pulmonary fibrosis: an integrated multiomics analysis.” Frontiers in immunology (2026). PMID: 42327717 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management - [155]
Koo HK, An TJ, Joo H et al.. “Exploring cough hypersensitivity patterns across respiratory diseases.” Respiratory medicine (2026). PMID: 42323027 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism - [156]
Shao Y, Zhang J, Liu H et al.. “CAV1-dependent mitochondrial transfer from hucMSCs reprograms epithelial lipid metabolism to relieve pulmonary fibrosis.” Stem cell research & therapy (2026). PMID: 42321819 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism - [157]
Li S, Cai B, Zhang X et al.. “S100A4 Orchestrates Fibroblast Fate to Drive Fibrotic Remodeling.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2026). PMID: 42287596 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism - [158]
Corte TJ, Behr J, Cottin V et al.. “Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.” American journal of respiratory and critical care medicine (2025). PMID: 39393084 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [159]
Lancaster L, Cottin V, Ramaswamy M et al.. “Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial.” American journal of respiratory and critical care medicine (2024). PMID: 38843105 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [160]
Otsubo K, Kishimoto J, Ando M et al.. “Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.” The European respiratory journal (2022). PMID: 35361630 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History - [161]
Raghu G, Ghazipura M, Fleming TR et al.. “Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency.” American journal of respiratory and critical care medicine (2024). PMID: 38174955 ↗
L5TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification - [162]
Naccache JM, Jouneau S, Didier M et al.. “Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial.” The Lancet. Respiratory medicine (2021). PMID: 34506761 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History - [163]
Maher TM, Goldin JG, Hood J et al.. “Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial.” The Lancet. Respiratory medicine (2025). PMID: 41043447 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [164]
Troy LK, Grainge C, Corte TJ et al.. “Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study.” The Lancet. Respiratory medicine (2019). PMID: 31578168 ↗
L2RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History, 12. Special Populations and Prevention - [165]
Behr J, Nathan SD, Wuyts WA et al.. “Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.” The Lancet. Respiratory medicine (2020). PMID: 32822614 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue, 10. Complications, 12. Special Populations and Prevention - [166]
Dowman LM, Vainshelboim B, Holland AE. “Impact of Pulmonary Rehabilitation on Survival in People With Interstitial Lung Disease.” Chest (2025). PMID: 39805518 ↗
L2RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [167]
Kim JS, Murray S, Yow E et al.. “Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study.” Chest (2023). PMID: 38030064 ↗
L2RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [168]
Kreuter M, Maher TM, Wuyts WA et al.. “Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis.” Chest (2025). PMID: 40210090 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History - [169]
Hutchinson J, Fogarty A, Hubbard R et al.. “Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.” The European respiratory journal (2015). PMID: 25976683 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [170]
Richeldi L, Costabel U, Selman M et al.. “Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.” The New England journal of medicine (2011). PMID: 21992121 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [171]
Nathan SD, Albera C, Bradford WZ et al.. “Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.” The Lancet. Respiratory medicine (2016). PMID: 27876247 ↗
L1TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [172]
West A, Chaudhuri N, Barczyk A et al.. “Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial.” Thorax (2023). PMID: 36948586 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [173]
Wang T, Duan W, Jia X et al.. “Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study.” The European respiratory journal (2024). PMID: 38061785 ↗
L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors - [174]
Petnak T, Lertjitbanjong P, Thongprayoon C et al.. “Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.” Chest (2021). PMID: 34217681 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History - [175]
Sheng G, Chen P, Wei Y et al.. “Viral Infection Increases the Risk of Idiopathic Pulmonary Fibrosis: A Meta-Analysis.” Chest (2019). PMID: 31730835 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History - [176]
Bédard Méthot D, Leblanc É, Lacasse Y. “Meta-analysis of Gastroesophageal Reflux Disease and Idiopathic Pulmonary Fibrosis.” Chest (2018). PMID: 30120950 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors - [177]
Canestaro WJ, Forrester SH, Raghu G et al.. “Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.” Chest (2016). PMID: 26836914 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification - [178]
Maher TM, Oballa E, Simpson JK et al.. “An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study.” The Lancet. Respiratory medicine (2017). PMID: 29150411 ↗
L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors - [179]
Kawano-Dourado L, Kulkarni T, Ryerson CJ et al.. “Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases.” Thorax (2024). PMID: 38448221 ↗
L1TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [180]
Srivali N, De Giacomi F, Moua T et al.. “Corticosteroid therapy for treating acute exacerbation of interstitial lung diseases: a systematic review.” Thorax (2025). PMID: 39721758 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History, 12. Special Populations and Prevention - [181]
Lee CT, Gandhi SA, Elmrayed S et al.. “Inhalational exposures associated with risk of interstitial lung disease: a systematic review and meta-analysis.” Thorax (2025). PMID: 40518258 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [182]
Pitre T, Mah J, Helmeczi W et al.. “Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis.” Thorax (2022). PMID: 35145039 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History - [183]
Ikeda S, Ogura T, Kato T et al.. “Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis.” Annals of the American Thoracic Society (2024). PMID: 38364204 ↗
L1TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History - [184]
Ghazipura M, Mammen MJ, Herman DD et al.. “Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.” Annals of the American Thoracic Society (2022). PMID: 35499854 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [185]
Gandhi SA, Min B, Fazio JC et al.. “The Impact of Occupational Exposures on the Risk of Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.” Annals of the American Thoracic Society (2024). PMID: 38096107 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 12. Special Populations and Prevention - [186]
Ghazipura M, Mammen MJ, Bissell BD et al.. “Pirfenidone in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.” Annals of the American Thoracic Society (2022). PMID: 35499847 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [187]
Brown SW, Dobelle M, Padilla M et al.. “Idiopathic Pulmonary Fibrosis and Lung Cancer. A Systematic Review and Meta-analysis.” Annals of the American Thoracic Society (2019). PMID: 30892054 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [188]
Randall MJ, Andersen CA, Brown KK et al.. “Prognostic biomarkers for idiopathic pulmonary fibrosis: findings from ISABELA clinical trials.” ERJ open research (2026). PMID: 41704719 ↗
L2TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [189]
Oldham JM, Huang Y, Bose S et al.. “Proteomic Biomarkers of Survival in Idiopathic Pulmonary Fibrosis.” American journal of respiratory and critical care medicine (2024). PMID: 37847691 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [190]
Ley B, Collard HR, King TE. “Clinical course and prediction of survival in idiopathic pulmonary fibrosis.” American journal of respiratory and critical care medicine (2010). PMID: 20935110 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History - [191]
Yang P, Luo Q, Wang X et al.. “Comprehensive Analysis of Fibroblast Activation Protein Expression in Interstitial Lung Diseases.” American journal of respiratory and critical care medicine (2023). PMID: 35984444 ↗
L3OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 11. Prognosis and Natural History - [192]
O'Dwyer DN, Ashley SL, Gurczynski SJ et al.. “Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis.” American journal of respiratory and critical care medicine (2019). PMID: 30789747 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification - [193]
Zheng Q, Cox IA, Campbell JA et al.. “Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis.” ERJ open research (2022). PMID: 35295232 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [194]
Podolanczuk AJ, Thomson CC, Remy-Jardin M et al.. “Idiopathic pulmonary fibrosis: state of the art for 2023.” The European respiratory journal (2023). PMID: 36702498 ↗
L5OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 8. Long-term and Definitive Management, 10. Complications, 11. Prognosis and Natural History - [195]
Guan R, Yuan L, Li J et al.. “Bone morphogenetic protein 4 inhibits pulmonary fibrosis by modulating cellular senescence and mitophagy in lung fibroblasts.” The European respiratory journal (2022). PMID: 35777761 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [196]
Cui F, Sun Y, Xie J et al.. “Air pollutants, genetic susceptibility and risk of incident idiopathic pulmonary fibrosis.” The European respiratory journal (2023). PMID: 36137588 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management - [197]
Hambly N, Farooqi MM, Dvorkin-Gheva A et al.. “Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.” The European respiratory journal (2022). PMID: 35273032 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 8. Long-term and Definitive Management - [198]
Selman M, Buendia-Roldan I, Pardo A. “Decoding the complexity: mechanistic insights into comorbidities in idiopathic pulmonary fibrosis.” The European respiratory journal (2025). PMID: 40180336 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 10. Complications, 12. Special Populations and Prevention - [199]
Weng C, Zhao Y, Song M et al.. “Mosaic loss of chromosome Y, tobacco smoking and risk of age-related lung diseases: insights from two prospective cohorts.” The European respiratory journal (2024). PMID: 39401857 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors - [200]
Yoon HY, Kim H, Bae Y et al.. “Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study.” The European respiratory journal (2025). PMID: 39510556 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification - [201]
Spagnolo P, Guler SA, Chaudhuri N et al.. “Global epidemiology and burden of interstitial lung disease.” The Lancet. Respiratory medicine (2025). PMID: 40684782 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [202]
George PM, Patterson CM, Reed AK et al.. “Lung transplantation for idiopathic pulmonary fibrosis.” The Lancet. Respiratory medicine (2019). PMID: 30738856 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 10. Complications - [203]
Fainberg HP, Moodley Y, Triguero I et al.. “Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation.” The Lancet. Respiratory medicine (2024). PMID: 39025091 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management - [204]
Agarwala P, Salzman SH. “Six-Minute Walk Test: Clinical Role, Technique, Coding, and Reimbursement.” Chest (2019). PMID: 31689414 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications, 11. Prognosis and Natural History - [205]
Ryerson CJ, Vittinghoff E, Ley B et al.. “Predicting survival across chronic interstitial lung disease: the ILD-GAP model.” Chest (2014). PMID: 24114524 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [206]
Oldham JM, Neely ML, Wojdyla DM et al.. “Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis.” Chest (2025). PMID: 40020995 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [207]
Juge PA, Lee JS, Ebstein E et al.. “MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.” The New England journal of medicine (2018). PMID: 30345907 ↗
L3OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [208]
Hunninghake GM, Hatabu H, Okajima Y et al.. “MUC5B promoter polymorphism and interstitial lung abnormalities.” The New England journal of medicine (2013). PMID: 23692170 ↗
L3OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation - [209]
Xu J, Liu X, Liang X et al.. “Comparative efficacy and safety of monotherapy and combination pharmacotherapies for idiopathic pulmonary fibrosis: a network meta-analysis of randomized controlled trials.” BMC pulmonary medicine (2026). PMID: 42115887 ↗
L1SR_MA_RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [210]
Moss ST, Minelli C, Leavy OC et al.. “Assessing causal relationships between diabetes mellitus and idiopathic pulmonary fibrosis: a Mendelian randomisation study.” Thorax (2025). PMID: 39613458 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors - [211]
Karayama M, Miyashita K, Inoue Y et al.. “Survival benefit of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung diseases: a nationwide population-based study.” Thorax (2026). PMID: 41093568 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [212]
Kim JS, Pugashetti J, Ma SF et al.. “Associations of interstitial lung disease subtype and CT pattern with lung function and survival.” Thorax (2025). PMID: 40484639 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [213]
Dhooria S, Inoue Y, Rathi K et al.. “Global perspective on pulmonary fibrosis: epidemiology, regional variations, gaps in care and future directions.” Thorax (2026). PMID: 41802847 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 8. Long-term and Definitive Management - [214]
Yoon HY, Oh JH, Choi WI et al.. “Impact of indoor exposure to particulate matter on the progression of idiopathic pulmonary fibrosis: a prospective multicentre cohort study protocol.” BMJ open respiratory research (2026). PMID: 42303311 ↗
L2TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [215]
Kim K, Seok J, Yoon HY. “Association between smoking and prognosis in idiopathic pulmonary fibrosis: A systematic review and meta-analysis.” Pulmonology (2026). PMID: 42339520 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History - [216]
Kola N, Parker R, Hall A et al.. “Outcomes of invasive mechanical ventilation in critically ill patients with interstitial lung disease: protocol for a systematic review and meta-analysis.” BMJ open (2026). PMID: 42259559 ↗
L5SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications, 11. Prognosis and Natural History - [217]
Zou Y, Zhang L, Li Y et al.. “Life's Essential 8 and the incidence and progression trajectory of chronic lung diseases: A multistate analysis of a prospective cohort study.” Chinese medical journal (2026). PMID: 42218565 ↗
L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History, 12. Special Populations and Prevention - [218]
Ma S, Liu Y, Wang Z et al.. “Occupational physical workload and risk of lung cancer and chronic respiratory diseases: a prospective cohort study of the UK Biobank.” Translational lung cancer research (2026). PMID: 42170266 ↗
L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification - [219]
Nambiar S, Bong How S, Gummer J et al.. “Metabolomics in chronic lung diseases.” Respirology (Carlton, Vic.) (2019). PMID: 30907495 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors - [220]
Belloli EA, Beckford R, Hadley R et al.. “Idiopathic non-specific interstitial pneumonia.” Respirology (Carlton, Vic.) (2015). PMID: 26564810 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [221]
Jacob J, Hansell DM. “HRCT of fibrosing lung disease.” Respirology (Carlton, Vic.) (2015). PMID: 25900734 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [222]
Ibarra-Fernández AA, Robles-Hernández R, Orea-Tejeda A et al.. “Dynapenia and Sarcopenia as Risk Factors for Mortality in Interstitial Lung Disease.” Respirology (Carlton, Vic.) (2025). PMID: 39905591 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [223]
Smith DJF, Jenkins RG. “Contemporary Concise Review 2022: Interstitial lung disease.” Respirology (Carlton, Vic.) (2023). PMID: 37121779 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [224]
Li RM, Tan DBA, Tedja C et al.. “Pre-Treatment MMP7 Predicts Progressive Idiopathic Pulmonary Fibrosis in Antifibrotic Treated Patients.” Respirology (Carlton, Vic.) (2025). PMID: 39919729 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [225]
Brown AW, Kaya H, Nathan SD. “Lung transplantation in IIP: A review.” Respirology (Carlton, Vic.) (2015). PMID: 26635297 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 10. Complications, 11. Prognosis and Natural History - [226]
Li M, Yang J, Li H et al.. “Prevalence of Gastroesophageal reflux disease in patients with Idiopathic pulmonary fibrosis: a systematic review and meta-analysis.” BMC pulmonary medicine (2026). PMID: 42252392 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 12. Special Populations and Prevention - [227]
Kreuter M, Belloli EA, Bendstrup E et al.. “Acute exacerbations in patients with progressive pulmonary fibrosis.” ERJ open research (2024). PMID: 39624387 ↗
L1OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History - [228]
Leavy OC, Goemans AF, Hernandez-Beeftink T et al.. “Sex-specific genetic effects on susceptibility to idiopathic pulmonary fibrosis.” ERJ open research (2025). PMID: 41031098 ↗
L3OTHERCited in: 3. Epidemiology, Etiology and Risk Factors - [229]
Harada K, Nishimura Y, Vu QT et al.. “Global trends in idiopathic pulmonary fibrosis mortality rates during 2001-2022.” ERJ open research (2025). PMID: 41333986 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [230]
Todd JL, Page C, Wu P et al.. “Circulating prostasin is an independent marker of mortality risk in patients with idiopathic pulmonary fibrosis.” ERJ open research (2025). PMID: 40551789 ↗
L3OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification - [231]
Sokai A, Tanizawa K, Handa T et al.. “Asymmetry in acute exacerbation of idiopathic pulmonary fibrosis.” ERJ open research (2017). PMID: 28828379 ↗
L4OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [232]
Montesi SB, Cosgrove GP, Turner SM et al.. “Dual αvβ6 and αvβ1 Inhibition over 12 Weeks Reduces Active Type I Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinical Trial.” American journal of respiratory and critical care medicine (2025). PMID: 40153543 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue - [233]
Moor CC, Mostard RLM, Grutters JC et al.. “Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial.” American journal of respiratory and critical care medicine (2020). PMID: 32325005 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue - [234]
Wijsenbeek M, Swigris JJ, Inoue Y et al.. “Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis.” The European respiratory journal (2024). PMID: 38135442 ↗
L1RCTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [235]
Brown KK. “Chronic cough due to chronic interstitial pulmonary diseases: ACCP evidence-based clinical practice guidelines.” Chest (2006). PMID: 16428708 ↗
L1GUIDELINECited in: 4. Clinical Presentation - [236]
Raghu G, Collard HR, Anstrom KJ et al.. “Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.” American journal of respiratory and critical care medicine (2012). PMID: 22505745 ↗
L5TRIAL_NONRANDOMCited in: 4. Clinical Presentation - [237]
Nathan SD, Waxman A, Rajagopal S et al.. “Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.” The Lancet. Respiratory medicine (2021). PMID: 34214475 ↗
L2RCTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 10. Complications - [238]
Wu Z, Spencer LG, Banya W et al.. “Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial.” The Lancet. Respiratory medicine (2024). PMID: 38237620 ↗
L1RCTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [239]
Behr J, Bendstrup E, Crestani B et al.. “Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.” The Lancet. Respiratory medicine (2016). PMID: 27161257 ↗
L1RCTCited in: 4. Clinical Presentation - [240]
King TE, Bradford WZ, Castro-Bernardini S et al.. “A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.” The New England journal of medicine (2014). PMID: 24836312 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [241]
Dowman LM, McDonald CF, Hill CJ et al.. “The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial.” Thorax (2017). PMID: 28213592 ↗
L1RCTCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 10. Complications - [242]
Dutta P, Funston W, Mossop H et al.. “Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis.” Thorax (2019). PMID: 30610155 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue - [243]
Holland AE, Hill CJ, Conron M et al.. “Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease.” Thorax (2008). PMID: 18245143 ↗
L1RCTCited in: 4. Clinical Presentation - [244]
Birring SS, Kavanagh JE, Irwin RS et al.. “Treatment of Interstitial Lung Disease Associated Cough: CHEST Guideline and Expert Panel Report.” Chest (2018). PMID: 30036496 ↗
L1SR_OBSCited in: 4. Clinical Presentation - [245]
Morell F, Villar A, Montero MÁ et al.. “Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study.” The Lancet. Respiratory medicine (2013). PMID: 24429272 ↗
L2COHORTCited in: 4. Clinical Presentation - [246]
Scott MKD, Quinn K, Li Q et al.. “Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study.” The Lancet. Respiratory medicine (2019). PMID: 30935881 ↗
L2COHORTCited in: 4. Clinical Presentation - [247]
Saketkoo LA, Mittoo S, Huscher D et al.. “Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials.” Thorax (2013). PMID: 24368713 ↗
L5TRIAL_NONRANDOMCited in: 4. Clinical Presentation - [248]
Kalluri M, Sahn SA, Oddis CV et al.. “Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature.” Chest (2009). PMID: 19225060 ↗
L4COHORTCited in: 4. Clinical Presentation - [249]
Guler SA, Clarenbach C, Brutsche M et al.. “Azithromycin for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis: A Randomized Controlled Crossover Trial.” Annals of the American Thoracic Society (2021). PMID: 34015241 ↗
L1RCTCited in: 4. Clinical Presentation - [250]
Enomoto N, Homma S, Inase N et al.. “Prospective nationwide multicentre cohort study of the clinical significance of autoimmune features in idiopathic interstitial pneumonias.” Thorax (2021). PMID: 34272335 ↗
L2COHORTCited in: 4. Clinical Presentation - [251]
Klingsberg RC, Mutsaers SE, Lasky JA. “Current clinical trials for the treatment of idiopathic pulmonary fibrosis.” Respirology (Carlton, Vic.) (2010). PMID: 20199632 ↗
L5TRIAL_NONRANDOMCited in: 4. Clinical Presentation - [252]
Khor YH, Bissell B, Ghazipura M et al.. “Antacid Medication and Antireflux Surgery in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.” Annals of the American Thoracic Society (2022). PMID: 35486080 ↗
L1SR_OBSCited in: 4. Clinical Presentation, 10. Complications - [253]
Navaratnam V, Fogarty AW, McKeever T et al.. “Presence of a prothrombotic state in people with idiopathic pulmonary fibrosis: a population-based case-control study.” Thorax (2013). PMID: 24002055 ↗
L3CASE_CONTROLCited in: 4. Clinical Presentation - [254]
Newton CA, Thenappan A, Liu GY et al.. “Performance Characteristics for Physiological Measures of Progressive Pulmonary Fibrosis.” American journal of respiratory and critical care medicine (2025). PMID: 40530983 ↗
L2OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [255]
Putman RK, Rosas IO, Hunninghake GM. “Genetics and early detection in idiopathic pulmonary fibrosis.” American journal of respiratory and critical care medicine (2014). PMID: 24547893 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation - [256]
Khor YH, Johannson KA, Marcoux V et al.. “Epidemiology and Prognostic Significance of Cough in Fibrotic Interstitial Lung Disease.” American journal of respiratory and critical care medicine (2024). PMID: 38536110 ↗
L2OTHERCited in: 4. Clinical Presentation - [257]
Ghebre YT, Raghu G. “Idiopathic Pulmonary Fibrosis: Novel Concepts of Proton Pump Inhibitors as Antifibrotic Drugs.” American journal of respiratory and critical care medicine (2016). PMID: 27110898 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 10. Complications - [258]
Althobiani MA, Evans RA, Alqahtani JS et al.. “Home monitoring of physiology and symptoms to detect interstitial lung disease exacerbations and progression: a systematic review.” ERJ open research (2021). PMID: 34938799 ↗
L5SR_OBSCited in: 4. Clinical Presentation, 10. Complications - [259]
Prêle CM, Miles T, Pearce DR et al.. “Plasma cell but not CD20-mediated B-cell depletion protects from bleomycin-induced lung fibrosis.” The European respiratory journal (2022). PMID: 35798357 ↗
L5OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 10. Complications - [260]
Allen RJ, Guillen-Guio B, Croot E et al.. “Genetic overlap between idiopathic pulmonary fibrosis and COVID-19.” The European respiratory journal (2022). PMID: 35595312 ↗
L5OTHERCited in: 4. Clinical Presentation - [261]
Moor CC, Mostard RLM, Grutters JC et al.. “The use of online visual analogue scales in idiopathic pulmonary fibrosis.” The European respiratory journal (2022). PMID: 34326190 ↗
L5OTHERCited in: 4. Clinical Presentation - [262]
Kam MLW, Tjong ELH, Chaudhary S et al.. “Development and validation of a clinical, CT, genomic classifier and BAL scoring system for diagnosing idiopathic pulmonary fibrosis.” The European respiratory journal (2025). PMID: 39819571 ↗
L2OTHERCited in: 4. Clinical Presentation - [263]
Johannson KA, Strâmbu I, Ravaglia C et al.. “Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?” The Lancet. Respiratory medicine (2017). PMID: 28664861 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation - [264]
George PM, Wells AU, Jenkins RG. “Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy.” The Lancet. Respiratory medicine (2020). PMID: 32422178 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 8. Long-term and Definitive Management - [265]
Wakwaya Y, Ramdurai D, Swigris JJ. “Managing Cough in Idiopathic Pulmonary Fibrosis.” Chest (2021). PMID: 34171385 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation - [266]
Hyzy R, Huang S, Myers J et al.. “Acute exacerbation of idiopathic pulmonary fibrosis.” Chest (2007). PMID: 17998366 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [267]
Zhang D, Eckhardt CM, McGroder C et al.. “Clinical Impact of Telomere Length Testing for Interstitial Lung Disease.” Chest (2024). PMID: 38950694 ↗
L2OTHERCited in: 4. Clinical Presentation - [268]
Adegunsoye A, Vij R, Noth I. “Integrating Genomics Into Management of Fibrotic Interstitial Lung Disease.” Chest (2019). PMID: 30660786 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation - [269]
Mermigkis C, Bouloukaki I, Schiza SE. “Sleep as a New Target for Improving Outcomes in Idiopathic Pulmonary Fibrosis.” Chest (2017). PMID: 28774636 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation - [270]
Molyneaux PL, Mogulkoc N, Gunen H et al.. “Oral Nalbuphine in Idiopathic Pulmonary Fibrosis-Associated Cough: The CORAL Randomized Clinical Trial.” JAMA (2026). PMID: 41569557 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue - [271]
Bradding P, Wulff H. “Ion channels.” Thorax (2013). PMID: 23564342 ↗
L5OTHERCited in: 4. Clinical Presentation - [272]
Milger K, Yu Y, Brudy E et al.. “Pulmonary CCR2+CD4+ T cells are immune regulatory and attenuate lung fibrosis development.” Thorax (2017). PMID: 28780502 ↗
L5OTHERCited in: 4. Clinical Presentation - [273]
Dowman L, Hill CJ, May A et al.. “Pulmonary rehabilitation for interstitial lung disease.” The Cochrane database of systematic reviews (2021). PMID: 34559419 ↗
L1SR_OBSCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [274]
Holland A, Hill C. “Physical training for interstitial lung disease.” The Cochrane database of systematic reviews (2008). PMID: 18843713 ↗
L1SR_OBSCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [275]
Dowman L, Hill CJ, Holland AE. “Pulmonary rehabilitation for interstitial lung disease.” The Cochrane database of systematic reviews (2014). PMID: 25284270 ↗
L1SR_OBSCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History - [276]
Simon ST, Higginson IJ, Booth S et al.. “Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults.” The Cochrane database of systematic reviews (2010). PMID: 20091630 ↗
L1SR_OBSCited in: 4. Clinical Presentation, 10. Complications, 12. Special Populations and Prevention - [277]
Taniguchi H, Kondoh Y. “Acute and subacute idiopathic interstitial pneumonias.” Respirology (Carlton, Vic.) (2016). PMID: 27123874 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History - [278]
Cottin V. “Idiopathic interstitial pneumonias with connective tissue diseases features: A review.” Respirology (Carlton, Vic.) (2015). PMID: 26212251 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation - [279]
Ryerson CJ, Abbritti M, Ley B et al.. “Cough predicts prognosis in idiopathic pulmonary fibrosis.” Respirology (Carlton, Vic.) (2011). PMID: 21615619 ↗
L2OTHERCited in: 4. Clinical Presentation, 8. Long-term and Definitive Management - [280]
Vicary GW, Vergne Y, Santiago-Cornier A et al.. “Pulmonary Fibrosis in Hermansky-Pudlak Syndrome.” Annals of the American Thoracic Society (2016). PMID: 27529121 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [281]
DeDent AM, Collard HR, Thakur N. “Neighborhood Health and Outcomes in Idiopathic Pulmonary Fibrosis.” Annals of the American Thoracic Society (2024). PMID: 37962494 ↗
L3OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification - [282]
Sack C, Wojdyla DM, MacMurdo MG et al.. “Long-Term Air Pollution Exposure and Severity of Idiopathic Pulmonary Fibrosis: Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry.” Annals of the American Thoracic Society (2025). PMID: 39531618 ↗
L2OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [283]
Faverio P, Fumagalli A, Conti S et al.. “Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study.” ERJ open research (2022). PMID: 35265706 ↗
L2OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [284]
Rist C, Karlsson N, Necander S et al.. “Physical activity end-points in trials of chronic respiratory diseases: summary of evidence.” ERJ open research (2022). PMID: 35295234 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation - [285]
Raman L, Stewart I, Barratt SL et al.. “Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study.” ERJ open research (2023). PMID: 36949962 ↗
L3OTHERCited in: 4. Clinical Presentation - [286]
Davidsen JR, Lund LC, Laursen CB et al.. “Dynamics in diagnoses and pharmacotherapy before and after diagnosing idiopathic pulmonary fibrosis.” ERJ open research (2020). PMID: 33263059 ↗
L2OTHERCited in: 4. Clinical Presentation - [287]
Bordas-Martínez J, Gavaldà R, Shull JG et al.. “Idiopathic pulmonary fibrosis cluster analysis highlights diagnostic delay and cardiovascular comorbidity association with outcome.” ERJ open research (2021). PMID: 33981766 ↗
L3OTHERCited in: 4. Clinical Presentation, 12. Special Populations and Prevention - [288]
Eaden JA, Weatherley ND, Chan HF et al.. “Hyperpolarised xenon-129 diffusion-weighted magnetic resonance imaging for assessing lung microstructure in idiopathic pulmonary fibrosis.” ERJ open research (2023). PMID: 37650085 ↗
L2OTHERCited in: 4. Clinical Presentation - [289]
Yu Q, Pu J, Cao F et al.. “The Association Between Depression and Idiopathic Pulmonary Fibrosis: A Prospective Study in the UK Biobank.” Journal of epidemiology and global health (2026). PMID: 41903003 ↗
L2COHORTCited in: 4. Clinical Presentation - [290]
Zhou X, Zhao L, Ma W et al.. “Nintedanib combined with anticoagulant therapy in advanced lung cancer complicated with pulmonary fibrosis and pulmonary embolism: two case reports and clinical decision-making analysis.” Frontiers in cardiovascular medicine (2026). PMID: 42039347 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation - [291]
Frei-Stuber L, Mohren J, Mau E et al.. “Severe Occupational Hypersensitivity Pneumonitis: A Case Series of Four Patients Requiring Lung Transplantation.” American journal of industrial medicine (2026). PMID: 41845945 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 10. Complications - [292]
Erten HÇ, Cömert SŞ, Doğruyol T et al.. “Risk factors, clinical features, and impact on survival of lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective study.” Medicine (2026). PMID: 41686545 ↗
L3COHORTCited in: 4. Clinical Presentation - [293]
Rowland SD, Sharpe H, Ferrara G et al.. “Education needs in oxygen therapy for individuals with interstitial lung disease.” BMJ open respiratory research (2026). PMID: 42342293 ↗
L5OTHERCited in: 4. Clinical Presentation, 8. Long-term and Definitive Management - [294]
Yan B, Liu N, Zhou Y et al.. “Patient experiences of idiopathic pulmonary fibrosis (IPF) in China: a multicentre qualitative study.” BMJ open respiratory research (2026). PMID: 42342290 ↗
L5OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [295]
Koo HK, An TJ, Joo H et al.. “Clinical validation of the Rapid Cough Questionnaire across diverse lung diseases.” BMJ open respiratory research (2026). PMID: 42331391 ↗
L2OTHERCited in: 4. Clinical Presentation - [296]
Flaherty KR, Wells AU, Cottin V et al.. “Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial.” The European respiratory journal (2022). PMID: 34475231 ↗
L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 12. Special Populations and Prevention - [297]
Bermudo-Peloche G, Del Rio B, Vicens-Zygmunt V et al.. “Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial.” The European respiratory journal (2025). PMID: 40154560 ↗
L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [298]
Deterding RR, DeBoer EM, Cidon MJ et al.. “Approaching Clinical Trials in Childhood Interstitial Lung Disease and Pediatric Pulmonary Fibrosis.” American journal of respiratory and critical care medicine (2019). PMID: 31322415 ↗
L5TRIAL_NONRANDOMCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 12. Special Populations and Prevention - [299]
Behr J, Prasse A, Kreuter M et al.. “Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.” The Lancet. Respiratory medicine (2021). PMID: 33798455 ↗
L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [300]
Maher TM, van der Aar EM, Van de Steen O et al.. “Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial.” The Lancet. Respiratory medicine (2018). PMID: 29792287 ↗
L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [301]
Flaherty KR, Wells AU, Cottin V et al.. “Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.” The New England journal of medicine (2019). PMID: 31566307 ↗
L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [302]
Maher TM, Assassi S, Azuma A et al.. “Nerandomilast in Patients with Progressive Pulmonary Fibrosis.” The New England journal of medicine (2025). PMID: 40388329 ↗
L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [303]
Martinez FJ, de Andrade JA, Anstrom KJ et al.. “Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.” The New England journal of medicine (2014). PMID: 24836309 ↗
L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History - [304]
Verleden SE, Tanabe N, McDonough JE et al.. “Small airways pathology in idiopathic pulmonary fibrosis: a retrospective cohort study.” The Lancet. Respiratory medicine (2020). PMID: 32061334 ↗
L3COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management - [305]
Alonso-González A, Jáspez D, Lorenzo-Salazar JM et al.. “Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation.” The Lancet. Respiratory medicine (2025). PMID: 40311650 ↗
L2COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 11. Prognosis and Natural History - [306]
Duckworth A, Jackson L, Green H et al.. “Polygenic risk and rare variants in endotypes of idiopathic pulmonary fibrosis: a genetic analysis of population-based and case-control cohorts.” The Lancet. Respiratory medicine (2026). PMID: 41616791 ↗
L3CASE_CONTROLCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [307]
Kheir F, Uribe Becerra JP, Bissell B et al.. “Transbronchial Lung Cryobiopsy in Patients with Interstitial Lung Disease: A Systematic Review.” Annals of the American Thoracic Society (2022). PMID: 35499855 ↗
L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 10. Complications, 11. Prognosis and Natural History - [308]
Patolia S, Tamae Kakazu M, Chami HA et al.. “Bronchoalveolar Lavage Lymphocytes in the Diagnosis of Hypersensitivity Pneumonitis among Patients with Interstitial Lung Disease.” Annals of the American Thoracic Society (2020). PMID: 32757946 ↗
L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [309]
Jones S, Flewett M, Flewett R et al.. “Clinical trial simulations in pulmonary fibrosis: patient-focused insights and adaptations.” ERJ open research (2023). PMID: 37260456 ↗
L5TRIAL_NONRANDOMCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [310]
Yao C, Guan X, Carraro G et al.. “Senescence of Alveolar Type 2 Cells Drives Progressive Pulmonary Fibrosis.” American journal of respiratory and critical care medicine (2021). PMID: 32991815 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [311]
Huang Y, Ma SF, Oldham JM et al.. “Machine Learning of Plasma Proteomics Classifies Diagnosis of Interstitial Lung Disease.” American journal of respiratory and critical care medicine (2024). PMID: 38422478 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [312]
Culver DA, Behr J, Belperio JA et al.. “Patient Registries in Idiopathic Pulmonary Fibrosis.” American journal of respiratory and critical care medicine (2019). PMID: 31034241 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [313]
Molyneaux PL, Willis-Owen SAG, Cox MJ et al.. “Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis.” American journal of respiratory and critical care medicine (2017). PMID: 28085486 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [314]
Zhao A, Gudmundsson E, Mogulkoc N et al.. “Mortality surrogates in combined pulmonary fibrosis and emphysema.” The European respiratory journal (2024). PMID: 37973176 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [315]
Patel NM, Lederer DJ, Borczuk AC et al.. “Pulmonary hypertension in idiopathic pulmonary fibrosis.” Chest (2007). PMID: 17873194 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 10. Complications - [316]
Doyle TJ, Dellaripa PF. “Lung Manifestations in the Rheumatic Diseases.” Chest (2017). PMID: 28552544 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [317]
Imai R, Bermea RS, Zhao SH et al.. “Association of Anti-Ro52 Seropositive Interstitial Lung Disease With a Higher Risk of Disease Progression and Mortality.” Chest (2025). PMID: 40484372 ↗
L3OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [318]
Bush A, Cunningham S, de Blic J et al.. “European protocols for the diagnosis and initial treatment of interstitial lung disease in children.” Thorax (2015). PMID: 26135832 ↗
L1REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [319]
Njock MS, Guiot J, Henket MA et al.. “Sputum exosomes: promising biomarkers for idiopathic pulmonary fibrosis.” Thorax (2018). PMID: 30244194 ↗
L3OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [320]
Weatherley ND, Eaden JA, Stewart NJ et al.. “Experimental and quantitative imaging techniques in interstitial lung disease.” Thorax (2019). PMID: 30886067 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 8. Long-term and Definitive Management, 10. Complications - [321]
Gompelmann D, Gysan MR, Desbordes P et al.. “AI-powered evaluation of lung function for diagnosis of interstitial lung disease.” Thorax (2025). PMID: 40081903 ↗
L3OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [322]
Tikellis G, Corte TJ, Hey-Cunningham AJ et al.. “Top 10 research priorities for pulmonary fibrosis in Australia: an update.” Thorax (2025). PMID: 41062279 ↗
L5OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [323]
Assayag D, Morisset J, Johannson KA et al.. “Patient gender bias on the diagnosis of idiopathic pulmonary fibrosis.” Thorax (2020). PMID: 32054644 ↗
L3OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [324]
Weatherley ND, Eaden JA, Hughes PJC et al.. “Quantification of pulmonary perfusion in idiopathic pulmonary fibrosis with first pass dynamic contrast-enhanced perfusion MRI.” Thorax (2020). PMID: 33273022 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [325]
Spagnolo P, Del Giovane C, Luppi F et al.. “Non-steroid agents for idiopathic pulmonary fibrosis.” The Cochrane database of systematic reviews (2010). PMID: 20824834 ↗
L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 11. Prognosis and Natural History - [326]
Silva IS, Pedrosa R, Azevedo IG et al.. “Respiratory muscle training in children and adults with neuromuscular disease.” The Cochrane database of systematic reviews (2019). PMID: 31487757 ↗
L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 10. Complications, 11. Prognosis and Natural History - [327]
Shin H, Yang K, Yoo H et al.. “Prospective study of proton beam therapy for non-small cell lung cancer patients with idiopathic pulmonary fibrosis.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2026). PMID: 42314836 ↗
L2COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 11. Prognosis and Natural History - [328]
Humphries SM, Mackintosh JA, Jo HE et al.. “Quantitative computed tomography predicts outcomes in idiopathic pulmonary fibrosis.” Respirology (Carlton, Vic.) (2022). PMID: 35875881 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [329]
Kalafatis D, Joshua V, Hansson M et al.. “Presence of anti-modified protein antibodies in idiopathic pulmonary fibrosis.” Respirology (Carlton, Vic.) (2023). PMID: 37376768 ↗
L3OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [330]
Platenburg MGJP, Nakshbandi G, Moor CC et al.. “Lung Function Course of Patients With Pulmonary Fibrosis After Initiation of Anti-Fibrotic Treatment: Real-World Data From the Dutch National Registry.” Respirology (Carlton, Vic.) (2025). PMID: 40122143 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [331]
Schwartz DA. “Idiopathic Pulmonary Fibrosis Is a Genetic Disease Involving Mucus and the Peripheral Airways.” Annals of the American Thoracic Society (2018). PMID: 30431344 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [332]
Brown AW, Nathan SD. “The Value and Application of the 6-Minute-Walk Test in Idiopathic Pulmonary Fibrosis.” Annals of the American Thoracic Society (2018). PMID: 28933948 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [333]
Wang BR, Edwards R, Freiheit EA et al.. “The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods.” Annals of the American Thoracic Society (2020). PMID: 32776789 ↗
L5OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [334]
Yan RN, Hu HY, Ma ZR et al.. “A systematic review of artificial intelligence-based diagnosis models for idiopathic pulmonary fibrosis.” Journal of thoracic disease (2026). PMID: 42306685 ↗
L5SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [335]
Wijsenbeek MS, Bonella F, Orsatti L et al.. “Communicating with patients with idiopathic pulmonary fibrosis: can we do it better?” ERJ open research (2022). PMID: 35083325 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [336]
Wuyts WA, Bonella F, Ishii H et al.. “Design of a phase II randomised, double-blind, placebo-controlled, dose-finding trial of BI 1819479 in patients with idiopathic pulmonary fibrosis.” ERJ open research (2026). PMID: 41846682 ↗
L5OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History, 12. Special Populations and Prevention - [337]
Nakshbandi G, Moor CC, Magrì T et al.. “Online home spirometry in national pulmonary fibrosis care: insights from daily practice.” ERJ open research (2025). PMID: 40989781 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [338]
Behr J, Kreuter M, Guenther AU et al.. “Real-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry.” ERJ open research (2025). PMID: 40491463 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 8. Long-term and Definitive Management - [339]
Delameillieure A, Wuyts WA, Pironet A et al.. “Electronically monitored medication adherence in idiopathic pulmonary fibrosis: prevalence, predictors and outcomes.” ERJ open research (2022). PMID: 35923422 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [340]
Goda S, Yamada T, Goto Y et al.. “Efficacy and safety of nintedanib for older adults with idiopathic pulmonary fibrosis or progressive fibrosing interstitial lung disease: A multicenter retrospective study in Japan.” Respiratory investigation (2026). PMID: 42247823 ↗
L2COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [341]
Hou Y, Peng J, Liu W et al.. “Development of a dual-mode immunoassay kit for periostin detection in exhaled breath condensate using α-NaYF4@ZIF-67 core-shell nanostructures.” Biosensors & bioelectronics (2026). PMID: 42341698 ↗
L5OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function and Imaging Anchored) - [342]
Raghu G, Amatto VC, Behr J et al.. “Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review.” The European respiratory journal (2015). PMID: 26424523 ↗
L2SR_OBSCited in: 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History - [343]
Richeldi L, du Bois RM, Raghu G et al.. “Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.” The New England journal of medicine (2014). PMID: 24836310 ↗
L1RCTCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History - [344]
Distler O, Highland KB, Gahlemann M et al.. “Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.” The New England journal of medicine (2019). PMID: 31112379 ↗
L1RCTCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [345]
Aktan R, Tertemiz KC, Yiğit S et al.. “Effects of home-based telerehabilitation-assisted inspiratory muscle training in patients with idiopathic pulmonary fibrosis: A randomized controlled trial.” Respirology (Carlton, Vic.) (2024). PMID: 39129185 ↗
L1RCTCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [346]
Ghanem M, Archer G, Justet A et al.. “FGF21 Signaling Exerts Antifibrotic Properties during Pulmonary Fibrosis.” American journal of respiratory and critical care medicine (2025). PMID: 39637324 ↗
L5OTHERCited in: 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management - [347]
Zhu J, Wang Y, Liu H et al.. “Early-Life Exposure to Tobacco Smoke and the Risk of Idiopathic Pulmonary Fibrosis: A Population-Based Cohort Study.” Annals of the American Thoracic Society (2025). PMID: 39879538 ↗
L2COHORTCited in: 6. Severity, Staging and Risk Stratification - [348]
Song S, Fu Z, Guan R et al.. “Intracellular hydroxyproline imprinting following resolution of bleomycin-induced pulmonary fibrosis.” The European respiratory journal (2022). PMID: 34561295 ↗
L5OTHERCited in: 6. Severity, Staging and Risk Stratification - [349]
Raghu G, Ley B, Brown KK et al.. “Risk factors for disease progression in idiopathic pulmonary fibrosis.” Thorax (2019). PMID: 31611341 ↗
L2OTHERCited in: 6. Severity, Staging and Risk Stratification - [350]
Guillen-Guio B, Marcelino-Rodriguez I, Lorenzo-Salazar JM et al.. “Polygenic risk of idiopathic pulmonary fibrosis and COVID-19 severity.” ERJ open research (2025). PMID: 40247961 ↗
L3OTHERCited in: 6. Severity, Staging and Risk Stratification, 10. Complications - [351]
Oldham JM, Azuma A, Kreuter M et al.. “Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial.” American journal of respiratory and critical care medicine (2026). PMID: 41738262 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [352]
Richeldi L, Schiffman C, Behr J et al.. “Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial.” American journal of respiratory and critical care medicine (2024). PMID: 38354066 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue - [353]
Swaminathan AC, Snyder LD, Hong H et al.. “External Control Arms in Idiopathic Pulmonary Fibrosis Using Clinical Trial and Real-World Data Sources.” American journal of respiratory and critical care medicine (2023). PMID: 37384378 ↗
L3RCTCited in: 7. Acute Management and Exacerbation Rescue - [354]
Newton CA, Zhang D, Oldham JM et al.. “Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis.” American journal of respiratory and critical care medicine (2019). PMID: 30566847 ↗
L3RCTCited in: 7. Acute Management and Exacerbation Rescue - [355]
Taniguchi H, Ebina M, Kondoh Y et al.. “Pirfenidone in idiopathic pulmonary fibrosis.” The European respiratory journal (2009). PMID: 19996196 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [356]
Nathan SD, Gao J, Kim HC et al.. “Development and validation of a predictive 6-min walk score in patients with idiopathic pulmonary fibrosis.” The European respiratory journal (2025). PMID: 40610052 ↗
L4RCTCited in: 7. Acute Management and Exacerbation Rescue - [357]
Strambu IR, Seemayer CA, Fagard LMA et al.. “GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial.” The European respiratory journal (2023). PMID: 36328358 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue - [358]
Raghu G, Nathan SD, Behr J et al.. “Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction.” The European respiratory journal (2015). PMID: 26250495 ↗
L4RCTCited in: 7. Acute Management and Exacerbation Rescue, 10. Complications - [359]
Sakamoto S, Kataoka K, Kondoh Y et al.. “Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial.” The European respiratory journal (2021). PMID: 32703779 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [360]
Crestani B, Huggins JT, Kaye M et al.. “Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.” The Lancet. Respiratory medicine (2018). PMID: 30224318 ↗
L4RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [361]
Richeldi L, Fernández Pérez ER, Costabel U et al.. “Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.” The Lancet. Respiratory medicine (2019). PMID: 31575509 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue - [362]
Raghu G, van den Blink B, Hamblin MJ et al.. “Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.” The Lancet. Respiratory medicine (2019). PMID: 31122893 ↗
L4RCTCited in: 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 10. Complications - [363]
Collard HR, Anstrom KJ, Schwarz MI et al.. “Sildenafil improves walk distance in idiopathic pulmonary fibrosis.” Chest (2007). PMID: 17356110 ↗
L4RCTCited in: 7. Acute Management and Exacerbation Rescue, 10. Complications - [364]
Richeldi L, Azuma A, Cottin V et al.. “Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.” The New England journal of medicine (2025). PMID: 40387033 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [365]
Richeldi L, Azuma A, Cottin V et al.. “Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.” The New England journal of medicine (2022). PMID: 35569036 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [366]
Raghu G, Anstrom KJ, King TE et al.. “Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.” The New England journal of medicine (2012). PMID: 22607134 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [367]
Kataoka K, Nishiyama O, Ogura T et al.. “Long-term effect of pulmonary rehabilitation in idiopathic pulmonary fibrosis: a randomised controlled trial.” Thorax (2023). PMID: 37012071 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [368]
Kreuter M, Bonella F, Maher TM et al.. “Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis.” Thorax (2016). PMID: 27708114 ↗
L4RCTCited in: 7. Acute Management and Exacerbation Rescue - [369]
Shulgina L, Cahn AP, Chilvers ER et al.. “Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial.” Thorax (2012). PMID: 23143842 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [370]
Kolb M, Richeldi L, Behr J et al.. “Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.” Thorax (2016). PMID: 27672117 ↗
L4TRIAL_NONRANDOMCited in: 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [371]
Arai T, Kida H, Ogata Y et al.. “Recombinant thrombomodulin for acute exacerbation in idiopathic interstitial pneumonias.” Respirology (Carlton, Vic.) (2019). PMID: 30835911 ↗
L3RCTCited in: 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [372]
Lasky JA, Case A, Unterman A et al.. “The Impact of the Envisia Genomic Classifier in the Diagnosis and Management of Patients with Idiopathic Pulmonary Fibrosis.” Annals of the American Thoracic Society (2022). PMID: 34889723 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue - [373]
Ghincea A, Ryu C, Herzog EL. “An Acute Exacerbation of Idiopathic Pulmonary Fibrosis After BNT162b2 mRNA COVID-19 Vaccination: A Case Report.” Chest (2022). PMID: 35131075 ↗
L4CASE_REPORTCited in: 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 12. Special Populations and Prevention - [374]
Bando T, Takei R, Mutoh Y et al.. “Acute exacerbation of idiopathic pulmonary fibrosis after SARS-CoV-2 vaccination.” The European respiratory journal (2022). PMID: 35144990 ↗
L4OTHERCited in: 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 12. Special Populations and Prevention - [375]
Hu X, Lee JS, Pianosi PT et al.. “Aspiration-related pulmonary syndromes.” Chest (2015). PMID: 25732447 ↗
L5OTHERCited in: 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [376]
Chi E, Holland AE, Hill CJ et al.. “Validation and minimum important difference of the chronic respiratory disease questionnaire in patients with interstitial lung disease.” Respiratory medicine (2026). PMID: 42067073 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue - [377]
Khor YH, Palm A, Wong AW et al.. “Effects of long-term oxygen therapy on acute exacerbation and hospital burden: the national DISCOVERY study.” Thorax (2025). PMID: 40113248 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 10. Complications - [378]
Cho SJ, Moon JS, Nikahira K et al.. “GLUT1-dependent glycolysis regulates exacerbation of fibrosis via AIM2 inflammasome activation.” Thorax (2019). PMID: 31822523 ↗
L5OTHERCited in: 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [379]
Kulkarni T, Funke-Chambour M, Jones S et al.. “Challenging the status quo for therapeutic clinical trials in fibrotic interstitial lung diseases.” Thorax (2026). PMID: 41932836 ↗
L5TRIAL_NONRANDOMCited in: 7. Acute Management and Exacerbation Rescue, 10. Complications - [380]
Mondoni M, Albrici C, Puci MV et al.. “Outcomes of patients with acute exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids: a systematic review and meta-analysis.” Respiratory research (2026). PMID: 41957608 ↗
L1SR_OBSCited in: 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [381]
Sharp C, Adamali H, Millar AB. “Ambulatory and short-burst oxygen for interstitial lung disease.” The Cochrane database of systematic reviews (2016). PMID: 27383922 ↗
L1SR_OBSCited in: 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 11. Prognosis and Natural History - [382]
Yoon HY, Kim SY, Park SW et al.. “Association between air pollution and health outcomes in patients with IPF: A nationwide multicenter cohort study.” Environmental pollution (Barking, Essex : 1987) (2026). PMID: 41747851 ↗
L2COHORTCited in: 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [383]
Tikellis G, Corte TJ, Teoh AKY et al.. “Barriers and facilitators to best care for idiopathic pulmonary fibrosis in Australia.” Respirology (Carlton, Vic.) (2021). PMID: 34783108 ↗
L3OTHERCited in: 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [384]
Zhao J, Fares J, George G et al.. “Racial and ethnic disparities in antifibrotic therapy in idiopathic pulmonary fibrosis.” Respirology (Carlton, Vic.) (2023). PMID: 37534632 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [385]
Tsubouchi K, Yanagihara T, Kiyomi F et al.. “Association Between Single Nucleotide Polymorphisms and Disease Susceptibility, Survival, and Acute Exacerbation in Idiopathic Pulmonary Fibrosis.” Respirology (Carlton, Vic.) (2025). PMID: 40887773 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [386]
Suzuki A, Kondoh Y, Brown KK et al.. “Acute exacerbations of fibrotic interstitial lung diseases.” Respirology (Carlton, Vic.) (2019). PMID: 31426125 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [387]
Arcadu A, Moua T. “Bronchoscopy assessment of acute respiratory failure in interstitial lung disease.” Respirology (Carlton, Vic.) (2016). PMID: 27712021 ↗
L3OTHERCited in: 7. Acute Management and Exacerbation Rescue - [388]
Clark KP, Nouraie SM, Lindell KO et al.. “A Ramped Treadmill Protocol Exercise Test Identifies Higher Ambulatory Oxygen Needs in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2025). PMID: 39565187 ↗
L3OTHERCited in: 7. Acute Management and Exacerbation Rescue - [389]
Salisbury ML, Conoscenti CS, Culver DA et al.. “Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry.” Annals of the American Thoracic Society (2020). PMID: 32574517 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [390]
Crothers K, Adams SV, Turner AP et al.. “COVID-19 Severity and Mortality in Veterans with Chronic Lung Disease.” Annals of the American Thoracic Society (2024). PMID: 38530061 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue - [391]
Saleem F, Ryerson CJ, Sarma N et al.. “Predicting New-onset Exertional and Resting Hypoxemia in Fibrotic Interstitial Lung Disease.” Annals of the American Thoracic Society (2023). PMID: 37676933 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [392]
Cottin V, Crestani B, Planès C et al.. “Design of PROGRESSION-IPF: A pragmatic, open-label, randomized trial of patients with progressive disease in idiopathic pulmonary fibrosis.” Respiratory medicine and research (2026). PMID: 42025256 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue - [393]
Archontakis Barakakis P, Wolfe A, Schwartz A et al.. “Supplementary oxygen efficacy for chronic pulmonary disorders and exertion desaturation.” ERJ open research (2024). PMID: 39655174 ↗
L1OTHERCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [394]
Isshiki T, Shimizu H, Sakamoto S et al.. “Serum autotaxin levels in chronic disease and acute exacerbation of fibrosing interstitial lung disease.” ERJ open research (2022). PMID: 35415191 ↗
L3OTHERCited in: 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [395]
Dotan Y, Shapiro WB, Male E et al.. “Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis.” ERJ open research (2020). PMID: 33043049 ↗
L3OTHERCited in: 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [396]
Blanc K, Bonnet N, Ouedraogo E et al.. “Interstitial lung disease-related pneumomediastinum in COVID-19 patients.” ERJ open research (2021). PMID: 33718492 ↗
L5OTHERCited in: 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [397]
Awano N, Jo T, Yasunaga H et al.. “Body mass index and in-hospital mortality in patients with acute exacerbation of idiopathic pulmonary fibrosis.” ERJ open research (2021). PMID: 34195254 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [398]
Margaritopoulos GA, Proklou A, Trachalaki A et al.. “Overnight desaturation in interstitial lung diseases: links to pulmonary vasculopathy and mortality.” ERJ open research (2024). PMID: 38348245 ↗
L3OTHERCited in: 7. Acute Management and Exacerbation Rescue - [399]
Chandel A, King CS, Ignacio RV et al.. “External validation and longitudinal application of the DO-GAP index to individualise survival prediction in idiopathic pulmonary fibrosis.” ERJ open research (2023). PMID: 37228268 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue - [400]
Kijlertsuphasri S, Petnak T, Moua T. “Antifibrotic therapy and lung cancer risk in patients with idiopathic pulmonary fibrosis: a large retrospective propensity-weighted cohort study.” Thorax (2026). PMID: 41571308 ↗
L2COHORTCited in: 8. Long-term and Definitive Management - [401]
Valeyre D, Albera C, Bradford WZ et al.. “Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.” Respirology (Carlton, Vic.) (2014). PMID: 24836849 ↗
L1SR_OBSCited in: 8. Long-term and Definitive Management - [402]
Kotloff RM, Thabut G. “Lung transplantation.” American journal of respiratory and critical care medicine (2011). PMID: 21471083 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management, 10. Complications - [403]
Ahangari F, Becker C, Foster DG et al.. “Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis.” American journal of respiratory and critical care medicine (2022). PMID: 35998281 ↗
L2OTHERCited in: 8. Long-term and Definitive Management - [404]
Thillai M, Oldham JM, Ruggiero A et al.. “Deep Learning-based Segmentation of Computed Tomography Scans Predicts Disease Progression and Mortality in Idiopathic Pulmonary Fibrosis.” American journal of respiratory and critical care medicine (2024). PMID: 38452227 ↗
L2OTHERCited in: 8. Long-term and Definitive Management - [405]
Tsoyi K, Liang X, De Rossi G et al.. “CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis.” American journal of respiratory and critical care medicine (2021). PMID: 33784491 ↗
L2OTHERCited in: 8. Long-term and Definitive Management - [406]
Maddali MV, Moore AR, Sinha P et al.. “Molecular Endotypes of Idiopathic Pulmonary Fibrosis: A Latent Class Analysis of Two Multicenter Observational Cohorts.” American journal of respiratory and critical care medicine (2024). PMID: 38913573 ↗
L2OTHERCited in: 8. Long-term and Definitive Management - [407]
Oldham JM, Allen RJ, Lorenzo-Salazar JM et al.. “PCSK6 and Survival in Idiopathic Pulmonary Fibrosis.” American journal of respiratory and critical care medicine (2023). PMID: 36780644 ↗
L2OTHERCited in: 8. Long-term and Definitive Management - [408]
Wang S, Niroula S, Hoffman A et al.. “Inflammatory Activity of Epithelial Stem Cell Variants from Cystic Fibrosis Lungs Is Not Resolved by CFTR Modulators.” American journal of respiratory and critical care medicine (2023). PMID: 37695863 ↗
L2OTHERCited in: 8. Long-term and Definitive Management - [409]
Nathan SD, Kim HC, King CS et al.. “Serial Pulmonary Hemodynamics in Patients with Idiopathic Pulmonary Fibrosis Listed for Lung Transplant.” American journal of respiratory and critical care medicine (2025). PMID: 39928362 ↗
L2OTHERCited in: 8. Long-term and Definitive Management, 10. Complications - [410]
Selman M, Buendia-Roldan I, Pardo A. “Artificial intelligence in idiopathic pulmonary fibrosis: advances, challenges and future directions.” The European respiratory journal (2026). PMID: 41381227 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management - [411]
Shah PD, Armanios M. “Viewpoint: Pre- and post-lung transplant considerations for patients with ultra-short telomere length.” The European respiratory journal (2025). PMID: 39884762 ↗
L5OTHERCited in: 8. Long-term and Definitive Management, 10. Complications - [412]
Zhang X, Liu X, Noble PW. “From fibroblast foci to dense scars: PAK2-activated fibroblasts drive fibrosis progression in idiopathic pulmonary fibrosis.” The European respiratory journal (2025). PMID: 41198410 ↗
L5OTHERCited in: 8. Long-term and Definitive Management - [413]
Mora Cuesta VM, Iturbe Fernández D, Aguado Ibáñez S et al.. “Antifibrotics and lung transplantation: A Spanish multicentre case-controlled study.” Respirology (Carlton, Vic.) (2022). PMID: 36053911 ↗
L3CASE_CONTROLCited in: 8. Long-term and Definitive Management - [414]
Noth I, Martinez FJ. “Recent advances in idiopathic pulmonary fibrosis.” Chest (2007). PMID: 17699135 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management, 10. Complications - [415]
Meyer KC, Danoff SK, Lancaster LH et al.. “Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient: Addressing Key Questions.” Chest (2015). PMID: 26149553 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management, 12. Special Populations and Prevention - [416]
Kern RM, Singer JP, Koth L et al.. “Lung transplantation for hypersensitivity pneumonitis.” Chest (2015). PMID: 25412059 ↗
L3OTHERCited in: 8. Long-term and Definitive Management - [417]
Karampitsakos T, Tourki B, Herazo-Maya JD. “The Dawn of Precision Medicine in Fibrotic Interstitial Lung Disease.” Chest (2024). PMID: 39521375 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management - [418]
Adegunsoye A, Strek ME. “Therapeutic Approach to Adult Fibrotic Lung Diseases.” Chest (2016). PMID: 27521738 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management, 10. Complications - [419]
Ozaltin B, Chapman R, Follet T et al.. “Mortality Outcomes and Angiotensin-Converting Enzyme Inhibitor Use in Patients With Idiopathic Pulmonary Fibrosis.” Chest (2025). PMID: 40818772 ↗
L3OTHERCited in: 8. Long-term and Definitive Management - [420]
Pommerolle L, Beltramo G, Biziorek L et al.. “CD206+ macrophages are relevant non-invasive imaging biomarkers and therapeutic targets in experimental lung fibrosis.” Thorax (2024). PMID: 39033028 ↗
L2OTHERCited in: 8. Long-term and Definitive Management - [421]
Nathan SD, Johri S, Joly JM et al.. “Survival analysis from the INCREASE study in PH-ILD: evaluating the impact of treatment crossover on overall mortality.” Thorax (2024). PMID: 37979971 ↗
L2OTHERCited in: 8. Long-term and Definitive Management, 10. Complications - [422]
Avitzur N, Noth EM, Lamidi M et al.. “Relative environmental and social disadvantage in patients with idiopathic pulmonary fibrosis.” Thorax (2021). PMID: 34949724 ↗
L2OTHERCited in: 8. Long-term and Definitive Management - [423]
Naoi H, Suzuki Y, Mori K et al.. “Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis.” Thorax (2022). PMID: 35354649 ↗
L2OTHERCited in: 8. Long-term and Definitive Management - [424]
Teoh AKY, Corte TJ. “Contemporary Concise Review 2020: Interstitial lung disease.” Respirology (Carlton, Vic.) (2021). PMID: 33913200 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management - [425]
Mackintosh JA, Keir G, Troy LK et al.. “Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision.” Respirology (Carlton, Vic.) (2024). PMID: 38211978 ↗
L1OTHERCited in: 8. Long-term and Definitive Management - [426]
White ES, Brown KK, Collard HR et al.. “Open-access biorepository for idiopathic pulmonary fibrosis. The way forward.” Annals of the American Thoracic Society (2014). PMID: 25167209 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management - [427]
Xu H, Hui SL, Lee JS et al.. “Effect of Antifibrotic Use on Mortality in Patients with Idiopathic Pulmonary Fibrosis.” Annals of the American Thoracic Society (2024). PMID: 39012168 ↗
L2OTHERCited in: 8. Long-term and Definitive Management - [428]
Fernandez IE, Heinzelmann K, Verleden S et al.. “Characteristic patterns in the fibrotic lung. Comparing idiopathic pulmonary fibrosis with chronic lung allograft dysfunction.” Annals of the American Thoracic Society (2015). PMID: 25830833 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management, 10. Complications - [429]
Handa T, Tanizawa K, Oguma T et al.. “Novel Artificial Intelligence-based Technology for Chest Computed Tomography Analysis of Idiopathic Pulmonary Fibrosis.” Annals of the American Thoracic Society (2022). PMID: 34410886 ↗
L2OTHERCited in: 8. Long-term and Definitive Management - [430]
Wallaert B, Duthoit L, Drumez E et al.. “Long-term evaluation of home-based pulmonary rehabilitation in patients with fibrotic idiopathic interstitial pneumonias.” ERJ open research (2019). PMID: 30972352 ↗
L4OTHERCited in: 8. Long-term and Definitive Management - [431]
Stark C, Koskenvuo JW, Nykänen A et al.. “Monogenic gene variants in lung transplant recipients with usual interstitial pneumonia.” ERJ open research (2022). PMID: 35083318 ↗
L4OTHERCited in: 8. Long-term and Definitive Management, 10. Complications - [432]
Fleitas Sosa DC, Gayen S, Zheng M et al.. “Sarcoidosis lung transplantation waitlist mortality, a national registry database study.” ERJ open research (2023). PMID: 37465560 ↗
L2OTHERCited in: 8. Long-term and Definitive Management - [433]
Kaunisto J, Salomaa ER, Hodgson U et al.. “Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry.” ERJ open research (2019). PMID: 31304177 ↗
L2OTHERCited in: 8. Long-term and Definitive Management - [434]
Nishiyama O, Kataoka K, Ando M et al.. “Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis.” ERJ open research (2021). PMID: 34435033 ↗
L5OTHERCited in: 8. Long-term and Definitive Management - [435]
Hilberg O, Bendstrup E, Ibsen R et al.. “Economic consequences of idiopathic pulmonary fibrosis in Denmark.” ERJ open research (2018). PMID: 29850467 ↗
L2OTHERCited in: 8. Long-term and Definitive Management - [436]
Sivakumar P, Thompson JR, Ammar R et al.. “RNA sequencing of transplant-stage idiopathic pulmonary fibrosis lung reveals unique pathway regulation.” ERJ open research (2019). PMID: 31423451 ↗
L3OTHERCited in: 8. Long-term and Definitive Management - [437]
Saito S, Shirakawa C, Yamada K et al.. “Long-term prognostic impact of clinical frailty scale on acute exacerbation of fibrotic interstitial lung disease: a retrospective cohort study.” BMC pulmonary medicine (2026). PMID: 42098699 ↗
L2COHORTCited in: 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [438]
Sans-Pola C, Boy R, Villar A et al.. “Pirfenidone and nintedanib in fibrosing interstitial lung disease: A retrospective study based on a regional university hospital data registry and literature review.” International journal of clinical pharmacology and therapeutics (2026). PMID: 42233448 ↗
L2COHORTCited in: 8. Long-term and Definitive Management - [439]
Cottin V, Najean M, Arnee E et al.. “Real-world persistence with antifibrotic treatments: a nationwide study on claims data in France (The REPEAT study).” Respiratory research (2026). PMID: 42316168 ↗
L2OTHERCited in: 8. Long-term and Definitive Management - [440]
Kim H, Hwang SY, Lee SH et al.. “AI-driven discovery of bronopol for the treatment of pulmonary fibrosis via inhibition of fibroblast activation.” Life sciences (2026). PMID: 42276357 ↗
L5OTHERCited in: 8. Long-term and Definitive Management - [441]
Li B, Xu R, Zheng H et al.. “Danthron prevents pulmonary fibrosis through improving mitochondrial function by upregulating carboxylesterase 3.” Respiratory research (2026). PMID: 42265751 ↗
L5OTHERCited in: 8. Long-term and Definitive Management - [442]
Krishna R, Lindell K. “Holistic management of symptom burden in fibrosing interstitial lung diseases (F-ILDs).” Thorax (2026). PMID: 42264936 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management, 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 12. Special Populations and Prevention - [443]
Wen B, Wu X, Ma X et al.. “The rise and fall of glucocorticoids and immunosuppressants in idiopathic pulmonary fibrosis: a historical paradigm shift driven by mechanistic understanding.” Frontiers in immunology (2026). PMID: 42254000 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management - [444]
Zhang SM, Huang MZ, Wang YW et al.. “A new perspective on idiopathic pulmonary fibrosis research: From multi-dimensional mechanistic exploration to advances in precision therapy.” Respiratory medicine (2026). PMID: 42251910 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management - [445]
Kondoh Y, Azuma A, Inoue Y et al.. “Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial.” American journal of respiratory and critical care medicine (2020). PMID: 31917621 ↗
L1RCTCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [446]
Raghu G, Mouded M, Chambers DC et al.. “A Phase IIb Randomized Clinical Study of an Anti-αvβ6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis.” American journal of respiratory and critical care medicine (2022). PMID: 35771569 ↗
L1RCTCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [447]
Costabel U, Inoue Y, Richeldi L et al.. “Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.” American journal of respiratory and critical care medicine (2016). PMID: 26393389 ↗
L1RCTCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [448]
Raghu G, Pellegrini CA, Yow E et al.. “Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial.” The Lancet. Respiratory medicine (2018). PMID: 30100404 ↗
L1RCTCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 10. Complications - [449]
Rosas IO, Goldberg HJ, Collard HR et al.. “A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis.” Chest (2017). PMID: 29100885 ↗
L1RCTCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [450]
Khor YH, Holland AE, Goh NSL et al.. “Ambulatory Oxygen in Fibrotic Interstitial Lung Disease: A Pilot, Randomized, Triple-Blinded, Sham-Controlled Trial.” Chest (2020). PMID: 32113924 ↗
L1RCTCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [451]
Fidler L, Sitzer N, Shapera S et al.. “Treatment of Gastroesophageal Reflux in Patients With Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.” Chest (2018). PMID: 29559309 ↗
L1SR_OBSCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [452]
Khor YH, Gutman L, Abu Hussein N et al.. “Incidence and Prognostic Significance of Hypoxemia in Fibrotic Interstitial Lung Disease: An International Cohort Study.” Chest (2021). PMID: 33905679 ↗
L2COHORTCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [453]
Lindell KO, Klein SJ, Veatch MS et al.. “Nurse-Led Palliative Care Clinical Trial Improves Knowledge and Preparedness in Caregivers of Patients with Idiopathic Pulmonary Fibrosis.” Annals of the American Thoracic Society (2021). PMID: 34003726 ↗
L1RCTCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [454]
Wootton SC, Kim DS, Kondoh Y et al.. “Viral infection in acute exacerbation of idiopathic pulmonary fibrosis.” American journal of respiratory and critical care medicine (2011). PMID: 21471095 ↗
L3OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [455]
McMillan TR, Moore BB, Weinberg JB et al.. “Exacerbation of established pulmonary fibrosis in a murine model by gammaherpesvirus.” American journal of respiratory and critical care medicine (2008). PMID: 18187693 ↗
L5OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [456]
McElroy AN, Invernizzi R, Laskowska JW et al.. “Candidate Role for Toll-like Receptor 3 L412F Polymorphism and Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.” American journal of respiratory and critical care medicine (2022). PMID: 34985402 ↗
L3OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [457]
Akira M, Kozuka T, Yamamoto S et al.. “Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis.” American journal of respiratory and critical care medicine (2008). PMID: 18451320 ↗
L4OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [458]
Kreuter M, Polke M, Walsh SLF et al.. “Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation.” The European respiratory journal (2020). PMID: 32060068 ↗
L5OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 12. Special Populations and Prevention - [459]
Johannson KA, Vittinghoff E, Lee K et al.. “Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure.” The European respiratory journal (2013). PMID: 24176998 ↗
L2OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [460]
Karayama M, Aoshima Y, Suzuki T et al.. “A predictive model for acute exacerbation of idiopathic interstitial pneumonias.” The European respiratory journal (2023). PMID: 36822633 ↗
L2OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [461]
Kim DS, Park JH, Park BK et al.. “Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features.” The European respiratory journal (2006). PMID: 16387947 ↗
L4OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [462]
Nishikiori H, Kuronuma K, Hirota K et al.. “Deep-learning algorithm to detect fibrosing interstitial lung disease on chest radiographs.” The European respiratory journal (2023). PMID: 36202411 ↗
L4OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [463]
Harari S, Elia D, Humbert M. “Pulmonary Hypertension in Parenchymal Lung Diseases: Any Future for New Therapies?” Chest (2017). PMID: 28629920 ↗
L5REVIEW_NARRATIVECited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 10. Complications - [464]
Knippenberg S, Ueberberg B, Maus R et al.. “Streptococcus pneumoniae triggers progression of pulmonary fibrosis through pneumolysin.” Thorax (2015). PMID: 25964315 ↗
L5OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 12. Special Populations and Prevention - [465]
Sesé L, Nunes H, Cottin V et al.. “Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis.” Thorax (2017). PMID: 28798214 ↗
L2OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [466]
Valenzi E, Yang H, Sembrat JC et al.. “Topographic heterogeneity of lung microbiota in end-stage idiopathic pulmonary fibrosis: the Microbiome in Lung Explants-2 (MiLEs-2) study.” Thorax (2020). PMID: 33268457 ↗
L3OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [467]
Tiitto L, Bloigu R, Heiskanen U et al.. “Relationship between histopathological features and the course of idiopathic pulmonary fibrosis/usual interstitial pneumonia.” Thorax (2006). PMID: 16769713 ↗
L2OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [468]
Wang Y, Wang D, Song Y et al.. “SARS-CoV-2 reinfection in interstitial lung disease patients and its association with clinical deterioration: a two-year prospective cohort study.” BMC infectious diseases (2025). PMID: 41286664 ↗
L2COHORTCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 10. Complications - [469]
Sasada T, Kishi R, Shirakawa C et al.. “Changes in virus-related exacerbations of chronic respiratory diseases before and after the relaxation of COVID-19 infection control measures: a single-centre retrospective study in Japan.” Therapeutic advances in infectious disease (2025). PMID: 41048209 ↗
L2COHORTCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [470]
Wuyts WA, Richeldi L, Assassi S et al.. “Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON).” BMC pulmonary medicine (2025). PMID: 41345848 ↗
L5TRIAL_NONRANDOMCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [471]
Koshy K, Barnes H, Farrand E et al.. “Steroid therapy in acute exacerbation of fibrotic interstitial lung disease.” Respirology (Carlton, Vic.) (2024). PMID: 38825348 ↗
L2OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [472]
Hyung K, Lee JH, Kim JY et al.. “Pulse versus non-pulse corticosteroid therapy in patients with acute exacerbation of idiopathic pulmonary fibrosis.” Respirology (Carlton, Vic.) (2023). PMID: 38087838 ↗
L2OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [473]
Arai T, Kagawa T, Sasaki Y et al.. “Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial pneumonia.” Respirology (Carlton, Vic.) (2016). PMID: 27460223 ↗
L2OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [474]
Ekström M, Bornefalk-Hermansson A. “Cardiovascular and antacid treatment and mortality in oxygen-dependent pulmonary fibrosis: A population-based longitudinal study.” Respirology (Carlton, Vic.) (2016). PMID: 27009834 ↗
L2OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive), 12. Special Populations and Prevention - [475]
Singer D, Bengtson LGS, Conoscenti CS et al.. “Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.” Annals of the American Thoracic Society (2022). PMID: 35015982 ↗
L2OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [476]
Nicod LP, Kolls JK. “Chair's Summary: Mechanisms of Exacerbation of Lung Diseases.” Annals of the American Thoracic Society (2015). PMID: 26595726 ↗
L5OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [477]
Pascoe A, Smallwood N, Philip J et al.. “Consensus palliative care referral criteria for people with idiopathic pulmonary fibrosis: An international Delphi study.” Annals of the American Thoracic Society (2026). PMID: 41866293 ↗
L5OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [478]
Paterniti MO, Bi Y, Rekić D et al.. “Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.” Annals of the American Thoracic Society (2017). PMID: 28388260 ↗
L2OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [479]
Breuls S, Somogyi V, Schenk S et al.. “The COCOS-IPF core outcome set for idiopathic pulmonary fibrosis/progressive pulmonary fibrosis care: a mixed-method multi-perspective approach.” ERJ open research (2026). PMID: 41846693 ↗
L5OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [480]
Schneeberger T, Leitl D, Gloeckl R et al.. “Acute effects of supplemental oxygen therapy using different nasal cannulas on walking capacity in patients with idiopathic pulmonary fibrosis: a randomised crossover trial.” ERJ open research (2020). PMID: 32832533 ↗
L1OTHERCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [481]
Teke NH, Agca M, Turkar A et al.. “Does combined pulmonary fibrosis and emphysema syndrome affect response to antifibrotic therapy and survival? A single-center retrospective cohort study.” Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG (2025). PMID: 41396111 ↗
L4COHORTCited in: 9. Inhaled and Oxygen Therapy and the Exacerbation Pathway (Specialty-Distinctive) - [482]
Corte TJ, Keir GJ, Dimopoulos K et al.. “Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia.” American journal of respiratory and critical care medicine (2014). PMID: 24937643 ↗
L1RCTCited in: 10. Complications - [483]
Behr J, Kolb M, Song JW et al.. “Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE).” American journal of respiratory and critical care medicine (2019). PMID: 31365829 ↗
L2RCTCited in: 10. Complications - [484]
Yogeswaran A, Hassoun PM, Saleh K et al.. “Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in Pulmonary Hypertension in Interstitial Lung Disease: A PVRI GoDeep Meta-Registry Analysis.” American journal of respiratory and critical care medicine (2025). PMID: 40772955 ↗
L2OTHERCited in: 10. Complications - [485]
Nathan SD, Noble PW, Tuder RM. “Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots.” American journal of respiratory and critical care medicine (2007). PMID: 17255562 ↗
L5REVIEW_NARRATIVECited in: 10. Complications - [486]
Anderson MR, Tabah A, RoyChoudhury A et al.. “Procedure Preference and Intention-to-Treat Outcomes after Listing for Lung Transplantation among U.S. Adults. A Cohort Study.” Annals of the American Thoracic Society (2019). PMID: 30188172 ↗
L2COHORTCited in: 10. Complications - [487]
Hoffmann J, Wilhelm J, Olschewski A et al.. “Microarray analysis in pulmonary hypertension.” The European respiratory journal (2016). PMID: 27076594 ↗
L5REVIEW_NARRATIVECited in: 10. Complications - [488]
Bellaye PS, Yanagihara T, Granton E et al.. “Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension.” The European respiratory journal (2018). PMID: 29976656 ↗
L5OTHERCited in: 10. Complications - [489]
King CS, Nathan SD. “Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities.” The Lancet. Respiratory medicine (2016). PMID: 27599614 ↗
L5REVIEW_NARRATIVECited in: 10. Complications - [490]
Kim SY, Diggans J, Pankratz D et al.. “Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data.” The Lancet. Respiratory medicine (2015). PMID: 26003389 ↗
L3OTHERCited in: 10. Complications - [491]
Raj R, Raparia K, Lynch DA et al.. “Surgical Lung Biopsy for Interstitial Lung Diseases.” Chest (2016). PMID: 27471113 ↗
L5REVIEW_NARRATIVECited in: 10. Complications - [492]
Rahaghi FF, Kolaitis NA, Adegunsoye A et al.. “Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study.” Chest (2022). PMID: 35176276 ↗
L5OTHERCited in: 10. Complications, 12. Special Populations and Prevention - [493]
Du Y, Guo M, Wu Y et al.. “Lymphangioleiomyomatosis (LAM) Cell Atlas.” Thorax (2022). PMID: 36599466 ↗
L5OTHERCited in: 10. Complications - [494]
Im Y, Chung MP, Lee KS et al.. “Impact of interstitial lung abnormalities on postoperative pulmonary complications and survival of lung cancer.” Thorax (2022). PMID: 35688622 ↗
L2OTHERCited in: 10. Complications - [495]
Goga A, Soussi G, Mogenet A et al.. “Single-center retrospective cohort study of lung cancer associated with interstitial lung disease: Prognostic factors and molecular profile.” Lung cancer (Amsterdam, Netherlands) (2026). PMID: 41887129 ↗
L4COHORTCited in: 10. Complications - [496]
Lee SI, Chae EJ, Song JS et al.. “Pleuroparenchymal fibroelastosis in patients with idiopathic pulmonary fibrosis.” Respirology (Carlton, Vic.) (2020). PMID: 32147954 ↗
L4OTHERCited in: 10. Complications - [497]
Berend N. “Respiratory disease and respiratory physiology: putting lung function into perspective interstitial lung disease.” Respirology (Carlton, Vic.) (2014). PMID: 25039623 ↗
L5REVIEW_NARRATIVECited in: 10. Complications - [498]
Poletti V, Ravaglia C, Gurioli C et al.. “Invasive diagnostic techniques in idiopathic interstitial pneumonias.” Respirology (Carlton, Vic.) (2016). PMID: 26682637 ↗
L5REVIEW_NARRATIVECited in: 10. Complications - [499]
Jacob J, Bartholmai BJ, Rajagopalan S et al.. “Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema.” Respirology (Carlton, Vic.) (2017). PMID: 29237236 ↗
L2OTHERCited in: 10. Complications - [500]
Moncomble E, Weisenburger G, Picard C et al.. “Effect of antifibrotic agents on postoperative complications after lung transplantation for idiopathic pulmonary fibrosis.” Respirology (Carlton, Vic.) (2023). PMID: 37789612 ↗
L2OTHERCited in: 10. Complications - [501]
van der Plas MN, van Kan C, Blumenthal J et al.. “Pulmonary vascular limitation to exercise and survival in idiopathic pulmonary fibrosis.” Respirology (Carlton, Vic.) (2013). PMID: 24251797 ↗
L4OTHERCited in: 10. Complications - [502]
Mizumura K, Cloonan S, Choi ME et al.. “Autophagy: Friend or Foe in Lung Disease?” Annals of the American Thoracic Society (2016). PMID: 27027951 ↗
L5REVIEW_NARRATIVECited in: 10. Complications - [503]
Pastre J, Khandhar S, Barnett S et al.. “Surgical Lung Biopsy for Interstitial Lung Disease. Safety and Feasibility at a Tertiary Referral Center.” Annals of the American Thoracic Society (2021). PMID: 32970474 ↗
L4OTHERCited in: 10. Complications - [504]
Shirahata T, Nardelli P, Jesudasen S et al.. “Detection of pulmonary hypertension in idiopathic pulmonary fibrosis using random forest models and automated measures of central computed tomography structures.” ERJ open research (2025). PMID: 40989790 ↗
L3OTHERCited in: 10. Complications - [505]
Gaikwad AV, Lu W, Dey S et al.. “Endothelial-to-mesenchymal transition: a precursor to pulmonary arterial remodelling in patients with idiopathic pulmonary fibrosis.” ERJ open research (2023). PMID: 37077555 ↗
L4OTHERCited in: 10. Complications - [506]
Kalafatis D, Björnson M, Svobodová B et al.. “Protein profiling in intensive care unit-treated COVID-19 patients identifies biomarkers of residual lung abnormalities.” ERJ open research (2025). PMID: 40551787 ↗
L4OTHERCited in: 10. Complications - [507]
Song Y, Wang Y, Dilixiati N et al.. “Distinct comorbidity profiles and outcomes in asbestosis versus idiopathic pulmonary fibrosis: a 6-year prospective cohort study.” BMC pulmonary medicine (2026). PMID: 41612278 ↗
L2COHORTCited in: 10. Complications - [508]
Chen R, Zhao Y, Shao C et al.. “Clinical characteristics of hospitalized lung cancer patients with concomitant idiopathic pulmonary fibrosis: a retrospective cohort study.” Journal of thoracic disease (2025). PMID: 41229789 ↗
L3COHORTCited in: 10. Complications - [509]
Toshniwal A, Ghewade B, Jain A et al.. “Case series: Interstitial lung disease with IPF pattern presenting with spontaneous pneumothorax-clinical course of two patients.” Frontiers in medicine (2025). PMID: 41169414 ↗
L4CASE_REPORTCited in: 10. Complications - [510]
Allen RJ, Stockwell A, Oldham JM et al.. “Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis.” Thorax (2022). PMID: 35688625 ↗
L1SR_OBSCited in: 11. Prognosis and Natural History - [511]
Unterman A, Zhao AY, Neumark N et al.. “Single-Cell Profiling Reveals Immune Aberrations in Progressive Idiopathic Pulmonary Fibrosis.” American journal of respiratory and critical care medicine (2024). PMID: 38717443 ↗
L4OTHERCited in: 11. Prognosis and Natural History - [512]
Kim DH, Kim HC, Im K et al.. “Inhibition of AXL ameliorates pulmonary fibrosis via attenuation of M2 macrophage polarisation.” The European respiratory journal (2025). PMID: 39788632 ↗
L5OTHERCited in: 11. Prognosis and Natural History - [513]
Zhang D, Adegunsoye A, Oldham JM et al.. “Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease.” The European respiratory journal (2023). PMID: 37591536 ↗
L3OTHERCited in: 11. Prognosis and Natural History - [514]
Zhao C, Song C, Zhou Y et al.. “Global landscape for pulmonary fibrosis treatment: a data-driven perspective from clinical trials.” BMC pulmonary medicine (2026). PMID: 42316178 ↗
L5TRIAL_NONRANDOMCited in: 11. Prognosis and Natural History - [515]
Maher TM, Jenkins RG, Cottin V et al.. “Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trial.” ERJ open research (2024). PMID: 39040590 ↗
L1OTHERCited in: 11. Prognosis and Natural History - [516]
Vancheri C, Kreuter M, Richeldi L et al.. “Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.” American journal of respiratory and critical care medicine (2018). PMID: 28889759 ↗
L1RCTCited in: 12. Special Populations and Prevention - [517]
Verma A, Minnier J, Wan ES et al.. “A MUC5B Gene Polymorphism, rs35705950-T, Confers Protective Effects Against COVID-19 Hospitalization but Not Severe Disease or Mortality.” American journal of respiratory and critical care medicine (2022). PMID: 35771531 ↗
L2SR_OBSCited in: 12. Special Populations and Prevention - [518]
Richeldi L, Fletcher S, Adamali H et al.. “No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone.” The European respiratory journal (2019). PMID: 30442716 ↗
L1TRIAL_NONRANDOMCited in: 12. Special Populations and Prevention - [519]
Tran T, Assayag D, Ernst P et al.. “Effectiveness of Proton Pump Inhibitors in Idiopathic Pulmonary Fibrosis: A Population-Based Cohort Study.” Chest (2020). PMID: 32882251 ↗
L2COHORTCited in: 12. Special Populations and Prevention - [520]
Hunninghake GM, Quesada-Arias LD, Carmichael NE et al.. “Interstitial Lung Disease in Relatives of Patients with Pulmonary Fibrosis.” American journal of respiratory and critical care medicine (2020). PMID: 32011908 ↗
L4OTHERCited in: 12. Special Populations and Prevention - [521]
Drake TM, Docherty AB, Harrison EM et al.. “Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study.” American journal of respiratory and critical care medicine (2020). PMID: 33007173 ↗
L2OTHERCited in: 12. Special Populations and Prevention - [522]
du Bois RM, Weycker D, Albera C et al.. “Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.” American journal of respiratory and critical care medicine (2011). PMID: 21940789 ↗
L2OTHERCited in: 12. Special Populations and Prevention - [523]
Robbins IM, Moore TM, Blaisdell CJ et al.. “Improving outcomes for pulmonary vascular disease.” American journal of respiratory and critical care medicine (2012). PMID: 22335936 ↗
L5OTHERCited in: 12. Special Populations and Prevention - [524]
Hutchinson JP, Fogarty AW, McKeever TM et al.. “In-Hospital Mortality after Surgical Lung Biopsy for Interstitial Lung Disease in the United States. 2000 to 2011.” American journal of respiratory and critical care medicine (2016). PMID: 26646481 ↗
L3OTHERCited in: 12. Special Populations and Prevention - [525]
Yoon HY, Kim SY, Kim OJ et al.. “Nitrogen dioxide increases the risk of mortality in idiopathic pulmonary fibrosis.” The European respiratory journal (2021). PMID: 33184121 ↗
L2OTHERCited in: 12. Special Populations and Prevention - [526]
Maher TM, Brown KK, Kreuter M et al.. “Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.” The European respiratory journal (2022). PMID: 34210788 ↗
L1OTHERCited in: 12. Special Populations and Prevention - [527]
Matson S, Lee J, Eickelberg O. “Two sides of the same coin? A review of the similarities and differences between idiopathic pulmonary fibrosis and rheumatoid arthritis-associated interstitial lung disease.” The European respiratory journal (2021). PMID: 33303554 ↗
L5REVIEW_NARRATIVECited in: 12. Special Populations and Prevention - [528]
Cordier JF, Cottin V. “Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis.” The European respiratory journal (2013). PMID: 23598958 ↗
L5OTHERCited in: 12. Special Populations and Prevention - [529]
Raghu G, Lynch D, Godwin JD et al.. “Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial.” The Lancet. Respiratory medicine (2014). PMID: 24717624 ↗
L2OTHERCited in: 12. Special Populations and Prevention - [530]
Patterson KC, Shah RJ, Porteous MK et al.. “Interstitial Lung Disease in the Elderly.” Chest (2016). PMID: 27865876 ↗
L2OTHERCited in: 12. Special Populations and Prevention - [531]
Jeganathan N, Smith RA, Sathananthan M. “Mortality Trends of Idiopathic Pulmonary Fibrosis in the United States From 2004 Through 2017.” Chest (2020). PMID: 32805236 ↗
L2OTHERCited in: 12. Special Populations and Prevention - [532]
Lancaster LH, Mason WR, Parnell JA et al.. “Obstructive sleep apnea is common in idiopathic pulmonary fibrosis.” Chest (2009). PMID: 19567497 ↗
L3OTHERCited in: 12. Special Populations and Prevention - [533]
King CS, Shlobin OA. “The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment.” Chest (2020). PMID: 32387520 ↗
L5REVIEW_NARRATIVECited in: 12. Special Populations and Prevention - [534]
Hunninghake GM. “Interstitial lung abnormalities: erecting fences in the path towards advanced pulmonary fibrosis.” Thorax (2019). PMID: 30723182 ↗
L2REVIEW_NARRATIVECited in: 12. Special Populations and Prevention - [535]
Carmichael N, Martinez Manzano JM, Quesada-Arias LD et al.. “Psychological impact of genetic and clinical screening for pulmonary fibrosis on asymptomatic first-degree relatives of affected individuals.” Thorax (2021). PMID: 33483364 ↗
L2OTHERCited in: 12. Special Populations and Prevention - [536]
Hewitt RJ, Bartlett EC, Ganatra R et al.. “Lung cancer screening provides an opportunity for early diagnosis and treatment of interstitial lung disease.” Thorax (2022). PMID: 35940878 ↗
L3OTHERCited in: 12. Special Populations and Prevention - [537]
Tikellis G, Tong A, Lee JYT et al.. “Top 10 research priorities for people living with pulmonary fibrosis, their caregivers, healthcare professionals and researchers.” Thorax (2020). PMID: 33277429 ↗
L5OTHERCited in: 12. Special Populations and Prevention - [538]
Hartmann S, Chan Kwong A, Ribbing J et al.. “Population Pharmacokinetics and Exposure-Response Model-Based Bayesian Extrapolation of FVC-Based Efficacy Endpoints From Adults to Pediatric Patients Receiving Nintedanib.” CPT: pharmacometrics & systems pharmacology (2025). PMID: 41364596 ↗
L2TRIAL_NONRANDOMCited in: 12. Special Populations and Prevention - [539]
Su K, Feng Z, Wang L et al.. “Psychometric properties of health-related quality of life assessment instruments in idiopathic pulmonary fibrosis: a systematic review applying COSMIN methodology.” Health and quality of life outcomes (2026). PMID: 41872861 ↗
L1SR_OBSCited in: 12. Special Populations and Prevention - [540]
Mihart D, Crisan AF, Carunta V et al.. “Neurocognitive Impairment in Idiopathic Pulmonary Fibrosis: A Systematic Review of Current Evidence.” Medical sciences (Basel, Switzerland) (2025). PMID: 41440520 ↗
L2SR_OBSCited in: 12. Special Populations and Prevention - [541]
Levra S, Rivero C, Giannoccaro F et al.. “Maintenance of Effectiveness of Pirfenidone in Elderly Patients with Progressive Functional Impairment: A Real-World Retrospective Study in IPF.” Biomedicines (2025). PMID: 41301899 ↗
L3COHORTCited in: 12. Special Populations and Prevention - [542]
Moodley Y. “Contemporary Concise Review 2023: Interstitial lung disease.” Respirology (Carlton, Vic.) (2024). PMID: 39438044 ↗
L5REVIEW_NARRATIVECited in: 12. Special Populations and Prevention - [543]
Terwiel M, Borie R, Crestani B et al.. “Genetic testing in interstitial lung disease: An international survey.” Respirology (Carlton, Vic.) (2022). PMID: 35652243 ↗
L3OTHERCited in: 12. Special Populations and Prevention - [544]
Gaugg MT, Engler A, Bregy L et al.. “Molecular breath analysis supports altered amino acid metabolism in idiopathic pulmonary fibrosis.” Respirology (Carlton, Vic.) (2019). PMID: 30681243 ↗
L3OTHERCited in: 12. Special Populations and Prevention - [545]
Nishimoto K, Fujisawa T, Yoshimura K et al.. “The prognostic significance of pneumothorax in patients with idiopathic pulmonary fibrosis.” Respirology (Carlton, Vic.) (2017). PMID: 29130562 ↗
L3OTHERCited in: 12. Special Populations and Prevention - [546]
Furukawa T, Oyama S, Yokota H et al.. “A comprehensible machine learning tool to differentially diagnose idiopathic pulmonary fibrosis from other chronic interstitial lung diseases.” Respirology (Carlton, Vic.) (2022). PMID: 35697345 ↗
L3OTHERCited in: 12. Special Populations and Prevention - [547]
Holland AE, Fiore JF, Bell EC et al.. “Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease.” Respirology (Carlton, Vic.) (2014). PMID: 25112470 ↗
L3OTHERCited in: 12. Special Populations and Prevention - [548]
Khor YH, Glaspole I, Goh NSL. “Therapeutic burden in interstitial lung disease: Lessons to learn.” Respirology (Carlton, Vic.) (2019). PMID: 30790404 ↗
L3OTHERCited in: 12. Special Populations and Prevention - [549]
Vaszar LT, Larsen BT, Swanson KL et al.. “Diagnostic utility of surgical lung biopsies in elderly patients with indeterminate interstitial lung disease.” Respirology (Carlton, Vic.) (2017). PMID: 29178216 ↗
L3OTHERCited in: 12. Special Populations and Prevention - [550]
Lee YC, Chang KY, Mirsaeidi M. “Association of County-degree Social Vulnerability with Chronic Respiratory Disease Mortality in the United States.” Annals of the American Thoracic Society (2023). PMID: 36044720 ↗
L2OTHERCited in: 12. Special Populations and Prevention - [551]
Collard HR, Chen SY, Yeh WS et al.. “Health care utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older.” Annals of the American Thoracic Society (2015). PMID: 25923447 ↗
L2OTHERCited in: 12. Special Populations and Prevention - [552]
Gore B, Demirel A. “Effects of respiratory muscle training in patients with interstitial lung diseases: Systematic review.” Heart & lung : the journal of critical care (2025). PMID: 41352327 ↗
L1SR_OBSCited in: 12. Special Populations and Prevention - [553]
Castaldo A, Delestrain C, Diesler R et al.. “Idiopathic pulmonary fibrosis with benign SFTPC variant and pathogenic MARS1 mutations: can't see the forest for the trees!” ERJ open research (2023). PMID: 37936900 ↗
L5OTHERCited in: 12. Special Populations and Prevention - [554]
Rajala K, Lehto JT, Sutinen E et al.. “mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis.” ERJ open research (2017). PMID: 29255720 ↗
L4OTHERCited in: 12. Special Populations and Prevention - [555]
Shen Q, Zhou S, Ouyang X et al.. “Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: a real-world cohort study.” Heart & lung : the journal of critical care (2026). PMID: 42030746 ↗
L3COHORTCited in: 12. Special Populations and Prevention